<PAGE>

--------------------------------------------------------------------------------
--------------------------------------------------------------------------------
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                   FORM 10-K

                      FOR ANNUAL AND TRANSITIONAL REPORTS
                    PURSUANT TO SECTIONS 13 AND 15(d) OF THE
                        SECURITIES EXCHANGE ACT OF 1934

              ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
                        SECURITIES EXCHANGE ACT OF 1934

                [X]  FOR THE FISCAL YEAR ENDED DECEMBER 31, 2002
                                       OR
            TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
                        SECURITIES EXCHANGE ACT OF 1934

             FOR THE TRANSITION PERIOD FROM           TO

                        COMMISSION FILE NUMBER: 0-21003

                              TWINLAB CORPORATION
             (Exact name of registrant as specified in its charter)

<Table>
<Caption>

<S>                                                      <C>
                        DELAWARE                                                11-3317986
            (State or Other jurisdiction of                                  (I.R.S. Employer
             Incorporation or organization)                                Identification No.)
                   150 MOTOR PARKWAY                                              11788
                  HAUPPAUGE, NEW YORK                                           (Zip Code)
             (Address of principal offices)
</Table>

       REGISTRANT'S TELEPHONE NUMBER, INCLUDING AREA CODE: (631) 467-3140

          SECURITIES REGISTERED PURSUANT TO SECTION 12(b) OF THE ACT:
                                      NONE

          SECURITIES REGISTERED PURSUANT TO SECTION 12(g) OF THE ACT:
                         COMMON STOCK, $1.00 PAR VALUE
                             ---------------------
     Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days. Yes  [X]  No  [ ]

     Indicate by check mark if disclosure of delinquent filers pursuant to Item
405 of Regulation S-K is not contained herein, and will not be contained, to the
best of the registrant's knowledge, in definitive proxy or information
statements incorporated by reference in Part III of this Form 10-K or any
amendment to this Form 10-K.  [X]

     The aggregate market value of shares of Common Stock of the registrant held
by non-affiliates based on the last reported sales price for the Common Stock on
March 24, 2003, as reported on the OTC Bulletin Board, was approximately
$1,731,000.

     Indicate by check mark whether the registrant is an accelerated filer (as
defined in Rule 12b-2 of the Act).  Yes  [ ]  No  [X]

     The aggregate market value of shares of Common Stock of the registrant held
by non-affiliates based on the last reported sales price for the Common Stock on
June 28, 2002, as reported on the Nasdaq National Market, was approximately
$6,800,000.

     As of March 24, 2003, the registrant had 29,222,106 shares of Common stock
outstanding.

                      DOCUMENTS INCORPORATED BY REFERENCE

     Portions of the registrant's definitive proxy statement for the 2003 Annual
Meeting of Stockholders are incorporated by reference into Part III of this
Annual Report.
--------------------------------------------------------------------------------
--------------------------------------------------------------------------------
<PAGE>

                                      NOTE

Twinlab Corporation's Annual Report on Form 10-K filed with the Securities and
Exchange Commission includes all exhibits required to be filed with the Annual
Report. Copies of this Annual Report on Form 10-K, not including any of the
exhibits listed under Item 15(c) of this Annual Report, are available without
charge upon written request. Please contact the office set forth below to
request copies of this Annual Report on Form 10-K and for information as to the
number of pages contained in each of the exhibits and to request copies of such
exhibits:

                              Corporate Secretary
                              Twinlab Corporation
                               150 Motor Parkway
                              Hauppauge, NY 11788

                                        i
<PAGE>

              TWINLAB CORPORATION 2002 ANNUAL REPORT ON FORM 10-K

                               TABLE OF CONTENTS

<Table>
<Caption>
                                                                         PAGE
                                                                         ----
<S>       <C>                                                            <C>
                                   PART I
Item 1.   Business....................................................     1
Item 2.   Properties..................................................    13
Item 3.   Legal Proceedings...........................................    13
Item 4.   Submission of Matters to a Vote of Security Holders.........    15

                                   PART II
Item 5.   Market for Registrant's Common Equity and Related
          Stockholder Matters.........................................    16
Item 6.   Selected Financial Data.....................................    16
Item 7.   Management's Discussion and Analysis of Financial Condition
          and Results of Operations...................................    18
Item 7A.  Quantitative and Qualitative Disclosures About Market
          Risk........................................................    27
Item 8.   Financial Statements and Supplementary Data.................    28
Item 9.   Changes in and Disagreements with Accountants on Accounting
          and Financial Disclosure....................................    28

                                  PART III
Item 10.  Directors and Executive Officers of the Registrant..........    28
Item 11.  Executive Compensation......................................    28
Item 12.  Security Ownership of Certain Beneficial Owners and
          Management..................................................    28
Item 13.  Certain Relationships and Related Party Transactions........    28

                                   PART IV
Item 14.  Controls and Procedures.....................................    28
Item 15.  Exhibits, Financial Statement Schedules, and Reports on Form
          8-K.........................................................    29
SIGNATURES............................................................    35
CERTIFICATIONS........................................................    36
</Table>

                                        ii
<PAGE>

                                     PART I

     Information contained or incorporated by reference in this Annual Report
may contain "forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995. Forward-looking statements can be
identified by the use of forward-looking terminology such as "believes,"
"expects," "may," "will," "should" or "anticipates" or the negative thereof or
other variations thereon or comparable terminology, or by discussions of
strategy. See, e.g., "Management's Discussion and Analysis of Financial
Condition and Results of Operations" and "Business -- Business Strategy."
Forward-looking statements involve substantial risks and uncertainties and
represent the Company's expectations or beliefs, including, but not limited to,
statements concerning industry performance, the Company's operations,
performance, financial condition, growth and acquisition strategies, margins and
growth in sales of the Company's products. Such forward looking statements by
their nature involve known and unknown risks, uncertainties and contingencies,
many of which are beyond the Company's control, which may cause actual results,
performance or achievements to differ materially from those projected or implied
in such forward-looking statements. As a result, no assurance can be given that
the future results covered by such forward-looking statements will be achieved.
Factors that might cause actual results, performance or achievements to differ
materially from those projected or implied in such forward-looking statements
include, among other things, those discussed in "Factors Affecting Future
Performance" under the caption "Business" in Item 1 of this Annual Report. Other
important factors and risks that may affect future results include but are not
limited to: (i) the impact of competitive products; (ii) changes in law and
regulations; (iii) adequacy and availability of insurance coverage; (iv)
limitations on future financing; (v) increases in the cost of borrowings and
unavailability of debt or equity capital; (vi) the effect of adverse publicity
regarding nutritional supplements; (vii) uncertainties relating to acquisitions;
(viii) the inability of the Company to gain and/or hold market share; (ix)
exposure to and expense of resolving and defending product liability claims and
other litigation; (x) consumer acceptance of the Company's products; (xi)
managing and maintaining growth; (xii) customer demands; (xiii) the inability to
achieve cost savings and operational efficiencies from the recent consolidation
of the manufacturing and distribution facilities; (xiv) dependence on individual
products; (xv) dependence on individual customers, (xvi) market and industry
conditions including pricing, demand for products, levels of trade inventories
and raw materials availability, (xvii) the success of product development and
new product introductions into the marketplace including the Company's line of
ephedra-free products; (xviii) lack of available product liability insurance for
ephedra-containing products; (xix) slow or negative growth in the nutritional
supplement industry; (xx) the departure of key members of management; (xxi) the
absence of clinical trials for many of the Company's products; (xxii) the
ability of the Company to efficiently manufacture its products; as well as other
risks and uncertainties that are described from time to time in the Company's
filings with the Securities and Exchange Commission. For the purpose of this
Annual Report, any statements contained herein that are not statements of
historical fact may be deemed to be forward-looking statements. The Company
accepts no obligation to update any forward-looking statements and does not
intend to do so.

     Unless the context otherwise requires, the terms "Company" and "Twinlab"
refer to Twinlab Corporation and, as applicable, its direct and indirect
subsidiaries, Twin Laboratories Inc. ("Twin"), Twin Laboratories (U.K.) Ltd.,
Twinlab Mail Order, Inc. (formerly PR*Nutrition, Inc. ("PR*Nutrition")), Twinlab
Catalog Corp. (formerly Bronson Laboratories, Inc. ("Bronson")) and Tempe
Manufacturing Corp. (formerly Health Factors International, Inc. ("Health
Factors")).

ITEM 1.  BUSINESS

RECENT DEVELOPMENTS

     On February 28, 2003, the U.S. Food and Drug Administration, Department of
Health and Human Services ("HHS") announced a series of actions that will
potentially regulate the manner in which products containing the ingredient
ephedra are marketed, including a thirty-day comment period to create a record
to support potential restrictions that could range from label requirements to a
ban of the ingredient.

     On November 11, 2002, the Company announced that it decided to discontinue
the sale of products that contain ephedra effective on or about March 31, 2003.
This decision was reached as a result of increasing costs

                                        1
<PAGE>

that have been negatively impacting the profitability of these products, coupled
with consumer demand for non-ephedra weight loss products. The Company expects
to experience a reduction in net sales due to the discontinuation of these
products. Based upon anticipated costs savings expected to be achieved, however,
the Company does not believe that the decision to discontinue the sale of
products that contain ephedra should have a material adverse effect on the
profitability of the Company.

     On January 17, 2003, the Company sold substantially all of the assets,
including inventory, of Bronson to a privately held dietary supplement
manufacturer for approximately $8 million. The Company anticipates recording an
aggregate pre-tax gain of approximately $1.7 million during the first quarter of
2003 in connection with the sale of these assets. Bronson's results of
operations have been classified as discontinued operations and prior periods
have been reclassified.

     In addition, as a result of the sale of Bronson, effective January 17,
2003, the Company completed an amendment to its Revolving Credit Facility. The
amendment, among other things, revised the financial covenants relating to
EBITDA (as defined therein) and reduced the total facility from $50 million to
$45 million.

     On July 24, 2002, the Company announced a comprehensive restructuring of
its operations designed to improve the Company's financial performance and
operating results. The restructuring, designed to reduce costs and better align
the Company's operational infrastructure to its sales volume, resulted in the
consolidation of the New York manufacturing and distribution facilities into the
Company's modern FDA-registered facility located in American Fork, Utah. The
Company's corporate offices and certain operational functions remain in New
York. The consolidation of the facilities has been substantially completed
during fiscal 2002 and is anticipated to be completed during the first half of
2003. The Company recorded restructuring charges of $9.6 million and asset
impairment charges of $7.2 million in connection with the consolidation of the
facilities. The Company anticipates recording additional restructuring charges
in connection with this consolidation of up to $1.0 million, substantially all
of which are expected to be recorded during the first half of 2003.

     On May 22, 2002, the Company completed the sale of substantially all of the
fixed assets of its Health Factors subsidiary for approximately $2.1 million to
Anabolic Laboratories, Inc. ("Anabolic"). The products manufactured by Health
Factors were, in significant part, transferred to other Twinlab manufacturing
facilities. Other production related to Bronson was outsourced to Anabolic while
the manufacture of certain private label products was discontinued.

GENERAL

     The Company is a leading manufacturer and marketer of brand name
nutritional supplements sold through health and natural food stores, national
and regional drug store chains, supermarkets, mass merchandise retailers and
military post exchanges. The Company develops, manufactures and sells vitamins,
minerals and specialty supplements ("VMS"), sports nutrition products and diet
and energy products under the Twinlab, Ironman Triathlon, "Fuel" and other brand
names; an extensive line of herbal supplements and phytonutrients under the
Nature's Herb brand name; and a full line of herbal teas under the Alvita brand
name. The Company emphasizes the development and introduction of high-quality,
unique nutraceutical products. The Company's premium product quality, broad
product line, strong history of new product introductions and innovations have
established Twinlab as a leading and widely-recognized brand in the industry.
The Company targets its products to consumers who utilize nutritional
supplements in their daily diet and who demand premium quality ingredients in a
broad variety of dosages and delivery methods.

     As previously disclosed, the Company completed the sale of substantially
all of the assets of Bronson on January 17, 2003 and Bronson's results of
operations have been classified as discontinued operations. As a result of this
transaction, the Company no longer operates in the direct-to-consumer segment.
Accordingly, the Company operates in one segment, the retail segment. Products
sold through this segment are distributed through the health and natural food
store channel and mass market channel.

                                        2
<PAGE>

     - Health and Natural Food Store Channel -- The Company's Twinlab, Nature's
       Herbs and Alvita brand products are sold primarily through a network of
       distributors to nearly 11,000 health and natural food stores and other
       selected retail outlets. The health and natural food store channel of
       distribution includes national chains such as General Nutrition
       Companies, Inc. ("GNC"), Whole Foods Markets, Inc. ("WFM"), Wild Oats
       Markets, Inc. ("Wild Oats") and Vitamin Shoppe Industries, Inc. ("Vitamin
       Shoppe") as well as local and regional chains and stores. Sales to the
       health and natural food store channel, primarily through distributors,
       continue to represent the Company's largest market, totaling
       approximately $92.3 million, or 63.0%, of the Company's net sales in
       2002.

     - Mass Market Channel -- The mass market channel consists of drug store
       chains, supermarkets and other mass merchandisers. The Company provides
       Twinlab-branded products as well as private label herbal products to
       Wal-Mart Stores, Inc. ("Wal-Mart"), which are sold under Wal-Mart's
       proprietary Spring Valley brand name. The Company also sells its products
       through national and regional drug store and supermarket chains and other
       mass merchandisers, such as Rite Aid Corporation, Walgreens, CVS, Kroger,
       Albertson's and Target. Approximately $54.3 million, or 37.0%, of the
       Company's 2002 net sales were attributable to the mass market channel.

     For additional financial information regarding the Company's operating
segments, see Note 15 to the Notes to the Consolidated Financial Statements.

     Twinlab was incorporated under the laws of the State of Delaware in 1996
and maintains its principal executive offices at 150 Motor Parkway, Hauppauge,
New York 11788. Its telephone number is 631-467-3140.

BUSINESS STRATEGY

     The Company's strategy is to increase sales, profits and market share by
further enhancing its leadership position in the sale of vitamins, sports
nutrition products, weight management and other nutritional supplements to
health and natural food stores and mass market accounts. The Company plans to
implement this strategy by: (i) capitalizing on the strength of its established
brands; (ii) developing and introducing innovative channel-specific products;
(iii) increasing penetration of foreign markets; and (iv) improving
manufacturing and operational efficiencies.

     Specifically, the Company seeks to:

     (i) Further Strengthen Portfolio of Brands -- Twinlab has developed a
portfolio of core brands that is among the most recognized in the vitamin and
nutritional supplement industry. The Company intends to expand on this awareness
and increase loyalty of the Twinlab brand in the health and natural food store
and mass market distribution channel through incremental distribution, customer
specific marketing programs and national advertising.

     (ii) Continue to Introduce Innovative Products -- A cornerstone of the
Company's strategy is to utilize innovative scientific and medical findings in
its new product development efforts. The Company has consistently been among the
first in its industry to introduce new products and product innovations that
anticipate and meet customer demands for newly identified nutritional supplement
benefits. Product innovation and distribution will be driven by consumer needs
and purchasing behavior. Specifically, sports nutrition products will be focused
on meeting demands of consumers shopping in specialty sports retailers, diet and
energy products will be focused on consumers of national mass market accounts
and VMS will be focused on national chain and independent health and natural
food store consumers. The Company's geographically diverse network of wholesale
distributors allows it to achieve rapid and broad distribution for new product
launches. Over ten new products have already been introduced in 2003.

     (iii) Increase Penetration of Foreign Markets -- Management believes there
are opportunities for the Company to expand its presence in foreign markets. The
Company's international sales force is supported by a

                                        3
<PAGE>

network of approximately 60 overseas distributor organizations, serving over 70
foreign countries. Approximately $12.9 million or 8.8%, of the Company's net
sales in 2002 were derived from international sales.

     (iv) Improve Manufacturing and Operational Efficiencies -- As previously
disclosed, in fiscal 2002, the Company sold several non-strategic businesses and
substantially completed the consolidation of its manufacturing and distribution
facilities. In addition, the Company implemented numerous cost saving
initiatives by reducing headcount and streamlining operations. The Company
believes these decisions will have a positive impact on its operations in fiscal
2003.

     There can be no assurance that the Company will successfully implement all
or any part of its business strategy.

INDUSTRY

     Based on estimates in recent market reports, management believes the U.S.
nutrition industry for vitamins, minerals and other supplements, including
sports nutrition products and nutritionally enhanced foods and diet products,
was approximately $53 billion in 2001. Of this total, supplement sales,
including vitamin, herbs and minerals, accounted for approximately $18 billion.
The supplements category grew significantly during the late 1990's due in part
to widespread publicity surrounding the purported benefits of herbs such as
echinacea, garlic, ginseng, gingko, saw palmetto and St. John's Wort.

     Despite the aforementioned growth, however, industry sources indicate that
the growth rate in the nutritional supplement industry slowed significantly in
1999 through 2001. In 2001, industry sources indicated that vitamin sales grew
less than 1%, minerals grew 3%, herbal supplements grew 1.4%, specialty
supplements grew 7%-10% and sports nutrition and weight management grew 13%. For
2001, total supplement sales grew 4.2% and the overall nutrition industry grew
6.7%. Management believes this slowdown was partially due to a decline in sales
at the retail level of St. John's Wort and other herbal products, largely as a
result of media attention and a more generalized industry-wide slowing of growth
across most product categories.

     In addition, while public awareness of the positive effects of vitamins and
nutritional supplements on health was heightened by widely publicized reports of
scientific findings supporting such claims during 1997-1998, management believes
that negative media attention focusing on questions of efficacy, safety and
label claim content have had a significant adverse impact on the supplement
industry during 2000-2002. Management believes that the slowdown in growth in
the nutritional supplement industry has also been caused by the lack of a new
"blockbuster" product and increasing competition, including intense private
label expansion.

     Management remains cautiously optimistic about potential growth of certain
segments of the nutritional supplement industry due, in part, to the presence of
the following trends: (i) favorable demographic trends towards older Americans,
who are more likely to be health conscious as they experience middle age and
older age health issues; (ii) product introductions in response to new
scientific research findings supporting the positive health effects of certain
nutrients; (iii) increased consumer interest in specific supplements; and (iv)
the heightened understanding and awareness of healthier lifestyles and a
connection between diet and health.

PRODUCTS

     The Company develops, manufactures and markets a highly diversified array
of high quality products in many product categories. The Company's product line
includes: vitamins, minerals and specialty supplements, sports nutrition
products and diet and energy products, marketed under the Twinlab, Ironman
Triathlon, "Fuel" and other brand names, an extensive line of herbal supplements
and phytonutrients under the Nature's Herbs brand name and a full line of herbal
teas under the Alvita brand name. The Company is also engaged in the private
label manufacture of products for a limited number of third parties.

     Among the innovative products launched by Twinlab in 2002 were Power Pro
Fuel 50, Xtreme Anabolic Fuel, Diet Fuel Weight Loss Drink, Dia-Balance, Carp-L
Care and Glucosamine Chondroitin MSM with

                                        4
<PAGE>

Natural Astaxanthin. Additionally, the Company significantly improved the
formulas of its leading products to improve efficacy including Daily One Caps,
Infant Care and Pre-Natal Care. These launches are strategically aligned with
the Company's strategy to develop channel-specific products to optimize sales
and best serve key consumer targets.

     The Company's products are generally available in a variety of forms,
including, capsules, tablets, powders and liquids to accommodate a variety of
consumer preferences. The Company targets a broad array of health conscious
consumers, with particular emphasis on consumers who utilize nutritional
supplements in their daily diet and who prefer premium quality ingredients in a
variety of dosages and delivery methods.

     VMS products sold include multivitamins such as Daily One Caps and Animal
Friends, single-entity vitamins such as B-1 Caps and Mega E Softgels, minerals
such as Calcium Citrate Caps and Magnesium Caps and amino acids such as
L-Glutamine Caps and Mega L-Carnitine Tabs. Twinlab's specialty supplements
consist of a broad assortment of products formulated to meet the needs of
consumer concerns. Specialty supplements are primarily targeted to sophisticated
users of health related products who primarily purchase their supplements in
health and natural food stores.

     Sports nutrition products sold consist of a wide variety of nutritional
supplements designed for and targeted to active lifestyle consumers. Sports
nutrition products include Ultra 3 Growth Fuel, Power Pro Fuel 50 and Xtreme
Anabolic Fuel.

     Diet and energy products consist of four distinct brands: Ripped Fuel, Diet
Fuel, Metabolift and Energy Fuel. These brands have unique (ephedra free)
formulas that help individuals achieve their personal physical goals. Ripped
Fuel is targeted toward active males who are trying to lose weight and improve
their appearance, Diet Fuel is for younger active females who want to get toned,
Metabolift is for females who want to lose weight and Energy Fuel is for those
who are seeking to gain positive energy.

     The Company believes that its sports nutrition and diet and energy products
serve to increase the Company's brand awareness among customers who, as they
grow older, are likely to shift their buying patterns to include the Company's
vitamins, herbs and other nutraceuticals.

     Through its Nature's Herbs brand, the Company produces an extensive line of
herbal supplement and phytonutrient products, many of which offer natural
alternatives to over-the-counter medications. The Company's herbal products
include single herbs, such as saw palmetto, garlic, ginseng and golden seal;
traditional combinations, such as echinacea-golden seal; standardized extracts,
such as St. John's Wort Power, Gingko Power and Bilberry Power sold under the
Nature's Herbs POWER HERBS(R) brand name; and natural health care product
formulations, such as Allerin and Coldrin. The Company manufactures and supplies
herbal supplements to Wal-Mart for its Spring Valley private label line.

     Through its Alvita product line, the Company offers herb teas in both
single use bags and bulk. Created in 1922, Alvita is one of the nation's oldest
herbal tea brands. The Company purchases tea in bulk form, formulates blends of
natural herb teas and designs the packaging for its products. Alvita's teas are
currently blended and packaged at the Utah Facility and by an independent
contractor. Alvita teas include Peppermint Leaf, Chamomile, Echinacea, Golden
Seal, Ginger and Senna Leaf, as well as new-age blends such as Chinese Green
Tea, available in a variety of citrus flavors.

PRODUCT DEVELOPMENT

     The Company closely monitors consumer trends and scientific research, and
has consistently introduced innovative products and programs in response
thereto. The Company regularly studies scientific, health and nutrition
periodicals, including the New England Journal of Medicine and the Journal of
the American Medical Association, in order to generate ideas for new product
formulations. The Company intends to continue developing new products and
programs in the future through internal development, strategic third party
alliances and licensing agreements. Several new products were introduced in
2002, including Power Pro Fuel 50, Xtreme Anabolic Fuel, Diet Fuel Weight Loss
Drink, Dia-Balance, Carp-L Care and Glucosamine Chondroitin MSM with Natural
Astaxanthin. The Company's research and development expenses were approximately
$2.0 million, $2.7 million and $2.5 million in 2002, 2001 and 2000,
respectively.

                                        5
<PAGE>

SALES AND DISTRIBUTION

     The Company sells its products primarily through a network of distributors,
which service approximately 11,000 health and natural food stores throughout the
country and other selected retail outlets. Sales to domestic distributors
represented approximately 54.2% of the Company's net sales in 2002. The
Company's distributor customers include Tree of Life, United Natural Foods,
Inc.("UNFI"), Nature's Best Distributors and other distributors that supply
retailers of vitamins, herbs and other nutritional supplements. Management
believes that it sells its products to every major domestic nutritional
supplement distributor servicing health and natural food stores and is generally
the largest independent supplier of nutritional supplements to such
distributors.

     Several of the Company's distributors, such as Tree of Life and UNFI, are
national in scope, but most are regional in nature and operate one or more
localized distribution centers. Health and natural food store retailers
typically place orders with, and are supplied directly by, the Company's
distributors. In the past ten years, the Company has not lost a major
distributor customer other than through consolidation with an existing customer
of the Company or the cessation of distribution activities by a distributor.

     Tree of Life, Wal-Mart and UNFI accounted for approximately 18%, 14% and
13%, respectively, of the Company's net sales in 2002. No other single customer
accounted for more than 10% of the Company's net sales in 2002. The largest
retail organization in the health and natural food store channel that sells the
Company's products is GNC, with over 4,200 stores.

     The Company's customers among mass market retailers include Wal-Mart,
Albertson's, Rite Aid Corporation, Walgreens, CVS, Kroger and Target.

     Approximately $12.9 million, or 8.8%, of the Company's net sales in 2002
were derived from international sales. The Company presently has distribution
agreements covering many western European countries including Great Britain,
France, Belgium, the Netherlands and the Scandinavian countries; Latin American
countries including Mexico, Chile and Argentina; Middle Eastern countries
including Israel and Saudi Arabia; and several other countries in Asia.

ADVERTISING AND MARKETING

     The Company's advertising expenditures were approximately $14.1 million in
2002, $14.9 million in 2001, and $16.8 million in 2000. The Company's
advertising strategy is to generate consumer awareness and trial of new products
in addition to increasing loyalty and generating trial of its existing brands.
The communication focuses on building brand equity and demonstrating unique
and/or superior benefits to consumers.

     Print advertisements continue to be an integral part of the Company's
advertising efforts. During 2002, the Company advertised in consumer magazines
and newspapers such as Maxim, GQ, Flex, Prevention, Physical, Muscular
Development, Better Nutrition and Cosmopolitan.

     Other marketing and advertising programs conducted by the Company include
participation in or sponsorship of sporting events such as the Ironman Triathlon
World Championship in Hawaii, and bodybuilding shows, including The Arnold
Classic, The Olympia and Fitness America. In addition, the Company promotes its
products at major industry trade shows and through in-store point of sale
materials. The Company also, from time to time, engages athletic personalities
as well as scientists to communicate on the Company's behalf with the trade and
the public and to promote the Company's products.

     The Company's internet presence includes various sites on the World Wide
Web, including http://www.twinlab.com, which provides an overview of the
Company. The site also provides a list of retailers carrying the Company's
products and is "linked" to other Company sites, including those of the
Company's herbal supplement and teas business http://www.herbalvillage.com.
Information and other materials contained in any of the Company's World Wide Web
sites shall not be deemed to be a part of or incorporated by reference into this
Annual Report on Form 10-K.

     In addition, the Company's products are sold through many third-party
websites including vitaminshoppe.com and drugstore.com. These third-party
websites are not affiliated with the Company in any manner whatsoever.

                                        6
<PAGE>

CUSTOMER SALES SUPPORT

     The Company's customer relationships at the wholesale and retail levels are
based upon the Company's long-standing commitment to customer service. The
Company's sales force consists of approximately 40 dedicated sales professionals
who work to gain better placement and additional shelf space for Twinlab
products and to stay abreast of customer needs. These sales representatives are
assigned to specific territories located within the continental United States.
These sales people work with distributors and retailers to enhance knowledge of
the Company's products and to maximize shelf exposure for Twinlab products. The
Company services its mass market accounts through a full-time in-house staff of
sales professionals and a nationwide broker network. The Company, through its
in-house creative services team, also designs, produces and supplies a broad
range of marketing literature, including brochures, pamphlets and in-store
display materials to help educate retailers and consumers as to the benefits of
the Company's products.

     The Company maintains in-house consumer service and customer sales support
departments to respond to inquiries concerning product applications, background
data, ingredient compositions and the efficacy of products. The consumer service
departments are staffed by full-time nutrition experts and other specially
trained employees.

MANUFACTURING AND PRODUCT QUALITY

     Most of the Company's products are manufactured at the Company's 168,000
square foot FDA-registered facility located in American Fork, Utah (the "Utah
Facility") and, through January 2003, at the Company's 72,000 square foot
manufacturing facility located in Ronkonkoma, New York (the "Ronkonkoma
Facility"). The Company's products are packaged at and distributed from the Utah
Facility and, through December 2002, at the Company's 106,515 square foot
warehousing and packaging facility located in Bohemia, New York (the "Bohemia
Facility"). On July 24, 2002, the Company announced a comprehensive
restructuring of its operations that resulted in the consolidation of the
Ronkonkoma and Bohemia Facilities into the Company's Utah Facility. The
consolidation of the facilities has been substantially completed during 2002 and
is anticipated to be completed during the first half of 2003. In January 2003,
the Company agreed with its landlord to an early termination of the Bohemia
Facility lease. The Ronkonkoma Facility is being actively marketed for sale. The
Company's manufacturing facilities provide the Company with a high level of
quality control. The Company actively upgrades its facilities and enhances its
manufacturing capabilities through new equipment purchases and technological
improvements. Management believes that the Company's Utah Facility will be
sufficient to enable the Company to meet sales demand for the foreseeable
future. Management believes that the Utah Facility is among the most advanced in
the nutritional supplement industry. See Item 2 "Properties."

     The Company's modern manufacturing operations feature the highest quality
blending, filling and packaging capabilities, which enable the Company to offer
quality and consistency in formulation and dosage forms. The Company operates
flexible manufacturing lines which enable it to efficiently and effectively
shift output among various products as dictated by customer demand. In addition,
the Company utilizes outside contractors for the hydration and bottling of its
single-serving sports drink products and its food bar products and in 2003 has
outsourced the production of many of its powder and liquid products under the
Company's supervision and specifications.

     In 2003, the Company was presented with ConsumerLab.com's Consumer
Satisfaction Award for receiving the highest ratings among retail brands in its
"Supplement Users Survey." The results of the survey showed that 83 percent of
Twinlab users rated their overall satisfaction with Twinlab products as
"excellent" or "very high."

     In 2000, the National Nutritional Foods Association ("NNFA") provided
Twinlab's manufacturing facilities with an "A" rating. An "A" rating indicates
the Company has excellent compliance with the Good Manufacturing Practices
promulgated by the NNFA, a leading industry trade association.

     The Company sources its raw material needs from many different suppliers,
including some of the largest pharmaceutical and chemical companies in the
world. The Company's raw materials and packaging supplies

                                        7
<PAGE>

are readily available from multiple suppliers and the Company is not dependent
on any single supplier for its needs. No single supplier accounted for more than
10% of the Company's total purchases in 2002.

     The Company believes that it has established a reputation for superior
product quality based on the premium nature of its products. All capsule and
tablet products manufactured by the Company are visually inspected before being
packaged. Moreover, the Company's products undergo comprehensive quality control
testing procedures from the receipt of raw materials to the release of the
packaged product. The Company utilizes real-time computerized monitoring of its
manufacturing processes to ensure proper product weights and measures. In
addition, the Company maintains in-house laboratories with state-of-the-art
testing and analysis equipment where the Company performs most of its testing,
including stability tests, active component characterization utilizing
thin-layer and high-pressure liquid chromatography, and UV visible and infrared
spectrometry. The Company contracts with independent laboratories to perform the
balance of its testing requirements. A team of full-time quality assurance
professionals regularly conducts a wide variety of visual and scientific tests
on finished products, and samples of raw materials and finished products are
generally retained for quality control purposes.

     The Company has a strong commitment to maintaining the quality of the
environment. The Company's plastic and corrugated cardboard containers are
recyclable. In addition, the Company has removed most solvents from its
production processes (using natural, environmentally-safe alternatives). The
Company believes it is in material compliance with all applicable environmental
regulations.

     During 2001, the Company completed the implementation of a corporate-wide
Enterprise Resource Planning ("ERP") system which is providing enhanced delivery
of management information and has strengthened the Company's financial
processes.

COMPETITION

     Vitamins and nutritional supplements are sold primarily through the
following channels of distribution: health and natural food stores, mass market
retailers (drug store chains, supermarkets and other mass merchandisers) and
direct sales channels (including network marketing, catalog and internet
distribution).

     The Company's principal competitors in the health and natural food store
channel include Nutraceutical International Corporation, Weider Nutrition
International, Inc., Nature's Way Products, Inc., Natrol, Inc., Nature's Plus
Inc., and Solgar Vitamin and Herb Company. Private label products of the
Company's retail customers also provide competition to the Company's products.
For example, a substantial portion of GNC's vitamin and mineral supplement
offerings are products offered under GNC's own private label.

     The Company believes that it competes favorably with other nutritional
supplement companies because of its comprehensive line of premium products,
premium brand name, commitment to quality, ability to introduce innovative
products, strong and effective sales force and distribution network, and
targeted advertising and promotional support.

     In the mass market channel of distribution, the Company competes with major
private label and broadline brand manufacturers, including, Pharmavite Corp.,
Rexall Sundown, Inc., NBTY, Inc. and Leiner Health Products Inc., most of which
are larger and have access to greater resources than the Company. Several major
pharmaceutical companies including Wyeth, Warner-Lambert and Bayer, all of whom
have substantially greater financial and personnel resources than the Company,
have also introduced proprietary branded lines of supplements into the mass
market channel. The Company believes it competes on the basis of customer
service, product quality and marketing support. The Company believes that it
competes favorably with other companies because of its (i) sales and marketing
support, (ii) customer service and (iii) reputation as being a supplier of
premium quality products.

                                        8
<PAGE>

REGULATORY MATTERS

GOVERNMENT REGULATION

     The manufacturing, processing, formulating, packaging, labeling and
advertising of the Company's products are subject to regulation by several
federal agencies, including the United States Food and Drug Administration (the
"FDA"), the Federal Trade Commission (the "FTC"), the United States Department
of Agriculture and the Environmental Protection Agency. These activities are
also regulated by various agencies of the states, localities and foreign
countries in which the Company's products are manufactured, distributed and
sold. The FDA, in particular, regulates the formulation, manufacture and
labeling of vitamin and other nutritional supplements in the United States while
the FTC governs marketing and advertising claims.

     On October 25, 1994, the President of the United States of America signed
into law the Dietary Supplement Health and Education Act of 1994 ("DSHEA"). This
law revised the provisions of the Federal Food, Drug, and Cosmetic Act (the
"FFDC Act") concerning the composition and labeling of dietary supplements. The
legislation created a statutory class of "dietary supplements." This class
includes vitamins, minerals, herbs, amino acids and other dietary substances for
human use to supplement the diet, and the legislation grandfathers, with certain
limitations, dietary ingredients on the market before October 15, 1994. A
dietary supplement which contains a new dietary ingredient, one not on the
market before October 15, 1994, requires evidence of a history of use or other
evidence of safety establishing that it will reasonably be expected to be safe.
The substantial majority of the products marketed by the Company are classified
as dietary supplements under the FFDC Act.

     Both foods and dietary supplements are subject to the Nutrition Labeling
and Education Act of 1990 (the "NLEA"), which prohibits the use of any health
claim for foods, including dietary supplements, unless the health claim is
supported by significant scientific agreement and is either pre-approved by the
FDA or the subject of substantial government scientific publications and a
notification to the FDA. To date, the FDA has approved the use of only a limited
number of health claims for dietary supplements. However, among other things,
the DSHEA amends, for dietary supplements, the NLEA by providing that
"statements of nutritional support" may be used in labeling for dietary
supplements without FDA preapproval if certain requirements, including prominent
disclosure on the label of the lack of FDA review of the relevant statement,
possession by the marketer of substantiating evidence for the statement and
post-use notification to the FDA, are met. Such statements, commonly referred to
as "structure function" claims, may describe how particular nutritional
supplements affect the structure, function or general well-being of the body
(e.g. "promotes your cardiovascular health").

     The Company believes it is in material compliance with FDA labeling
regulations. On February 28, 2003, the Company received, along with numerous
other companies in the industry, a "warning letter" from the FDA contending that
certain structure/function claims made on the Company's website with respect to
its Energy Fuel, Diet Fuel and Ultimate Diet Fuel products are not substantiated
by the scientific data available to the FDA. The claims at issue relate to the
promotion and preservation of lean muscle mass. The Company disagrees with the
position of the FDA on this issue and has submitted a response to the FDA
setting forth the scientific substantiation that it believes supports the claims
at issue.

     Advertising and label claims for dietary supplements and conventional foods
have been regulated by state and federal authorities under a number of disparate
regulatory schemes. There can be no assurance that a state will not interpret
claims presumptively valid under federal law as illegal under that state's
regulations, or that future FDA regulations or FTC decisions will not restrict
the permissible scope of such claims.

     Governmental regulations in foreign countries where the Company plans to
commence or expand manufacturing or sales may prevent or delay entry into the
market or prevent or delay the introduction, or require the reformulation or
relabeling of certain of the Company's products. Compliance with such foreign
governmental regulations is generally the responsibility of the Company and the
Company's distributors for those countries. These distributors are independent
contractors over whom the Company has limited control.

     As a result of the Company's efforts to comply with applicable statutes and
regulations, the Company has from time to time reformulated, eliminated or
relabeled certain of its products and ingredients and revised

                                        9
<PAGE>

certain provisions of its sales and marketing program. The Company cannot
predict the nature of any future laws, regulations, interpretations or
applications, nor can it determine what effect additional governmental
regulations or administrative orders, when and if promulgated, would have on its
business in the future. They could, however, require the reformulation of
certain products to meet new standards, the recall or discontinuance of certain
products not capable of reformulation, additional record keeping, expanded
documentation of the properties of certain products, expanded or different
labeling, and/or scientific substantiation. Any or all of such requirements
could have a material adverse effect on the Company's results of operations and
financial condition.

     The Company's Utah Facility is registered with the FDA as a manufacturer of
OTC drugs and is subject to periodic inspection by the FDA.

     Compliance with the provisions of national, state and local environmental
laws and regulations has not had a material adverse effect upon the capital
expenditures, earnings, financial position, liquidity or competitive position of
the Company.

     On February 28, 2003, the HHS announced a series of actions that will
potentially regulate the manner in which products containing the ingredient
ephedra are marketed, including a thirty-day comment period to create a record
to support potential restrictions that could range from label requirements to a
ban of the ingredient.

     See "Factors Affecting Future Performance -- Ma Huang" and Item 3. "Legal
Proceedings."

EMPLOYEES

     At February 28, 2003, the Company employed 486 persons, of which 182 were
involved in executive, sales, marketing and administrative activities. The
balance of the Company's employees were engaged in production, packaging and
shipping activities. None of the Company's employees are covered by a collective
bargaining agreement and management considers relations with its employees to be
good.

TRADEMARKS AND PATENTS

     The Company owns well over 200 trademarks registered with the United States
Patent and Trademark Office and/or similar regulatory authorities in many other
countries for its Twinlab, Nature's Herbs, Alvita and the Fuel family of
trademarks, and has rights to use other marks material to its business. The
Ironman Triathlon trademark is licensed to the Company. Federally registered
trademarks have perpetual life, provided they are renewed on a timely basis and
used properly as trademarks, subject to the rights of third parties to seek
cancellation of the marks. The Company regards its trademarks and other
proprietary rights as valuable assets and believes that they have significant
value in the marketing of its products. The Company vigorously protects its
trademarks against infringement. The Company currently owns one patent and is a
licensee of several other patents.

FACTORS AFFECTING FUTURE PERFORMANCE

AVAILABILITY OF FINANCING

     The Company's Revolving Credit Facility expires on March 29, 2004. The
Company intends to enter into negotiations to extend the term of the Revolving
Credit Facility or to enter into an alternative borrowing arrangement which
would provide for future borrowings. There can be no assurance, however, that by
March 29, 2004, an extension of the Revolving Credit Facility will be
successfully negotiated or the Company will be able to enter into an alternative
borrowing arrangement on terms favorable to the Company. The absence of an
extension of the Revolving Credit Facility or alternative borrowing arrangement
would have a material adverse effect on the financial condition of the Company.
The Company anticipates that borrowings outstanding under the Revolving Credit
Facility will be classified as a current liability as of March 31, 2003.

     The Company was in default of certain financial covenants relating to the
mortgage payable during fiscal 2002 for which a waiver was obtained through
April 3, 2003. The Company will be subject to the financial

                                        10
<PAGE>

covenant tests for the quarter ended June 30, 2003 and does not currently
anticipate being in compliance. Accordingly, the mortgage payable has been
classified as a current liability as of December 31, 2002. The Company has
entered into negotiations with the lender to amend the mortgage agreement,
however, there can be no assurance that an amendment will be successfully
negotiated. In the event that the Company is unable to amend the mortgage
agreement, the Company will be required to repay the mortgage in order to avoid
a cross-default under the terms of the Revolving Credit Facility.

RESTRICTIONS IMPOSED BY TERMS OF THE COMPANY'S INDEBTEDNESS

     The Company's borrowing arrangements impose upon the Company certain
financial and operating covenants, including, among others, requirements that
the Company maintain certain financial ratios and satisfy certain financial
tests, limitations on capital expenditures and restrictions on the ability of
the Company to incur debt, pay dividends or take certain other corporate
actions, all of which may restrict the Company's ability to expand or to pursue
its business strategies. Changes in economic or business conditions, results of
operations or other factors could in the future cause a violation of one or more
covenants in the Company's debt instruments.

MA HUANG

     A number of the Company's products include alkaloids from the herb known as
"Ma Huang," also known as ephedra, which contains naturally-occurring ephedrine
alkaloids. Some of the Company's products also contain caffeine or other central
nervous system stimulants. Products containing Ma Huang accounted for
approximately 21% of the Company's net sales in 2002.

     Ma Huang has been the subject of extensive negative publicity in the United
States and other countries relating to alleged harmful or adverse effects. This
publicity has led to recent congressional hearings addressing the safety of Ma
Huang and several state governments have passed legislation regulating the sale
of products that contain Ma Huang. Recently, the Suffolk County (New York)
legislature passed a bill that bans retail sales of ephedra products in Suffolk
County. Other jurisdictions have proposed similar legislation. The current media
and political attention to Ma Huang is likely to lead to further legislation
related to the sale of products containing Ma Huang including the possible ban
of sale of these products.

     On February 28, 2003, the HHS announced a series of actions that will
potentially regulate the manner in which products containing the ingredient
ephedra are marketed, including a thirty-day comment period to create a record
to support potential restrictions that could range from label requirements to a
ban of the ingredient. By letter dated March 13, 2003, the Committee on Energy
and Commerce of the U.S. House of Representatives requested certain information
from the Company related to, among other things, the sales history of its
products containing ephedra, any adverse health events associated with such
products, scientific studies related to such products and information related to
certain of the Company's non-ephedra products. The Company has provided a
comprehensive response to the Committee.

     The Company has been named as a defendant in a number of pending lawsuits,
alleging that its Ma Huang products caused injury, death and/or damages, as well
as certain proceedings seeking class action certification for consumer fraud
related to the sale of such products. The Company is vigorously defending these
lawsuits. However, the Company is incurring, and expects to incur, significant
costs associated with this litigation activity. These costs are due in part to:
(i) greater costs for insurance premiums; (ii) significant self-insured
retention limits for claims alleging injuries after December 31, 2000; and (iii)
legal fees that are not covered under certain of the Company's insurance
policies. In particular, several of the class actions, as economic injury cases,
are not generally covered by insurance. At least one of the Ma Huang lawsuits
involving a claim of wrongful death is not currently covered by insurance.

     The Company believes in the safety and efficacy of its products that
contain Ma Huang based on the scientific evidence. Nevertheless, as a result of
the increasing costs that are negatively impacting the profitability of these
products, coupled with consumer demand for non-ephedra weight loss products, the
Company decided to discontinue the sale of products that contain Ma Huang
effective on or about March 31, 2003. The Company expects to experience a
reduction in net sales due to the discontinuation of its products
                                        11
<PAGE>

that contain Ma Huang. Based upon anticipated costs savings expected to be
achieved, however, the Company does not believe that the decision to discontinue
the sale of products that contain Ma Huang should have a material adverse effect
on the profitability of the Company. The Company is committed to the Diet and
Energy category, specifically its Diet Fuel, Ripped Fuel and Metabolift brands,
and has launched a line of patented and clinically tested ephedra-free products.
See Item 3, "Legal Proceedings."

DEPENDENCE ON WHOLESALE DISTRIBUTORS AND CUSTOMERS

     The Company's success depends in part upon its ability to attract, retain
and motivate a large base of wholesale distributors and its ability to maintain
a satisfactory relationship with Tree of Life, UNFI and Wal-Mart. The loss of
Tree of Life or UNFI as distributors or Wal-Mart as a customer, or the loss of a
significant number of other distributors or customers, or a significant
reduction in purchase volume by Tree of Life, UNFI, Wal-Mart or such other
distributors or customers, for any reason, could have a material adverse effect
on the Company's results of operations and financial condition.

COMPETITION

     The business of developing, manufacturing and selling vitamins, minerals,
herbs, sports nutrition products, nutritional supplements and other
nutraceuticals is highly competitive in all channels of distribution. There are
numerous companies selling products competitive to the Company's products to
mass merchandisers, drug store chains, independent drug stores, supermarkets,
health and natural food stores, as well as through catalogs, the internet and
network marketing. Certain of the Company's competitors are substantially larger
and have greater financial resources than the Company. For example, GNC,
historically one of the Company's largest retail accounts, is owned by Royal
Numico N.V, which also owns Rexall Sundown, Met RX and Worldwide Sport
Nutrition, each of which is a competitor to the Company.

ABSENCE OF CLINICAL STUDIES AND SCIENTIFIC REVIEW; EFFECT OF PUBLICITY

     While the Company conducts extensive quality control testing on its
products, the Company does not regularly conduct or sponsor clinical studies on
its products. The Company's products consist of vitamins, minerals, herbs and
other ingredients that the Company regards as safe when taken as suggested by
the Company. However, because the Company is highly dependent upon consumers'
perception of the safety and quality of its products as well as similar products
distributed by other companies (which may not adhere to the same quality
standards as the Company), the Company could be adversely affected in the event
any of the Company's products, or any similar products distributed by other
companies, should prove or be asserted to be harmful to consumers. In addition,
because of the Company's dependence upon consumer perceptions, adverse publicity
associated with illness or other adverse effects resulting from consumers'
failure to consume the Company's products as suggested by the Company or other
misuse or abuse of the Company's products or any similar products distributed by
other companies could have a material adverse effect on the Company's results of
operations and financial condition.

     In addition, while public awareness of the positive effects of vitamins and
nutritional supplements on health was heightened by widely publicized reports of
scientific findings supporting such claims during 1997-1998, management believes
that negative media attention focusing on questions of efficacy, safety and
label claim content have had a significant adverse impact on the nutritional
supplement industry during 2000-2002. The low level of sales growth in the
nutritional supplement industry during 2000-2002 has also been caused by the
lack of new "blockbuster" products and increasing competition, including intense
private label expansion. There can be no assurance that these factors will not
be present in the future.

AVAILABILITY OF RAW MATERIALS

     Substantially all of the Company's herbal supplements and herb teas contain
ingredients that are harvested by and obtained from third-party suppliers, and
many of those ingredients are harvested internationally and only once per year
or on a seasonal basis. An unexpected interruption of supply, such as a harvest
failure, could cause the Company's results of operations derived from such
products to be adversely affected.

                                        12
<PAGE>

Although the Company has generally been able to raise its prices in response to
significant increases in the cost of such ingredients, the Company has not
always in the past been, and may not in the future always be, able to raise
prices quickly enough to offset the effects of such increased raw material
costs.

UNCERTAINTY RELATED TO ACQUISITIONS AND DIVESTITURES

     Acquisitions and divestitures involve a number of risks that could
adversely affect the Company's operating results, including the diversion of
management's attention, the assimilation of operations and personnel, the
amortization of acquired intangible assets and the potential loss of key
employees. There can be no assurance that any acquired product lines or
businesses will be successfully integrated or that such product lines or
businesses, or the sale or divestiture of any business, will ultimately have a
positive impact on the Company, its financial condition or operations.

ITEM 2.  PROPERTIES

     The Company owns the Ronkonkoma and Utah facilities. The Company leases
approximately 30,120 square feet of space in a modern office building in
Hauppauge, New York which serves as its executive and administrative offices.
The Company also leases 26,300 square feet of warehouse space and 5,000 square
feet of office space in Ronkonkoma, New York. Effective January 31, 2003, the
Company and its landlord agreed to an early termination of the lease relating to
the Bohemia Facility. The Company believes that its facilities and equipment
generally are well maintained and in good operating condition. Management
believes that the Company's Utah Facility, coupled with its leased space in
Hauppauge will be sufficient to enable the Company to meet administrative,
manufacturing, warehousing, distribution and sales demand for the foreseeable
future. See Item 1 "Manufacturing and Product Quality".

ITEM 3.  LEGAL PROCEEDINGS

     The Company, like other manufacturers and retailers of products that are
ingested, faces an inherent risk of exposure to product liability claims in the
event that, among other things, an injury occurs during or after the use of its
products. The Company may be subjected to various product liability claims,
including, among others, that its products are unsafe, inadequately researched,
make false or misleading claims, contain contaminants or include inadequate
instructions as to use or inadequate warnings concerning side effects and
interactions with other substances. While such claims to date have not been
material to the Company, there can be no assurance that product liability claims
or the adverse publicity associated with any such claims will not have a
material adverse effect on the Company. The Company carries insurance to cover
the product liability risks associated with substantially all of its products,
however, there can be no assurance that such insurance will be adequate to cover
the risks associated with the business or that such insurance will continue to
be available at a reasonable cost, or if available, will be adequate to cover
liabilities. Indeed, such insurance has become increasingly expensive for any
significant level of coverage.

     The Company has been named as a defendant in a number of pending product
liability lawsuits that the Company is vigorously defending. In reviewing its
potential exposure for product liability matters, the Company considers, among
other factors, recent and historical settlements and judgments, if any, the
incidence and trend of recent and historical claims, the nature of any alleged
injuries, the amount and availability of insurance coverage and the status of
litigation proceedings and settlement discussions.

     Based on a current analysis prepared by management, with the assistance of
actuarial consultants, the Company has estimated a range of potential liability
in an amount it deems reasonable in connection with certain product liability
matters involving ephedra. Accordingly, the Company has established a reserve of
$3.8 million for product liability indemnity claims that is primarily based on
known claims and an estimate of unasserted claims involving ephedra that are
probable of assertion and can be reasonably estimated as of the balance sheet
date. Management expects that any payments relating to these matters will occur
over a number of years and has not discounted the potential liability as of
December 31, 2002, because the timing of any payments are not fixed or reliably
determinable at the present time. This reserve assumes continuing insurance for
ephedra related personal injury actions, albeit with a significant retention and
limited total coverage.

                                        13
<PAGE>

     Because of the uncertainties related to the number of potential future
claims, ultimate settlement amounts, dismissal of such claims or any adverse
judgments, it is difficult to obtain precise estimates of the Company's ultimate
liability for such claims. It is possible that the total exposure to product
liability claims may be less than or greater than an amount within the Company's
estimated range of potential liability due to changes in facts or circumstances
after the date of each estimate. As additional experience is gained regarding
the Company's product liability claims, possible settlement discussions,
litigation history and insurance coverage, the Company will reassess its
potential liability and revise the amount of its reserve as appropriate.

     There can be no assurance that the impact of the Company's self-insured
retention limits in the event of multiple damage awards or settlements, or any
award of damages in excess of the Company's insurance coverage limits (which
limits are significantly lower than in prior periods) or any materially
increased legal costs, will not have a material adverse effect on the financial
condition or results of operations of the Company. In addition, one or more
large punitive damage awards, which are generally not insurable, could have a
material adverse effect on the financial condition and results of operations of
the Company.

     Further, the Company's 2003 comprehensive general liability ("CGL")
insurance policy for non-Ma Huang products has a significantly higher
self-insured retention limit than in 2002 and the herbal product Kava-Kava is
expressly excluded from coverage under the 2003 policy. The Company has received
one Kava-Kava related wrongful death complaint in 2003. The Company plans to
vigorously defend itself against this action and is investigating whether any of
its CGL policies apply to this claim. If a CGL policy is not applicable to this
claim, a finding of liability and damages could have a material adverse effect
on the results of operation and financial condition of the Company. The Company
is unable to predict the outcome of this matter or to estimate a range of
potential loss. Accordingly, the effect, if any, that such action may have on
the Company's consolidated financial position or results of operations cannot be
determined at this time.

SECURITIES LAW LITIGATION

     In March 2001, the Company announced that it reached an agreement in
principle to settle a shareholder securities class action lawsuit that was
pending against the Company and certain of its officers and directors before the
United States District Court for the Eastern District of New York (the "Court").
The lawsuit alleged that the Company and the other defendants violated the
securities laws by making material misstatements and failing to state material
facts about the Company's business and financial condition, among other things,
in securities act filings and public statements. The class of plaintiffs
included all buyers of the Company's stock from April 8, 1998 through February
24, 1999, other than the defendants and certain related parties. The Court
approved the settlement in February 2002. Pursuant to the settlement, the
Company paid $26 million, all of which was covered by the Company's insurance.

     A series of shareholder securities class action lawsuits were filed in late
2000 and are pending before the Court against the Company and certain of its
officers and directors. The plaintiffs allege that the Company and the other
defendants violated the securities laws by making material misstatements and
failing to state material facts about the Company's business and financial
condition, among other things, in securities act filings and public statements.
The alleged class of plaintiffs includes all buyers of the Company's stock from
April 27, 1999 to November 15, 2000, other than the defendants and certain
related parties. A derivative action against certain of the Company's directors
was filed in June of 2001. The derivative action alleges that the named
directors violated certain fiduciary duties and alleges mismanagement, based
upon the facts alleged in the two securities class actions described above. The
Company believes that the claims are without merit and intends to vigorously
defend against the securities action and the derivative action. The Company has
filed a motion to dismiss the securities action and the derivative action,
however, the Company is unable to predict the outcome of these uncertainties or
to estimate a range of potential losses. Accordingly, the effect, if any, that
such actions may have on the Company's consolidated financial position or
results of operations cannot be determined at this time.

                                        14
<PAGE>

OTHER LEGAL ACTIONS

     The Company is presently engaged in various other legal actions that arise
in the ordinary course of business, including product liability, breach of
contract claims and employment related matters. Although ultimate liability
cannot be determined at the present time, the Company believes that the amount
of any such liability, if any, from these other actions, after taking into
consideration the Company's insurance coverage, will not have a material adverse
effect on its results of operations or financial condition.

ITEM 4.  SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

     During the fourth quarter of fiscal year 2002, no matters were submitted to
a vote of security holders of the Company.

                                        15
<PAGE>

                                    PART II

ITEM 5.  MARKET FOR REGISTRANT'S COMMON EQUITY AND RELATED STOCKHOLDER MATTERS

     The Common Stock of the Company was traded on the NASDAQ National Market
until September 19, 2002 and was traded on the NASDAQ Small Cap Market until
December 16, 2002. Effective December 17, 2002, the Common Stock of the Company
is traded on the OTC Bulletin Board. On March 24, 2003, the last reported sales
price of the Company's Common Stock as reported on the OTC Bulletin Board was
$0.11. As of March 24, 2003, there were 233 holders of record of the Company's
Common Stock. The following table shows for the periods indicated the high and
low sale prices for the Common Stock as reported by the NASDAQ National Market,
the NASDAQ Small Cap Market or the OTC Bulletin Board (indicated by an
asterisk).

<Table>
<Caption>
                                                               HIGH     LOW
                                                              ------   ------
<S>                                                           <C>      <C>
2002
First Quarter...............................................  $1.530   $1.230
Second Quarter..............................................   1.200    0.440
Third Quarter...............................................   0.650    0.310
Fourth Quarter..............................................   0.470    0.080*

2001
First Quarter...............................................  $3.500   $1.188
Second Quarter..............................................   2.800    1.094
Third Quarter...............................................   2.700    1.020
Fourth Quarter..............................................   1.490    1.010
</Table>

     The Company currently intends to retain earnings to finance its operations
and future growth and does not anticipate paying any cash dividends on its
Common Stock in the foreseeable future. Twinlab conducts its business through
its direct and indirect subsidiaries and has no operations of its own. The
principal assets of Twinlab are the capital stock of its direct and indirect
subsidiaries. Accordingly, Twinlab has no independent means of generating
revenues. As a holding company, Twinlab's internal sources of funds to meet its
cash needs, including payment of expenses, are dividends and other permitted
payments from its direct and indirect subsidiaries. Financing arrangements under
which Twin is the borrower restrict the payment of dividends and the making of
loans, advances or other distributions to Twinlab, except in certain limited
circumstances. The payment of cash dividends in the future will depend upon,
among other things, the Company's results of operations, financial condition,
cash requirements and other factors deemed relevant by the Company's Board of
Directors.

     On August 1, 2002 and December 19, 2002, the Company issued 18,750 shares
of common stock (from shares held in treasury) to each of Brian Blechman, Dean
Blechman, Neil Blechman, Ross Blechman and Steve Blechman in consideration for
providing an aggregate letter of credit amounting to $15.0 million with respect
to the Company's obligations under its Revolving Credit Facility. Such common
stock was issued in transactions that were exempt from registration under
Section 4 (2) of the Securities Act.

ITEM 6.  SELECTED FINANCIAL DATA

     The selected financial data as of December 31, 2002, 2001, 2000, 1999 and
1998 and for each of the years then ended has been derived from the audited
consolidated financial statements of the Company. The consolidated financial
statements as of December 31, 2002 and 2001, and for each of the three years in
the period ended December 31, 2002, is included elsewhere herein. The selected
financial data below also presents pro forma financial data relating to
PR*Nutrition's conversion of tax status from an "S" corporation to a "C"
corporation as a result of its acquisition by the Company. The selected
financial data should be read in conjunction with, and is qualified in its
entirety by, the Consolidated Financial Statements of the Company and the notes
thereto and the other financial information included in Item 15 to this Annual
Report.

                                        16
<PAGE>

<Table>
<Caption>
                                            2002       2001       2000       1999       1998
                                          --------   --------   --------   --------   --------
<S>                                       <C>        <C>        <C>        <C>        <C>
OPERATING DATA:(A)(B)
Net sales(c)............................  $146,623   $187,107   $228,495   $252,721   $270,394
Gross profit............................    47,136     60,303     56,630     99,082    120,453
Operating expenses......................    62,757     77,313     87,148     84,978     64,269
Restructuring charges(d)................     9,616         --         --         --         --
Asset impairment charges(e).............     7,228      3,827         --         --         --
Merger expenses.........................        --         --         --         --      1,462
(Loss) income from operations...........   (32,465)   (20,837)   (30,518)    (4,896)    54,722
Interest expense, net...................     8,092      9,097      8,552      4,954      6,855
(Loss) income from continuing
  operations(f).........................   (33,514)   (52,740)   (50,322)    (6,027)    30,251
Net (loss) income.......................   (32,412)   (91,569)   (51,935)    (5,176)    29,691
BASIC AND DILUTED (LOSS) INCOME PER
  SHARE:
(Loss) income from continuing
  operations............................  $  (1.16)  $  (1.84)  $  (1.76)  $  (0.19)  $   0.96
Net (loss) income.......................     (1.12)     (3.19)     (1.81)     (0.16)      0.94
PRO FORMA RELATING TO CHANGE IN TAX
  STATUS:(G)
Pro forma net income....................                                              $ 28,524
Basic net income per share..............                                                  0.91
Diluted net income per share............                                                  0.90
OTHER DATA:
(Loss) income from operations
  margin(h).............................     (22.1)%    (11.1)%    (13.4)%     (1.9)%     20.2%
Capital expenditures....................     1,877      3,312      5,951     15,672     17,088
BALANCE SHEET DATA:(A)(B)
Net working capital (excluding cash and
  cash equivalents, current debt and
  including assets of discontinued
  operations)...........................  $ 20,734   $ 49,483   $135,834   $132,334   $148,196
Property, plant and equipment, net......    34,019     46,148     49,398     44,972     32,763
Total assets............................    97,177    128,614    248,175    286,257    290,018
Total debt (including current debt).....    71,016     79,370     97,971     63,800     43,531
Shareholders' (deficit) equity..........   (11,127)    21,022    111,987    163,525    205,485
</Table>

---------------

(a)  On April 17, 2001, the Company sold the assets of its Changes International
     subsidiary. Changes International's results of operations have been
     classified as discontinued operations and prior periods have been
     reclassified. See Note 3 to the Notes to the Consolidated Financial
     Statements.

(b)  On January 17, 2003, the Company sold substantially all of the assets of
     its Bronson subsidiary. Bronson's results of operations have been
     classified as discontinued operations and prior periods have been
     reclassified. See Note 3 to the Notes to the Consolidated Financial
     Statements.

(c)  Fiscal 2002 includes an incremental $8.8 million charge for sales returns
     and allowances recorded during the quarter ended September 30, 2002
     relating to a plan to rationalize product offerings to several key
     customers in the retail segment.

(d)  Represents costs recorded in connection with the consolidation of the
     Company's New York manufacturing and distribution facilities into the
     Company's Utah Facility. See Note 2 to the Notes to the Consolidated
     Financial Statements.

(e)  Represents non-cash impairment charges of $2,887 related to property and
     equipment and the goodwill of Health Factors and $940 related to idle
     packaging equipment leased under operating leases in fiscal 2001, and
     $7,228 related to certain manufacturing and distribution assets as a result
     of the consolidation of the facilities in fiscal 2002. See Note 2 to the
     Notes to the Consolidated Financial Statements.

(f)  Includes restructuring charges of $9,616 in fiscal 2002 discussed in (d)
     above, asset impairment charges of $3,827 in fiscal 2001 and $7,228 in
     fiscal 2002 discussed in (e) above and a provision for income taxes of
     $22,801 in fiscal 2001 to establish a full valuation allowance against the
     Company's deferred tax assets.

(g)  PR*Nutrition was an "S" corporation prior to its acquisition in August
     1998. Upon consummation of its acquisition, PR*Nutrition terminated its "S"
     corporation status.

(h)  (Loss) income from operations margin equals (loss) income from operations
     as a percentage of net sales. Excluding the effect of the restructuring
     charges discussed in (d) above and asset impairment charges discussed in
     (e) above, the loss from operations margin would have been (10.7)% and
     (9.1)% for fiscal 2002 and 2001, respectively.

                                        17
<PAGE>

ITEM 7.  MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS

     The following discussion and analysis should be read in conjunction with
"Selected Financial Data" and the audited Consolidated Financial Statements of
the Company and the notes thereto included elsewhere in this Annual Report.

RESULTS OF OPERATIONS

     The Company conducts its operations through one reportable segment, the
retail segment. Products sold by the retail segment include vitamins, minerals
and specialty supplements, sports nutrition products and diet and energy
products primarily under the Twinlab, Ironman Triathlon, "Fuel" and other brand
names; an extensive line of herbal supplements and phytonutrients under the
Nature's Herbs brand name; and a full line of herbal teas under the Alvita brand
name. In addition, the Company distributed vitamins, herbs, nutritional
supplements and health and beauty aids under the Bronson brand name, through
catalogs and specialty direct mailings to customers, including healthcare and
nutritional professionals, and also manufactured, through Health Factors,
private label vitamins and supplements for a number of other companies on a
contract manufacturing basis. On May 22, 2002, the Company sold its Health
Factors' operations and on January 17, 2003, the Company sold substantially all
of the assets of Bronson. The Company also marketed nutritionally enhanced food
bars and other nutritional products under the PR*Bar trademark through
PR*Nutrition and conducted its publishing activities through ARP. On April 17,
2001, the Company sold the assets of its Changes International, Inc. ("Changes
International") and PR*Nutrition subsidiaries and on June 1, 2001, the Company
sold ARP. Bronson's and Changes International's results of operations have been
classified as discontinued operations and prior periods have been reclassified.

     The following table sets forth, for the periods indicated, certain
historical income statement and other data for the Company and also sets forth
certain of such data as a percentage of net sales.

<Table>
<Caption>
                                                         YEAR ENDED DECEMBER 31,
                                          -----------------------------------------------------
                                               2002               2001               2000
                                          ---------------    ---------------    ---------------
                                                          (DOLLARS IN MILLIONS)
<S>                                       <C>       <C>      <C>       <C>      <C>       <C>
Net Sales:
  Retail Segment........................  $146.6    100.0%   $184.4     98.6%   $220.9     96.7%
  Other (ARP and PR*Nutrition)..........      --       --       2.7      1.4       7.6      3.3
                                          ------    -----    ------    -----    ------    -----
Net Sales...............................   146.6    100.0     187.1    100.0     228.5    100.0
                                          ------    -----    ------    -----    ------    -----
Gross Profit............................    47.1     32.2      60.3     32.2      56.6     24.8
Operating Expenses......................    62.8     42.8      77.3     41.3      87.1     38.1
Restructuring Charges...................     9.6      6.6        NA       NA        NA       NA
Asset Impairment Charges................     7.2      4.9       3.8      2.0        NA       NA
                                          ------    -----    ------    -----    ------    -----
Loss from Operations....................  $(32.5)   (22.1)%  $(20.8)   (11.1)%  $(30.5)   (13.3)%
                                          ======    =====    ======    =====    ======    =====
</Table>

FISCAL 2002 COMPARED TO FISCAL 2001

     Net Sales.  Net sales for fiscal 2002 were $146.6 million, a decrease of
$40.5 million, or 21.6%, as compared to net sales of $187.1 million for fiscal
2001. In connection with a continuing review of its operations, the Company
committed to a plan to rationalize product offerings to several key customers in
the retail segment. This plan was aimed at reducing the number of active SKUs
and achieving a more appropriate product mix. In connection with this plan, the
Company is allowing these customers to return inventory which resulted in an
incremental charge for sales returns and allowances of approximately $8.8
million (the "Product Rationalization Charge") during the quarter ended
September 30, 2002. In addition, net sales to the retail segment were negatively
impacted by a reduction in sales to a major customer and reduced promotional
allowances to customers in the Health and Natural Food Store Channel as well as
some disruption in customer service as a result of the consolidation of the
facilities.

                                        18
<PAGE>

     A number of the Company's products include alkaloids from the herb known as
"Ma Huang," also known as ephedra, which contains naturally-occurring ephedrine
alkaloids. Some of the Company's products also contain caffeine or other central
nervous system stimulants. Products containing Ma Huang accounted for
approximately 21% of the Company's net sales in 2002.

     Ma Huang has been the subject of extensive negative publicity in the United
States and other countries relating to alleged harmful or adverse effects. This
publicity has led to recent congressional hearings addressing the safety of Ma
Huang and several state governments have passed legislation regulating the sale
of products that contain Ma Huang. Recently, the Suffolk County (New York)
legislature passed a bill that bans retail sales of ephedra products in Suffolk
County. Other jurisdictions have proposed similar legislation. The current media
and political attention to Ma Huang is likely to lead to further legislation
related to the sale of products containing Ma Huang including the possible ban
of sale of these products.

     On February 28, 2003, the HHS announced a series of actions that will
potentially regulate the manner in which products containing the ingredient
ephedra are marketed, including a thirty-day comment period to create a record
to support potential restrictions that could range from label requirements to a
ban of the ingredient. By letter dated March 13, 2003, the Committee on Energy
and Commerce of the U.S. House of Representatives requested certain information
from the Company related to, among other things, the sales history of its
products containing ephedra, any adverse health events associated with such
products, scientific studies related to such products and information related to
certain of the Company's non-ephedra products. The Company has provided a
comprehensive response to the Committee.

     The Company has been named as a defendant in a number of pending lawsuits,
alleging that its Ma Huang products caused injury, death and/or damages, as well
as certain proceedings seeking class action certification for consumer fraud
related to the sale of such products. The Company is vigorously defending these
lawsuits. However, the Company is incurring, and expects to incur, significant
costs associated with this litigation activity. These costs are due in part to:
(i) greater costs for insurance premiums; (ii) significant self-insured
retention limits for claims alleging injuries after December 31, 2000; and (iii)
legal fees that are not covered under certain of the Company's insurance
policies. In particular, several of the class actions, as economic injury cases,
are not generally covered by insurance. At least one of the Ma Huang lawsuits
involving a claim of wrongful death is not currently covered by insurance.

     The Company believes in the safety and efficacy of its products that
contain Ma Huang based on the scientific evidence. Nevertheless, as a result of
the increasing costs that are negatively impacting the profitability of these
products, coupled with consumer demand for non-ephedra weight loss products, the
Company decided to discontinue the sale of products that contain Ma Huang
effective on or about March 31, 2003. The Company expects to experience a
reduction in net sales due to the discontinuation of its products that contain
Ma Huang. Based upon anticipated costs savings expected to be achieved, however,
the Company does not believe that the decision to discontinue the sale of
products that contain Ma Huang should have a material adverse effect on the
profitability of the Company. The Company is committed to the Diet and Energy
category, specifically its Diet Fuel, Ripped Fuel and Metabolift brands, and has
launched a line of patented and clinically tested ephedra-free products.

     Gross Profit.  Gross profit for fiscal 2002 was $47.1 million. Excluding
the effect of the Product Rationalization Charge, gross profit would have been
approximately $54.3 million, a decrease of $6.0 million, or 9.9% as compared to
$60.3 million for fiscal 2001. Excluding this charge, gross profit margin was
35.0% for fiscal 2002 as compared to 32.2% for fiscal 2001. This overall
decrease in gross profit dollars was primarily attributable to the lower sales
volume and the recording of a provision for excess and slow moving inventories
of $6.7 million. The increase in the gross profit margin was primarily
attributable to a reduction in overhead costs associated with cost reduction
initiatives.

     Operating Expenses.  Operating expenses were $62.8 million for fiscal 2002,
representing a decrease of $14.5 million, or 18.8%, as compared to $77.3 million
for fiscal 2001. As a percent of net sales, operating expenses decreased from
41.3% for fiscal 2001 to 40.4% for fiscal 2002 (excluding the Product
Rationalization Charge). The decrease in operating expenses was primarily
attributable to the elimination of ERP implementation costs, a reduction in
personnel related costs associated with cost reduction initiatives and the
elimination

                                        19
<PAGE>

of operating costs related to sold and discontinued businesses, partially offset
by increasing insurance costs and additional costs related to the consolidation
of the manufacturing and distribution facilities.

     Included in operating expenses for fiscal 2002 is a net expense of
approximately $0.6 million relating to litigation matters. Such expense relates
to the recording of reserves for litigation matters and related costs offset by
proceeds of $5.4 million received from litigation settlements.

     Restructuring and Asset Impairment Charges:  On July 24, 2002, the Company
announced a comprehensive restructuring of its operations designed to further
improve the Company's financial performance and operating results. The
restructuring, designed to reduce costs and better align the Company's
operational infrastructure to its sales volume, resulted in the consolidation of
the New York manufacturing and distribution facilities into the Company's modern
FDA-registered facility located in American Fork, Utah. The Company's corporate
offices and certain operational functions remain in New York. The consolidation
of the facilities has been substantially completed during fiscal 2002 and is
anticipated to be completed during the first half of 2003.

     Restructuring charges recorded during the year ended December 31, 2002
totaled $9.6 million and primarily represented facility and employee costs,
professional fees and other incremental costs. Facility costs represent
remaining lease payments for New York leased properties and equipment, and
holding and shutdown costs related to the New York manufacturing and
distribution facilities. Employee costs primarily represent severance and
related benefits associated with the separation of approximately 300 New York
employees. The majority of the employees left during the fourth quarter of 2002,
and it is anticipated that the balance will be leaving during the first half of
2003.

     In addition, as a result of the consolidation of the facilities, certain
manufacturing and distribution assets were determined to be impaired resulting
in asset impairment charges of $7.2 million. The Company anticipates selling
these assets during fiscal 2003.

     The consolidation of the manufacturing and distribution facilities is
expected to generate additional annualized cost reductions in excess of $6.0
million, commencing in the first quarter of 2003. The Company anticipates
recording additional restructuring charges of up to $1.0 million in connection
with this consolidation, substantially all of which are expected to be recorded
during the first half of 2003.

     The Company recorded non-cash impairment charges totaling $33.8 million
during the year ended December 31, 2001. These charges consisted of $30.0
million related to the tradename, customer lists and goodwill of Bronson
(included in income (loss) from discontinued operations) and $2.9 million
related to property and equipment and the goodwill of Health Factors. The
impairment charges resulted from projected changes in the operating plans of
Bronson and Health Factors. The Company calculated the present value of expected
cash flows of these companies to determine the fair value of these assets. In
addition, the Company recorded an impairment charge of $0.9 million related to
idle packaging equipment leased under operating leases.

     Loss from Operations.  The Company recorded a loss from operations of
$(32.5) million for fiscal 2002, as compared to $(20.8) million for fiscal 2001.

     Other (Expense) Income.  Other (expense) income was a net expense of $8.0
million for fiscal 2002, as compared to $9.1 million for fiscal 2001. The net
decrease of $1.1 million was primarily attributable to a decrease in interest
expense as a result of reduced borrowings and lower interest rates.

     Income Taxes.  The Company recorded a federal benefit from income taxes of
$6.9 million for fiscal 2002. The benefit recorded represented a refund received
by the Company as a result of the Job Creation and Worker Assistance Act of
2002. The Company did not record a benefit from income taxes for losses incurred
during fiscal 2002 as it is more likely than not that such benefit will not be
realized.

     The Company recorded a provision for income taxes of $22.8 million during
fiscal 2001 to establish a full valuation allowance against its deferred tax
assets. The Company did not record a benefit from income taxes for losses
incurred during fiscal 2001 as it is more likely than not that such benefit will
not be realized.

                                        20
<PAGE>

     Sale of Businesses.  On January 17, 2003, the Company sold substantially
all of the assets, including inventory, of Bronson to a privately held dietary
supplement manufacturer for approximately $8 million. The Company anticipates
recording an aggregate pre-tax gain of approximately $1.7 million during the
first quarter of 2003 in connection with the sale of these assets. Bronson's
results of operations have been classified as discontinued operations and prior
periods have been reclassified. Net sales for Bronson were $10.1 million, $11.1
million and $12.9 million and income (loss) from operations was $1.1 million,
$(30.3) million and $(0.9) million for fiscal 2002, fiscal 2001 and fiscal 2000,
respectively.

     On May 22, 2002, the Company completed the sale of substantially all of the
fixed assets of Health Factors for approximately $2.1 million to Anabolic. The
products manufactured by Health Factors were, in significant part, transferred
to other Twinlab manufacturing facilities. Other production related to Bronson
was outsourced to Anabolic while the manufacture of certain private label
products was discontinued.

     On June 1, 2001, the Company sold its publishing subsidiary, Advanced
Research Press, Inc. ("ARP"), to Steve Blechman, Executive Vice President and a
Director of Twinlab and President/CEO of ARP, for $1.0 million. Concurrent with
the sale of ARP, Steve Blechman elected to resign as an Executive Vice President
and employee of Twinlab. The Company recorded a pre-tax gain of approximately
$0.7 million in connection with the sale, which has been included as a reduction
of operating expenses.

     On April 17, 2001, the Company sold the assets of its Changes International
subsidiary to Goldshield Group plc for approximately $4.4 million. The Company
received $3.5 million upon closing the transaction, $0.4 million in October 2001
and $0.5 million in April 2002. The loss on the sale of the assets was $8.7
million. Changes International's results of operations have been classified as
discontinued operations and prior periods have been reclassified. Net sales for
Changes International were $8.4 million and $38.1 million and income (loss) from
operations was $0.4 million and $(1.6) million for fiscal 2001 and fiscal 2000,
respectively.

     On April 17, 2001, the Company sold the assets of PR*Nutrition, Inc. to
Goldshield Group plc for approximately $0.6 million. The Company received $0.5
million upon closing the transaction and $0.1 in October 2001 and April 2002.
The Company recorded a pre-tax gain of approximately $0.3 million in connection
with the sale, which has been included as a reduction of operating expenses.

FISCAL 2001 COMPARED TO FISCAL 2000

     Net Sales.  Net sales for fiscal 2001 were $187.1 million, a decrease of
$41.4 million, or 18.1%, as compared to net sales of $228.5 million for fiscal
2000. Net sales for fiscal 2001 were significantly impacted by a reduction in
sales to a major customer. This customer also purchased significantly less
product from the Company during fiscal 2002. In addition, the decrease in net
sales was attributable to a decrease in sales to the health and natural food
store channel, partially offset by an increase in sales to the mass market
channel.

     Gross Profit.  Gross profit for fiscal 2001 was $60.3 million, which
represented an increase of $3.7 million, or 6.5%, as compared to $56.6 million
($72.6 million before $16.0 million of herbal inventory adjustments recorded in
fiscal 2000 (the "2000 herbal inventory adjustments")) for fiscal 2000. Gross
profit margin was 32.2% for fiscal 2001 as compared to 24.8% (31.8% before the
2000 herbal inventory adjustments) for fiscal 2000. The overall decrease in
gross profit dollars (as compared to adjusted 2000) was attributable primarily
to the Company's lower sales volume. The overall gross profit margin (as
compared to adjusted 2000) remained relatively consistent.

     Operating Expenses.  Operating expenses were $77.3 million for fiscal 2001,
representing a decrease of $9.8 million, or 11.3%, as compared to $87.1 million
for fiscal 2000. As a percent of net sales, operating expenses increased from
38.1% for fiscal 2000 to 41.3% for fiscal 2001. The decrease in operating
expenses was primarily attributable to a reduction in the Company's advertising
and trade marketing expenses, a reduction in bad debt expense and the sale of
ARP and PR*Nutrition, Inc. Included in operating expenses for fiscal 2001 are
$3.6 million of costs incurred in connection with the implementation of the new
ERP system and approximately $1.6 million of charges related to reductions in
personnel costs.

     Asset Impairment Charges.  The Company recorded non-cash impairment charges
totaling $33.8 million during the year ended December 31, 2001. These charges
consisted of $30.0 million related to the tradename,
                                        21
<PAGE>

customer lists and goodwill of Bronson (included in income (loss) from
discontinued operations) and $2.9 million related to property and equipment and
the goodwill of Health Factors. The impairment charges resulted from projected
changes in the operating plans of Bronson and Health Factors. The Company
calculated the present value of expected cash flows of these companies to
determine the fair value of these assets. In addition, the Company recorded an
impairment charge of $0.9 million related to idle packaging equipment leased
under operating leases.

     Loss from Operations.  The Company recorded a loss from operations of
$(20.8) million for fiscal 2001, as compared to $(30.5) million for fiscal 2000.

     Other (Expense) Income.  Other (expense) income was a net expense of $9.1
million for fiscal 2001, as compared to $8.6 million for fiscal 2000. The
increase was attributable to an increase in interest expense.

     Income Taxes.  The Company recorded a provision for income taxes of $22.8
million during fiscal 2001 to establish a full valuation allowance against its
deferred tax assets. The Company did not record a benefit from income taxes for
losses incurred during fiscal 2001 as it is more likely than not that such
benefit will not be realized.

     The Company recorded a deferred tax valuation allowance of $26.0 million
during fiscal 2000. This valuation allowance reduced the Company's deferred tax
assets to a net amount which the Company believed to be more likely than not to
be realized through future taxable earnings.

     Sales of Businesses.  On June 1, 2001, the Company sold its publishing
subsidiary, ARP, to Steve Blechman, Executive Vice President and a Director of
Twinlab and President/CEO of ARP, for $1.0 million. Concurrent with the sale of
ARP, Steve Blechman elected to resign as an Executive Vice President and
employee of Twinlab. The Company recorded a pre-tax gain of approximately $0.7
million in connection with the sale, which has been included as a reduction of
operating expenses.

     On April 17, 2001, the Company sold the assets of its Changes International
subsidiary to Goldshield Group plc for approximately $4.4 million. The Company
received $3.5 million upon closing the transaction, $0.4 million in October 2001
and $0.5 million in April 2002. The loss on the sale of the assets was $8.7
million. Changes International's results of operations have been classified as
discontinued operations and prior periods have been reclassified. Net sales for
Changes International were $8.4 million and $38.1 million and income (loss) from
operations was $0.4 million and $(1.6) million for fiscal 2001 and fiscal 2000,
respectively.

     On April 17, 2001, the Company sold the assets of PR*Nutrition, Inc. to
Goldshield Group plc for approximately $0.6 million. The Company received $0.5
million upon closing the transaction and $0.1 in October 2001 and April 2002.
The Company recorded a pre-tax gain of approximately $0.3 million in connection
with the sale, which has been included as a reduction of operating expenses.

LIQUIDITY AND CAPITAL RESOURCES

     Cash provided by (used in) operating activities was $8.0 million, $14.2
million and $(22.5) million for fiscal 2002, 2001 and 2000, respectively. Cash
provided by operating activities for fiscal 2002 was primarily attributable to
the collection of an income tax refund of $6.9 million in addition to reductions
in accounts receivable and inventories. Cash provided by operating activities
for fiscal 2001 was primarily attributable to the collection of an income tax
refund of $11.7 million in addition to reductions in accounts receivable and
inventories partially offset by the timing of payments of accounts payable and
accrued expenses. Cash used in operating activities for fiscal 2000 was
primarily attributable to the timing of payments of accounts payable and accrued
expenses.

     Capital expenditures were $1.9 million in fiscal 2002, as compared to $3.3
million in fiscal 2001 and $6.0 million in fiscal 2000. Capital expenditures in
fiscal 2002 were primarily for the purchase of machinery and equipment. Capital
expenditures are expected to be approximately $2.0 million during fiscal 2003.
The Company estimates that its maintenance capital expenditures will be
approximately $0.5 million per fiscal year.

                                        22
<PAGE>

     Net cash used in financing activities was $8.8 million in 2002 and $20.7
million in 2001 and represented the repayment of outstanding debt and the
payment of debt issuance costs. Net cash provided by financing activities was
$29.7 million in 2000 and represented borrowings under the Company's revolving
credit facility offset by the payment of other debt.

     Effective March 29, 2001, the Company replaced its revolving credit
facility and entered into a new revolving line of credit inclusive of a term
loan (the "Revolving Credit Facility") with a group of financial institutions.
The Revolving Credit Facility, as amended, provides for maximum borrowings of
$45 million through March 29, 2004 with a termination fee of 2% for early
cancellation. The term loan portion of the Revolving Credit Facility totals $4.2
million and is payable at the expiration of the agreement. Borrowings are
subject to certain limitations based on a percentage of eligible accounts
receivable and inventories, as defined in the agreement. Interest is payable
monthly at the Prime Rate (4.25% at February 28, 2003), plus 1.75% per annum.
The Company is required to pay a commitment fee of 0.5% per annum on any unused
portion of the Revolving Credit Facility. Borrowings under the Revolving Credit
Facility are secured by substantially all of the Company's assets. The Revolving
Credit Facility, among other things, requires the Company to maintain specified
levels of EBITDA (as defined therein), places limitations on capital
expenditures and restrictions on the ability to incur debt and prohibits the
payments of dividends. As a result of the sale of Bronson, effective January 17,
2003, the Company completed an amendment to the Revolving Credit Facility, which
among other things, revised the financial covenants relating to EBITDA and
reduced the total facility from $50 million to $45 million. Borrowings
outstanding under the Revolving Credit Facility as of February 28, 2003 were
approximately $21 million. As of February 28, 2003, approximately $6 million of
borrowings were available under the Revolving Credit Facility.

     In connection with the Revolving Credit Facility, certain current and
former members of senior management of the Company provided a letter of credit
amounting to $15.0 million with respect to the Company's obligations under the
Revolving Credit Facility. In consideration for providing this letter of credit,
effective April 1, 2002, the Company agreed to pay an aggregate annual fee of
$0.4 million and 375,000 shares of common stock (to be issued from shares held
in treasury), payable in quarterly installments for the duration of the period
that the letter of credit remains outstanding. As of December 31, 2002, $0.2
million has been paid and 187,500 shares of common stock have been issued. The
fair value of the compensation for providing the letter of credit, $1.6 million,
has been recorded as deferred financing costs and is being amortized over the
remaining term of the Revolving Credit Facility.

     The Company's Revolving Credit Facility expires on March 29, 2004. The
Company intends to enter into negotiations to extend the term of the Revolving
Credit Facility or to enter into an alternative borrowing arrangement which
would provide for future borrowings. There can be no assurance, however, that by
March 29, 2004, an extension of the Revolving Credit Facility will be
successfully negotiated or the Company will be able to enter into an alternative
borrowing arrangement on terms favorable to the Company. The absence of an
extension of the Revolving Credit Facility or alternative borrowing arrangement
would have a material adverse effect on the financial condition of the Company.
The Company anticipates that borrowings outstanding under the Revolving Credit
Facility will be classified as a current liability as of March 31, 2003.

     The Company was in compliance with the covenants relating to the Revolving
Credit Facility and the Senior Subordinated Notes as of December 31, 2002.

     The Company was in default of certain financial covenants relating to the
mortgage payable during fiscal 2002 for which a waiver was obtained through
April 3, 2003. The Company will be subject to the financial covenant tests for
the quarter ended June 30, 2003 and does not currently anticipate being in
compliance. Accordingly, the mortgage payable has been classified as a current
liability as of December 31, 2002. The Company has entered into negotiations
with the lender to amend the mortgage agreement, however, there can be no
assurance that an amendment will be successfully negotiated. In the event that
the Company is unable to amend the mortgage agreement, the Company will be
required to repay the mortgage in order to avoid a cross-default under the terms
of the Revolving Credit Facility.

     The Company has been named as a defendant in a number of pending product
liability lawsuits that the Company is vigorously defending. In reviewing its
potential exposure for product liability matters, the Company considers, among
other factors, recent and historical settlements and judgments, if any, the

                                        23
<PAGE>

incidence and trend of recent and historical claims, the nature of any alleged
injuries, the amount and availability of insurance coverage and the status of
litigation proceedings and settlement discussions.

     Based on a current analysis prepared by management, with the assistance of
actuarial consultants, the Company has estimated a range of potential liability
in an amount it deems reasonable in connection with certain product liability
matters involving ephedra. Accordingly, the Company has established a reserve of
$3.8 million for product liability indemnity claims that is primarily based on
known claims and an estimate of unasserted claims involving ephedra that are
probable of assertion and can be reasonably estimated as of the balance sheet
date. Management expects that any payments relating to these matters will occur
over a number of years and has not discounted the potential liability as of
December 31, 2002, because the timing of any payments are not fixed or reliably
determinable at the present time. This reserve assumes continuing insurance for
ephedra related personal injury actions, albeit with a significant retention and
limited total coverage.

     Because of the uncertainties related to the number of potential future
claims, ultimate settlement amounts, dismissal of such claims or any adverse
judgments, it is difficult to obtain precise estimates of the Company's ultimate
liability for such claims. It is possible that the total exposure to product
liability claims may be less than or greater than an amount within the Company's
estimated range of potential liability due to changes in facts or circumstances
after the date of each estimate. As additional experience is gained regarding
the Company's product liability claims, possible settlement discussions,
litigation history and insurance coverage, the Company will reassess its
potential liability and revise the amount of its reserve as appropriate.

     There can be no assurance that the impact of the Company's self-insured
retention limits in the event of multiple damage awards or settlements, or any
award of damages in excess of the Company's insurance coverage limits (which
limits are significantly lower than in prior periods) or any materially
increased legal costs, will not have a material adverse effect on the financial
condition or results of operations of the Company. In addition, one or more
large punitive damage awards, which are generally not insurable, could have a
material adverse effect on the financial condition and results of operations of
the Company.

     Further, the Company's 2003 CGL insurance policy for non-Ma Huang products
has a significantly higher self-insured retention limit than in 2002 and the
herbal product Kava-Kava is expressly excluded from coverage under the 2003
policy. The Company has received one Kava-Kava related wrongful death complaint
in 2003. The Company plans to vigorously defend itself against this action and
is investigating whether any of its CGL policies apply to this claim. If a CGL
policy is not applicable to this claim, a finding of liability and damages could
have a material adverse effect on the results of operation and financial
condition of the Company. The Company is unable to predict the outcome of this
matter or to estimate a range of potential loss. Accordingly, the effect, if
any, that such action may have on the Company's consolidated financial position
or results of operations cannot be determined at this time.

     Twinlab Corporation has no operations of its own and accordingly has no
independent means of generating revenue. As a holding company, Twinlab
Corporation's internal sources of funds to meet its cash needs, including
payment of expenses, are dividends and other permitted payments from its direct
and indirect subsidiaries. The Indenture relating to the Company's 10 1/4%
senior subordinated notes and the Revolving Credit Facility impose upon the
Company certain financial and operating covenants, including, among others,
requirements that the Company satisfy certain financial tests, limitations on
capital expenditures and restrictions on the ability of the Company to incur
debt, pay dividends or take certain other corporate actions.

     The following table sets forth our contractual obligations and commercial
commitments as of December 31, 2002:

<Table>
<Caption>
                                                   YEARS ENDING DECEMBER 31,
                                          -------------------------------------------
   CONTRACTUAL OBLIGATIONS       TOTAL     2003      2004      2005     2006     2007   THEREAFTER
-----------------------------   -------   -------   -------   ------   -------   ----   ----------
<S>                             <C>       <C>       <C>       <C>      <C>       <C>    <C>
Long-term debt...............   $71,016   $ 6,565   $24,375   $   20   $39,938   $23       $95
Operating lease
  obligations................     9,196     3,691     2,997    1,965       543    --        --
Employment and severance/non-
  compete obligations........     4,299     1,838     1,700      761        --    --        --
                                -------   -------   -------   ------   -------   ---       ---
Total........................   $84,511   $12,094   $29,072   $2,746   $40,481   $23       $95
                                =======   =======   =======   ======   =======   ===       ===
</Table>

                                        24
<PAGE>

     Subject to the factors discussed above, management believes that the
Company has adequate capital resources and liquidity to meet its borrowing
obligations, fund all required capital expenditures and pursue its business
strategy for at least the next 12 months. The Company's capital resources and
liquidity are expected to be provided by the Company's cash flow from operations
and borrowings under its Revolving Credit Facility. See Item 1, "Factors
effecting future performance" and Item 3, "Legal Proceedings."

CRITICAL ACCOUNTING POLICIES AND ESTIMATES

     The Company's discussion and analysis of its financial condition and
results of operations are based upon its consolidated financial statements,
which have been prepared in accordance with accounting principles generally
accepted in the United States of America. The preparation of these financial
statements requires the Company to make estimates and assumptions that affect
the reported amounts of assets and liabilities and disclosure of contingent
assets and liabilities at the date of the financial statements and the reported
amounts of revenues and expenses during the reporting period. On an on-going
basis, the Company evaluates its estimates and assumptions including those
related to customer returns and allowances, allowance for doubtful accounts,
inventories, long-lived assets, income taxes, contingencies and litigation. The
Company bases its estimates on historical experience and on various other
factors that are believed to be reasonable. Actual results could materially
differ from those estimates.

     The Company believes the following critical accounting policies affect its
more significant judgments and estimates used in the preparation of its
consolidated financial statements.

     - The Company records estimated reductions to sales for customer returns
       and allowances. Should the Company's customers return products or claim
       allowances greater than estimated by the Company, additional reductions
       to sales may be required. As previously discussed, in fiscal 2002, the
       Company recorded an incremental $8.8 million charge for sales returns and
       allowances during the quarter ended September 30, 2002 relating to a plan
       to rationalize product offerings to several key customers in the retail
       segment.

     - The Company maintains allowances for doubtful accounts for estimated
       losses resulting from the inability of its customers to make required
       payments. If the financial condition of the Company's customers were to
       deteriorate, resulting in an impairment of their ability to make
       payments, additional allowances may be required.

     - The Company identifies slow moving or obsolete inventories and estimates
       appropriate loss provisions related thereto. If actual future demand or
       market conditions are less favorable than those projected by management,
       additional loss provisions may be required.

     - The Company reviews its long-lived assets, including its finite-lived
       intangible assets, for impairment whenever events or changes in
       circumstances indicate that the carrying amount of the assets may not be
       fully recoverable. The carrying value of these assets would be impaired
       if the best estimate of future undiscounted cash flows over their
       remaining amortization period is less than their carrying value. If an
       asset is impaired, the loss is measured using estimated fair value. As
       previously discussed, the Company recorded non-cash impairment charges
       totaling $7.2 million during fiscal 2002 and $33.8 million during fiscal
       2001.

     - The Company records a valuation allowance to reduce its deferred tax
       assets to the amount that is more likely than not to be realized. As a
       result of losses incurred, the Company has recorded a full valuation
       allowance against its net deferred tax assets of $73.0 million and $64.0
       million as of December 31, 2002 and 2001, respectively. Should the
       Company be profitable in the future at levels which cause management to
       conclude that it is more likely than not that it will realize all or a
       portion of the deferred tax assets, the Company would record the
       estimated net realizable value of the deferred tax assets at that time
       and would then provide for income taxes at its combined federal and state
       effective rates.

     - As discussed in "Business -- Factors Affecting Future Performance -- Ma
       Huang" in Item 1, "Legal Proceedings" in Item 3 and Note 12 to the Notes
       to the Consolidated Financial Statements, the
                                        25
<PAGE>

Company has been named as a defendant in a number of pending product liability
lawsuits that the Company is vigorously defending. In reviewing its potential
exposure for product liability indemnity claims, the Company considers, among
other factors, recent and historical settlements and judgments, if any, the
incidence and trend of recent and historical claims, the nature of any alleged
injuries, the amount and availability of insurance coverage and the status of
litigation proceedings and settlement discussions.

     Based on a current analysis prepared by management, with the assistance of
actuarial consultants, the Company has estimated a range of potential liability
in an amount it deems reasonable in connection with certain product liability
matters involving ephedra. Accordingly, the Company has established a reserve of
$3.8 million for product liability indemnity claims that is primarily based on
known claims and an estimate of unasserted claims involving ephedra that are
probable of assertion and can be reasonably estimated as of the balance sheet
date. Management expects that any payments relating to these matters will occur
over a number of years and has not discounted the potential liability as of
December 31, 2002, because the timing of any payments are not fixed or reliably
determinable at the present time. The reserve assumes continuing insurance for
ephedra related personal injury actions, albeit with significant retention and
limited total coverage.

IMPACT OF INFLATION

     Generally, the Company has been able to pass on inflation-related cost
increases; consequently, inflation has not had a material impact on the
Company's historical operations or profitability.

RECENT FINANCIAL ACCOUNTING STANDARDS BOARD STATEMENTS

     The Company adopted Statement of Financial Accounting Standards ("SFAS")
No. 142, "Goodwill and Other Intangible Assets", effective January 1, 2002. In
accordance with SFAS No. 142, goodwill and intangible assets with indefinite
lives are no longer subject to amortization, but are subject to at least an
annual assessment for impairment by applying a fair value based test. The
Company has completed a transitional fair value based impairment test on its
goodwill and an annual impairment test as of December 31, 2002, neither of which
resulted in an impairment charge. With the adoption of SFAS No. 142, the Company
ceased the amortization of goodwill with a book value of $0.4 million as of
January 1, 2002. Had amortization of goodwill and tradenames not been recorded
during the years ended December 31, 2001 and 2000, the net loss would have been
reduced by approximately $0.8 million and $1.1 million, net of taxes,
respectively, and basic and diluted net loss per share would have decreased by
$0.03 for both years.

     In August 2001, the Financial Accounting Standards Board ("FASB") issued
SFAS No. 143, "Accounting for Asset Retirement Obligations", which is effective
for fiscal years beginning after June 15, 2002. SFAS No. 143 addresses financial
accounting and reporting for obligations associated with the retirement of
tangible long-lived assets and the associated asset retirement costs. The
adoption of SFAS No. 143 is not expected to have a significant impact on the
Company's consolidated financial statements.

     The Company adopted SFAS No. 144, "Accounting for the Impairment or
Disposal of Long-Lived Assets", effective January 1, 2002. The adoption of SFAS
No. 144 did not have a significant impact on the Company's consolidated
financial statements.

     Effective January 1, 2002, the Company adopted Emerging Issues Task Force
("EITF") No. 01-9, "Accounting for Consideration Given by a Vendor to a Customer
(Including a Reseller of the Vendor's Products)," which required that
consideration paid to a distributor or retailer to promote the vendor's
products, such as slotting fees or buydowns, generally be characterized as a
reduction of revenue when recognized in the vendor's income statement.
Accordingly, the Company reported such costs as a reduction of net sales rather
than as operating expenses during the year ended December 31, 2002 and
reclassified costs totaling $1.6 million and $0.9 million for the years ended
December 31, 2001 and 2000, respectively.

     In April 2002, the FASB issued SFAS No. 145, "Rescission of FASB Statements
No. 4, 44 and 64, Amendment of FASB Statement No. 13, and Technical
Corrections". This statement provides guidance on the classification of gains
and losses from the extinguishment of debt and on the accounting for certain

                                        26
<PAGE>

specified lease transactions. The adoption of SFAS No. 145 is not expected to
have a significant impact on the Company's consolidated financial statements.

     In June 2002, the FASB issued SFAS No. 146, "Accounting for Costs
Associated with Exit or Disposal Activities". This statement provides guidance
on the recognition and measurement of liabilities associated with disposal
activities and will be adopted by the Company on January 1, 2003. The Company
currently accounts for costs associated with exit or disposal activities in
accordance with EITF 94-3, "Liability Recognition for Certain Employee
Termination Benefits and Other Costs to Exit an Activity (including Certain
Costs Incurred in a Restructuring)."

     In November 2002, the FASB approved FASB Interpretation ("FIN") No. 45,
"Guarantor's Accounting and Disclosure Requirements for Guarantees, including
Indirect Guarantees of Indebtedness of Others, an Interpretation of FASB
Statement No. 5, 57 and 107 and Rescission of FASB Interpretation No. 34". FIN
45 clarifies the requirements of SFAS No. 5, "Accounting for Contingencies",
relating to a guarantor's accounting for, and disclosure of, the issuance of
certain types of guarantees. Specifically, FIN 45 requires that a guarantor
recognize, at the inception of a guarantee, a liability for the fair value of
the obligation undertaken in issuing the guarantee. The provisions for initial
recognition and measurement are effective on a prospective basis for guarantees
that are issued or modified after December 31, 2002, irrespective of a
guarantor's fiscal year end. However, the disclosure provisions of FIN 45 are
effective for financial statements of interim or annual periods ending after
December 15, 2002. The adoption of FIN 45 is not expected to have a significant
impact on the Company's consolidated financial statements.

     In December 2002, the FASB issued SFAS No. 148, "Accounting for Stock-Based
Compensation -- Transition and Disclosure", an amendment of FASB Statement No.
123. SFAS No. 148 provides alternative methods of transition for a voluntary
change to the fair value based method of accounting for stock-based employee
compensation, as well as supplementary disclosure requirements giving more
prominence to the accounting method utilized and its effect on the reported
results. The statement is effective for the Company's 2002 consolidated
financial statements; however, the Company does not intend to change its policy
for accounting for stock options to the fair value method and, therefore, the
implementation of this statement did not have a significant impact on the
Company's consolidated financial statements.

ITEM 7A.  QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

GENERAL

     The following discussion and the estimated amounts generated from the
sensitivity analyses referred to below include forward-looking statements of
market risk which assume for analytical purposes that certain adverse market
conditions may occur. Actual future market conditions may differ materially from
such assumptions because the amounts noted below are the result of analyses used
for the purpose of assessing possible risks and the mitigation thereof.
Accordingly, the forward-looking statements should not be considered projections
by the Company of future events or losses.

     The Company's cash flows and earnings are subject to fluctuations resulting
from changes in interest rates. The Company's current policy does not allow
speculation in derivative instruments for profit or execution of derivative
instrument contracts for which there are no underlying exposures. The Company
does not use financial instruments for trading purposes.

     The Company measures its market risk, related to its holdings of financial
instruments, based on changes in interest rates utilizing a sensitivity
analysis. The sensitivity analysis measures the potential loss in fair values,
cash flows and earnings based on a hypothetical 10% change in interest rates.
The Company used current market rates on its market risk sensitive assets and
liabilities to perform the sensitivity analysis.

INTEREST RATE RISK

     The Company is exposed to changes in interest rates on its floating rate
Revolving Credit Facility and fixed rate Notes. At December 31, 2002 and 2001,
based on a hypothetical 10% decrease in interest rates related to the Company's
fixed rate Notes, the Company estimates that the fair value of its fixed rate
debt

                                        27
<PAGE>

would have increased by approximately $1.4 million. At December 31, 2002 and
2001, the Company had $24.4 million and $30.5 million, respectively, of
borrowings outstanding under its Revolving Credit Facility. A hypothetical 10%
change in interest rates would not have a material effect on the Company's
pretax loss or cash flow.

     Additional information regarding the Company's debt is contained in Note 7
to the Consolidated Financial Statements which are presented under Item 15 of
this Report.

ITEM 8.  FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

     The Consolidated Financial Statements and notes thereto are presented under
Item 15 of this Report.

ITEM 9.  CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND
         FINANCIAL DISCLOSURE

     Not applicable.

                                    PART III

     Information required under PART III (Items 10, 11, 12 and 13) is
incorporated herein by reference to the Company's definitive proxy statement to
be filed with the Securities and Exchange Commission within 120 days after the
year covered by this Form 10-K with respect to its Annual Meeting of
Stockholders to be held in May of 2003.

                                    PART IV

ITEM 14.  CONTROLS AND PROCEDURES

EVALUATION OF DISCLOSURE CONTROLS AND PROCEDURES

     The Company maintains disclosure controls and procedures that are designed
to ensure that information required to be disclosed in the Company's Exchange
Act reports is recorded, processed, summarized and reported within the time
periods specified in the SEC's rules and forms, and that such information is
accumulated and communicated to the Company's management, including its Chief
Executive Officer and Chief Financial Officer, as appropriate, to allow timely
decisions regarding required disclosure.

     Within the 90 days prior to the date of this report, the Company carried
out an evaluation, under the supervision and with the participation of the
Company's management, including the Company's Chief Executive Officer and Chief
Financial Officer, of the effectiveness of the design and operation of the
Company's disclosure controls and procedures pursuant to Exchange Act Rule
13a-14. Based upon that evaluation, the Chief Executive Officer and Chief
Financial Officer concluded that the Company's disclosure controls and
procedures are effective in timely alerting them to material information
relating to the Company (including its consolidated subsidiaries) required to be
included in the Company's periodic SEC filings.

     Management, including the Chief Executive Officer and the Chief Financial
Officer, does not expect that the Company's disclosure controls and procedures
or the Company's internal controls will prevent all error and all fraud. A
control system, no matter how well conceived and operated, provides reasonable
assurance that the objectives of the control system are met. The design of a
control system reflects resource constraints; the benefits of controls must be
considered relative to their costs. Because there are inherent limitations in
all control systems, no evaluation of controls can provide absolute assurance
that all control issues and instances of fraud, if any, within the Company have
been or will be detected. These inherent limitations include the realities that
judgments in decision-making can be faulty and that breakdowns occur because of
simple error or mistake. Controls can be circumvented by the individual acts of
some persons, by collusion of two or more people, or by management override of
the control. The design of any system of controls is based in part upon certain
assumptions about the likelihood of future events. There can be no assurance
that any design will succeed in achieving its stated goals under all future
conditions; over time, controls may become inadequate because of changes in
conditions or deterioration in the degree of compliance with the policies or
procedures.

                                        28
<PAGE>

Because of the inherent limitations in a cost-effective control system,
misstatements due to error or fraud may occur and not be detected.

CHANGES IN INTERNAL CONTROLS

     There were no significant changes in the Company's internal controls or in
other factors that could significantly affect these controls subsequent to the
date the Company completed its evaluation.

ITEM 15.  EXHIBITS, FINANCIAL STATEMENT SCHEDULES, AND REPORTS ON FORM 8-K

(a)(1) and (2). Consolidated Financial Statements and Financial Statement
Schedules:

<Table>
<Caption>
                                                               PAGE
                                                               ----
<S>                                                            <C>
TWINLAB CORPORATION AND SUBSIDIARIES
Independent Auditors' Report................................   F-1
(1) FINANCIAL STATEMENTS
  Consolidated Balance Sheets as of December 31, 2002 and
     2001...................................................   F-2
  Consolidated Statements of Operations for the Years Ended
     December 31, 2002, 2001 and 2000.......................   F-3
  Consolidated Statements of Shareholders' (Deficit) Equity
     for the Years Ended December 31, 2002, 2001 and 2000...   F-4
  Consolidated Statements of Cash Flows for the Years Ended
     December 31, 2002, 2001 and 2000.......................   F-5
  Notes to Consolidated Financial Statements................   F-6
(2) FINANCIAL STATEMENT SCHEDULES
  For the Three Years Ended December 31, 2002
  Schedule I -- Condensed Financial Information of
     Registrant.............................................   S-1
  Schedule II -- Valuation and Qualifying Accounts..........   S-4
</Table>

(b) Reports on Form 8-K:

     No reports on Form 8-K were filed by the Company during the last quarter of
the period covered by this Report.

(c) Exhibits:

<Table>
<Caption>
EXHIBIT
NUMBER                             DESCRIPTION OF EXHIBIT
-------                            ----------------------
<S>       <C>   <C>
  2.1     --    Stock Purchase and Sale Agreement, dated as of March 5,
                1996, among David Blechman, Jean Blechman, Brian Blechman,
                Neil Blechman, Ross Blechman, Steve Blechman, Dean Blechman,
                Stephen Welling, the Registrant, Natur-Pharma Inc. and GEI
                (the "Stock Purchase and Sale Agreement") (incorporated by
                reference to Exhibit 2.1 to the Registration Statement on
                Form S-1, dated June 4, 1996, as amended, filed by the
                Registrant, Registration No. 333-05191; "Twinlab S-1").
  2.1.1   --    Amendment to the Stock Purchase and Sale Agreement, dated
                May 6, 1996 (incorporated by reference to Exhibit 2.1.1 to
                Twinlab S-1).
  3.1     --    Second Amended and Restated Certificate of Incorporation of
                the Registrant (incorporated by reference to Exhibit 3.4 to
                the Registration Statement on Form S-4, dated June 25, 1996,
                as amended, filed by Twin, Registration No. 333-06781; "Twin
                S-4").
  3.2     --    Amended and Restated By-laws of the Registrant (incorporated
                by reference to Exhibit 3.5 to Twin S-4).
  4.1     --    Indenture, dated May 7, 1996, among Twin, and ARP and the
                Registrant (together, the "Guarantors"), and Fleet National
                Bank as Trustee, Registrar, Paying Agent and Securities
                Agent, regarding Twin's 10 1/4% Senior Subordinated Notes
                due 2006 and the 10 1/4% Senior Subordinated Notes due 2006
                issued in exchange therefor (incorporated by reference to
                Exhibit 4.2 to Twin S-1).
</Table>

                                        29
<PAGE>

<Table>
<Caption>
EXHIBIT
NUMBER                             DESCRIPTION OF EXHIBIT
-------                            ----------------------
<S>       <C>   <C>
  4.2     --    First Supplemental Indenture, dated as of December 1, 1997,
                to the Indenture dated as of May 7, 1996, among Twin and
                ARP, Changes International and the Registrant, as Guarantors
                and State Street Bank and Trust Company (as successor to
                Fleet National Bank), as Trustee regarding Twin's 10 1/4%
                Senior Subordinated Notes due 2006 (incorporated by
                reference to Exhibit 4.2 to the Registration Statement on
                Form S-3, dated March 17, 1998, Registration No. 333-48091).
  4.3     --    Second Supplemental Indenture, dated as of May 14, 1998, to
                the Indenture dated as of May 7, 1996, among Twin and ARP,
                Changes International, Bronson, Health Factors and the
                Registrant, as Guarantors and State Street Bank and Trust
                Company (as successor to Fleet National Bank), as Trustee
                regarding Twin's 10 1/4% Senior Subordinated Notes due 2006
                (incorporated by reference to Exhibit 4.3 to the 1998 Annual
                Report).
  4.4     --    Third Supplemental Indenture, dated as of September 15,
                1998, to the Indenture dated as of May 7, 1996, among Twin
                and ARP, Changes International, Bronson, Health Factors,
                PR*Nutrition and the Registrant, as Guarantors and State
                Street Bank and Trust Company (as successor to Fleet
                National Bank), as Trustee regarding Twin's 10 1/4% Senior
                Subordinated Notes due 2006 (incorporated by reference to
                Exhibit 4.4 to the 1998 Annual Report).
 10.1     --    Credit and Guarantee Agreement, dated May 7, 1996, among
                Twin, the Registrant, the financial institutions named
                therein, Chemical Bank as Administrative Agent and The Bank
                of New York as Documentation Agent (incorporated by
                reference to Exhibit 4.3 to Twinlab S-1).
 10.2     --    Guarantee and Collateral Agreement, dated May 7, 1996, among
                the Registrant, Twin, and ARP in favor of Chemical Bank, as
                Administrative Agent (incorporated by reference to Exhibit
                10.1 to Twinlab S-1).
 10.3     --    Form of Revolving Credit Note (incorporated by reference to
                Exhibit 10.4 to the 1996 Annual Report).
 10.4     --    Form of Swing Line Note (incorporated by reference to
                Exhibit 10.5 to the 1996 Annual Report).
 10.5     --    Deed of Trust, dated May 7, 1996 (the "Deed of Trust"), from
                Twin to First American Title Company of Utah, Trustee for
                the use and benefit of Chemical Bank, as Administrative
                Agent, Beneficiary (incorporated by reference to Exhibit
                10.6 to Twinlab S-1).
 10.6     --    Amendment to Deed of Trust, dated November 20, 1996, among
                Twin and The Chase Manhattan Bank (incorporated by reference
                to Exhibit 10.7 to the 1996 Annual Report).
 10.7     --    Stockholders Agreement, dated May 7, 1996, among Brian
                Blechman, Neil Blechman, Ross Blechman, Steve Blechman, Dean
                Blechman and Stephen Welling, the Registrant and GEI
                (incorporated by reference to Exhibit 10.8 to Twinlab S-1).
 10.8     --    Secondary Stockholders Agreement among Brian Blechman, Neil
                Blechman, Ross Blechman, Steve Blechman, Dean Blechman and
                Stephen Welling, the Registrant, GEI, DLJ Investment
                Funding, Inc., DLJ Investment Partners, L.P., Chase Equity
                Associates, L.P., PMI Mezzanine Fund, L.P. and State
                Treasurer of the State of Michigan, Custodian of the
                Michigan Public School Employees' Retirement System, State
                Employees' Retirement System, Michigan State Police
                Retirement System, and Michigan Judges Retirement System
                (incorporated by reference to Exhibit 10.9 to Twinlab S-1).
 10.9     --    Consulting Agreement, dated May 7, 1996, between Twin and
                David Blechman (incorporated by reference to Exhibit 10.10
                to Twinlab S-1).
 10.10    --    Consulting Agreement, dated May 7, 1996, between Twin and
                Jean Blechman (incorporated by reference to Exhibit 10.17 to
                Twinlab S-1).
 10.11    --    Noncompetition Agreement, dated May 7, 1996, between Twin
                and David Blechman (incorporated by reference to Exhibit
                10.18 to Twinlab S-1).
 10.12    --    Noncompetition Agreement, dated May 7, 1996, between Twin
                and Jean Blechman (incorporated by reference to Exhibit
                10.19 to Twinlab S-1).
 10.13    --    Noncompetition Agreement, dated May 7, 1996, between Twin
                and Brian Blechman (incorporated by reference to Exhibit
                10.20 to Twinlab S-1).
 10.14    --    Noncompetition Agreement, dated May 7, 1996, between Twin
                and Neil Blechman (incorporated by reference to Exhibit
                10.21 to Twinlab S-1).
</Table>

                                        30
<PAGE>

<Table>
<Caption>
EXHIBIT
NUMBER                             DESCRIPTION OF EXHIBIT
-------                            ----------------------
<S>       <C>   <C>
 10.15    --    Noncompetition Agreement, dated May 7, 1996, between Twin
                and Ross Blechman (incorporated by reference to Exhibit
                10.22 to Twinlab S-1).
 10.16    --    Noncompetition Agreement, dated May 7, 1996, between Twin
                and Steve Blechman (incorporated by reference to Exhibit
                10.23 to Twinlab S-1).
 10.17    --    Noncompetition Agreement, dated May 7, 1996, between Twin
                and Dean Blechman (incorporated by reference to Exhibit
                10.24 to Twinlab S-1).
 10.18    --    Noncompetition Agreement, dated May 7, 1996, between Twin
                and Stephen Welling (incorporated by reference to Exhibit
                10.25 to Twinlab S-1).
 10.19    --    Form of Restated Standard Indemnity Agreement, dated August
                1992, between Twin and Showa Denko America, Inc.
                (incorporated by reference to Exhibit 10.28 to Twinlab S-1).
 10.20    --    Form of SDR Guaranty Agreement, dated August 1992, between
                Twin and Showa Denko K.K. (incorporated by reference to
                Exhibit 10.29 to Twinlab S-1).
 10.21    --    Twinlab Corporation 1996 Stock Incentive Plan (incorporated
                by reference to Exhibit 10.30 to Twinlab S-1).
 10.22    --    Construction Contract, dated February 27, 1998, between Twin
                and Interwest Construction Company, Inc. (incorporated by
                reference to Exhibit 10.32 to the 1997 Annual Report).
 10.23    --    Lease, dated January 16, 1998, between Twin and Reckson
                Operating Partnership, L.P. (incorporated by reference to
                Exhibit 10.33 to the 1997 Annual Report).
 10.24    --    Asset Purchase Agreement, dated as of March 17, 1998, among
                Jones Medical Industries, Inc., JMI-Phoenix Laboratories,
                Inc., Twin and Bronson Laboratories, Inc. (incorporated by
                reference to Exhibit 10.34 to the 1997 Annual Report on Form
                10-K).
 10.25    --    Twinlab Corporation 1998 Stock Incentive Plan (incorporated
                by reference to Exhibit 10.36 to the 1998 Annual Report).
 10.26    --    Employment Agreement, dated May 7, 1999, between Twin and
                Steve Welling (incorporated by reference to Exhibit 10.37 to
                the 1999 Annual Report).
 10.27    --    Employment Agreement, dated January 1, 2000, between Twin
                and Ross Blechman (incorporated by reference to Exhibit
                10.38 to the 1999 Annual Report).
 10.28    --    Employment Agreement, dated January 1, 2000, between Twin
                and Dean Blechman (incorporated by reference to Exhibit
                10.39 to the 1999 Annual Report).
 10.29    --    Employment Agreement, dated January 1, 2000, between Twin
                and Neil Blechman (incorporated by reference to Exhibit
                10.40 to the 1999 Annual Report).
 10.30    --    Employment Agreement, dated January 1, 2000, between Twin
                and Steve Blechman (incorporated by reference to Exhibit
                10.41 to the 1999 Annual Report).
 10.31    --    Non-Competition Agreement, dated March 9, 2000, between Twin
                and Brian Blechman (incorporated by reference to Exhibit
                10.42 to the 1999 Annual Report).
 10.32    --    Fourth Supplemental Indenture, dated as of January 25, 2000,
                to the Indenture dated May 7, 1996, among Twin, ARP, Changes
                International, Bronson, Health Factors, PR*Nutrition,
                Twinlab FSC and the Registrant, as Guarantors and State
                Street Bank and Trust Company (as successor to Fleet
                National Bank) as Trustee regarding Twins 10 1/4% Senior
                Subordinated Notes due 2006 (incorporated by reference to
                Exhibit 10.43 to the 1999 Annual Report).
 10.33    --    First Amendment and Waiver dated as of March 22, 1999 to the
                Amended and Restated Credit and Guarantee Agreement (dated
                as of November 15, 1996) among the Registrant, Twin and
                several banks and financial institutions (incorporated by
                reference to Exhibit 10.44 to the 1999 Annual Report).
 10.34    --    Second Amendment, dated as of November 12, 1999, to the
                Amended and Restated Credit and Guarantee Agreement (dated
                as of November 15, 1996) among the Registrant, Twin and
                several banks and financial institutions (incorporated by
                reference to Exhibit 10.45 to the 1999 Annual Report).
</Table>

                                        31
<PAGE>

<Table>
<Caption>
EXHIBIT
NUMBER                             DESCRIPTION OF EXHIBIT
-------                            ----------------------
<S>       <C>   <C>
 10.35    --    Third Amendment and Waiver, dated as of November 13, 2000 to
                the Amended and Restated Credit and Guarantee Agreement
                (dated as of November 15, 1996) among the Registrant, Twin
                and several banks and financial institutions (incorporated
                by reference to Exhibit 10.46 to the Quarterly Report on
                Form 10-Q for the quarter ended September 30, 2000).
 10.36    --    Fifth Supplemental Indenture, dated as of March 30, 2001 to
                the Indenture dated May 7, 1996, among the Company, its
                subsidiaries and the Registrant, as Guarantors, and State
                Street Bank and Trust Company (as successor to Fleet
                National Bank) as Trustee regarding Twin's 10 1/4% Senior
                Subordinated Notes due 2006 (incorporated by reference to
                Exhibit 10.36 to Amendment No. 1 on Form 10-K/A to the 2000
                Form 10-K).
 10.37    --    Fourth Amendment and Waiver, dated as of December 15, 2000
                to the Amended and Restated Credit and Guarantee Agreement
                (dated as of November 15, 1996) among the Registrant, Twin
                and several banks and financial institutions (incorporated
                by reference to Exhibit 10.37 to Amendment No. 1 on Form
                10-K/A to the 2000 Form 10-K).
 10.38    --    Fifth Amendment and Waiver, dated as of February 15, 2001 to
                the Amended and Restated Credit and Guarantee Agreement
                (dated as of November 15, 1996) among the Registrant, Twin
                and several banks and financial institutions (incorporated
                by reference to Exhibit 10.38 to Amendment No. 1 on Form
                10-K/A to the 2000 Form 10-K).
 10.39    --    Sixth Amendment and Waiver, dated as of March 30, 2001 to
                the Amended and Restated Credit and Guarantee Agreement
                (dated as of November 15, 1996) among the Registrant, Twin
                and several banks and financial institutions (incorporated
                by reference to Exhibit 10.39 to Amendment No. 1 on Form
                10-K/A to the 2000 Form 10-K).
 10.40    --    Financing Agreement between The CIT Group/Business Credit,
                Inc. and other financial institutions and Twin Laboratories
                Inc., ARP, Changes, PR*Nutrition, Health Factors and Bronson
                dated as of March 29, 2001 (incorporated by reference to
                Exhibit 10.40 to Amendment No. 1 on Form 10-K/A to the 2000
                Form 10-K).
 10.41    --    Security Agreement between Dean and Ross Blechman and The
                CIT Group/Business Credit, Inc. dated as of March 29, 2001
                (incorporated by reference to Exhibit 10.41 to Amendment No.
                1 on Form 10-K/A to the 2000 Form 10-K).
 10.42    --    Intercreditor Agreement between Dean and Ross Blechman and
                The CIT Group/Business Credit, Inc. dated as of March 29,
                2001 (incorporated by reference to Exhibit 10.42 to
                Amendment No. 1 on Form 10-K/A to the 2000 Form 10-K).
 10.43    --    Guaranty between Dean and Ross Blechman and The CIT
                Group/Business Credit, Inc. dated as of March 29, 2001
                (incorporated by reference to Exhibit 10.43 to Amendment No.
                1 on Form 10-K/A to the 2000 Form 10-K).
 10.44    --    Reimbursement Agreement No. 1 between Twinlab Corporation,
                Twin Laboratories Inc., ARP, Changes, PR*Nutrition, Bronson
                and Dean and Ross Blechman dated as of March 29, 2001
                (incorporated by reference to Exhibit 10.44 to Amendment No.
                1 on Form 10-K/A to the 2000 Form 10-K).
 10.45    --    Deed of Trust, Assignment of Rents, Security Agreement and
                Fixture Filing dated as of March 29, 2001 between Twin
                Laboratories Inc. as grantor, Chicago Title Insurance
                Company, as trustee, and The CIT Group/Business Credit,
                Inc., as agent (incorporated by reference to Exhibit 10.45
                to Amendment No. 1 on Form 10-K/A to the 2000 Form 10-K).
 10.46    --    Mortgage, Assignment of Rents, Security Agreement and
                Fixture Filing dated as of March 29, 2001 between Twin
                Laboratories Inc. and The CIT Group/ Business (incorporated
                by reference to Exhibit 10.46 to Amendment No. 1 on Form
                10-K/A to the 2000 Form 10-K).
 10.47    --    Deed of Trust and Financing Statement dated as of March 29,
                2001 between Health Factors International, Inc., as trustor,
                Chicago Title Insurance Company, as trustee, and The CIT
                Group/ Business Credit, Inc. as agent (incorporated by
                reference to Exhibit 10.47 to Amendment No. 1 on Form 10-K/A
                to the 2000 Form 10-K).
 10.48    --    Guaranty (Parent) between the Registrant and The CIT
                Group/Business Credit, Inc. dated as of March 29, 2001
                (incorporated by reference to Exhibit 10.48 to Amendment No.
                1 on Form 10-K/A to the 2000 Form 10-K).
</Table>

                                        32
<PAGE>

<Table>
<Caption>
EXHIBIT
NUMBER                             DESCRIPTION OF EXHIBIT
-------                            ----------------------
<S>       <C>   <C>
 10.49    --    Guaranty (Co-Borrowers) between the subsidiaries of
                Registrant and The CIT Group/Business Credit, Inc. dated as
                of March 29, 2001 (incorporated by reference to Exhibit
                10.49 to Amendment No. 1 on Form 10-K/A to the 2000 Form
                10-K).
 10.50    --    Letter agreement concerning $15 million letter of credit
                between the Blechman Brothers and The CIT Group/Business
                Credit, Inc., dated as of March 29, 2001 (incorporated by
                reference to Exhibit 10.50 to Amendment No. 1 on Form 10-K/A
                to the 2000 Form 10-K).
 10.51    --    Stock Pledge Agreement between the subsidiaries of the
                Registrant and The CIT Group/Business Credit, Inc. dated as
                of March 29, 2001 (incorporated by reference to Exhibit
                10.51 to Amendment No. 1 on Form 10-K/A to the 2000 Form
                10-K).
 10.52    --    Stock Pledge Agreement between the Registrant and The CIT
                Group/Business Credit, Inc. dated as of March 29, 2001
                (incorporated by reference to Exhibit 10.52 to Amendment No.
                1 on Form 10-K/A to the 2000 Form 10-K).
 10.53    --    Grant of Security Interest in Patents, Trademarks,
                Copyrights and Licenses between the subsidiaries of the
                Registrant and The CIT Group/Business Credit, Inc., dated as
                of March 29, 2001 (incorporated by reference to Exhibit
                10.53 to Amendment No. 1 on Form 10-K/A to the 2000 Form
                10-K).
 10.54    --    April 10, 2001 - Amendment Number One to the Financing
                Agreement dated as of March 29, 2001 between CIT
                Group/Business Credit and Twin Laboratories Inc. and its
                affiliates as borrowers (incorporated by reference to
                Exhibit 10.54 to the 2001 Form 10-K).
 10.55    --    May 31, 2001 - Waiver and Amendment Number Two to the
                Financing Agreement and Loan Documents dated as of March 29,
                2001 between CIT Group/Business Credit and Twin Laboratories
                Inc. and its affiliates as borrowers (incorporated by
                reference to Exhibit 10.55 to the 2001 Form 10-K).
 10.56    --    June 5, 2001 - Waiver and Amendment Number Three to the
                Financing Agreement and Loan Documents dated as of March 29,
                2001 between CIT Group/Business Credit and Twin Laboratories
                Inc. and its affiliates as borrowers (incorporated by
                reference to Exhibit 10.56 to the 2001 Form 10-K).
 10.57    --    September 14, 2001 - Waiver and Amendment Number Four to the
                Financing Agreement and Loan Documents dated as of March 29,
                2001 between CIT Group/Business Credit, Inc., other lenders
                thereto and Twin Laboratories Inc. and certain subsidiaries
                as borrowers (incorporated by reference to Exhibit 10.57 to
                the 2001 Form 10-K).
 10.58    --    February 28, 2002 - Waiver and Amendment Number Five to the
                Financing Agreement and Loan Documents dated as of March 29,
                2001 between CIT Group/Business Credit, Inc., other lenders
                thereto and Twin Laboratories Inc. and certain subsidiaries
                as borrowers (incorporated by reference to Exhibit 10.58 to
                the 2001 Form 10-K).
 10.59    --    Asset Purchase Agreement between Goldshield Acquisitions
                Inc., Changes International, Inc. and Twinlab Corporation
                dated as of April 17, 2001 (incorporated by reference to
                Exhibit 10.59 to the 2001 Form 10-K).
 10.60    --    Asset Purchase Agreement between Goldshield Purchases Inc.,
                PR*Nutrition, Inc. and Twinlab Corporation dated as of April
                17, 2001 (incorporated by reference to Exhibit 10.60 to the
                2001 Form 10-K).
 10.61    --    Stock Purchase Agreement between Advance Research Press,
                Inc. and Steve Blechman dated as of June 1, 2001
                (incorporated by reference to Exhibit 10.61 to the 2001 Form
                10-K).
 10.62    --    Termination Agreement between Dean Blechman and Twin
                Laboratories Inc. dated as of January 1, 2002 (incorporated
                by reference to Exhibit 10.62 to the 2001 Form 10-K).
 10.63    --    Asset Purchase Agreement dated as of May 22, 2002 by and
                among Anabolic Laboratories, Inc., Health Factors
                International, Inc. and Twin Laboratories Inc. (incorporated
                by reference to Exhibit 10.63 to the Quarterly Report on
                Form 10-Q for the quarter ended June 30, 2002).
 10.64    --    Manufacturing and Supply agreement dated as of May 22, 2002
                by and between Anabolic Laboratories, Inc. and Twin
                Laboratories Inc. (incorporated by reference to Exhibit
                10.64 to the Quarterly Report on Form 10-Q for the quarter
                ended June 30, 2002).
</Table>

                                        33
<PAGE>

<Table>
<Caption>
EXHIBIT
NUMBER                             DESCRIPTION OF EXHIBIT
-------                            ----------------------
<S>       <C>   <C>
 10.65    --    November 8, 2002-Waiver and Amendment Number Six to the
                Financing Agreement and Loan Documents dated as of March 29,
                2001 between CIT Group/Business Credit, Inc. and other
                lenders thereto and Twin Laboratories Inc. and certain
                subsidiaries as borrowers (incorporated by reference to
                Exhibit 10.65 to the Quarterly Report on Form 10-Q for the
                quarter ended September 30, 2002).
 10.66    --    Separation Agreement between Brian Blechman and Twin
                Laboratories Inc. dated as of November 8, 2002.*
 10.67    --    Separation Agreement between Neil Blechman and Twin
                Laboratories Inc. dated as of November 8, 2002.*
 10.68    --    Asset Purchase Agreement dated as of January 17, 2003 by and
                among Bronson Nutritionals, LLC, Kabco Pharmaceuticals,
                Inc., Bronson Laboratories, Inc. and Twin Laboratories Inc.*
 10.69    --    January 17, 2003-Amendment Number Seven to the Financing
                Agreement and Loan Documents dated as of March 29, 2001
                between CIT Group/Business Credit, Inc. and other lenders
                thereto and Twin Laboratories Inc. and certain subsidiaries
                as borrowers.*
 10.70    --    Employment Agreement, dated March 1, 2003, between Twin and
                Ross Blechman.*
 21.1     --    List of Registrant's Subsidiaries.*
 23.1     --    Consent of Deloitte & Touche LLP.*
</Table>

---------------

* Filed herewith.

                                        34
<PAGE>

                                   SIGNATURES

     Pursuant to the requirements of Section 13 or 15 (d) of the Securities
Exchange Act of 1934, the registrant has duly caused this Report to be signed on
its behalf by the undersigned thereunto duly authorized.

                                          TWINLAB CORPORATION

                                          By:       /s/ ROSS BLECHMAN
                                            ------------------------------------
                                                       Ross Blechman
                                                   Chairman of the Board,
                                                Chief Executive Officer and
                                                          President

     Pursuant to the requirements of the Securities Exchange Act of 1934, this
Report has been signed below by the following persons on behalf of the
registrant and in the capacities and on the dates indicated.

<Table>
<Caption>
                     SIGNATURE                                   TITLE(S)                    DATE
                     ---------                                   --------                    ----




<S>                                                  <C>                                <C>



                 /s/ ROSS BLECHMAN                     Chairman of the Board, Chief     March 31, 2003
---------------------------------------------------  Executive Officer, President and
                   Ross Blechman                       Director (Principal Executive
                                                                 Officer)




                 /s/ NEIL BLECHMAN                               Director               March 31, 2003
---------------------------------------------------
                   Neil Blechman




                /s/ BRIAN BLECHMAN                               Director               March 31, 2003
---------------------------------------------------
                  Brian Blechman




                /s/ STEVE BLECHMAN                               Director               March 31, 2003
---------------------------------------------------
                  Steve Blechman




                 /s/ DEAN BLECHMAN                               Director               March 31, 2003
---------------------------------------------------
                   Dean Blechman




               /s/ JOSEPH SINICROPI                  Chief Operating Officer and Chief  March 31, 2003
---------------------------------------------------    Financial Officer (Principal
                 Joseph Sinicropi                    Financial and Accounting Officer)




              /s/ STEPHEN L. WELLING                  Vice President, General Manager   March 31, 2003
---------------------------------------------------     Key Specialty Accounts and
                Stephen L. Welling                               Director




             /s/ JONATHAN D. SOKOLOFF                            Director               March 31, 2003
---------------------------------------------------
               Jonathan D. Sokoloff




                /s/ JOHN G. DANHAKL                              Director               March 31, 2003
---------------------------------------------------
                  John G. Danhakl




            /s/ WILLIAM U. WESTERFIELD                           Director               March 31, 2003
---------------------------------------------------
              William U. Westerfield




               /s/ LEONARD SCHUTZMAN                             Director               March 31, 2003
---------------------------------------------------
                 Leonard Schutzman
</Table>

                                        35
<PAGE>

                                 CERTIFICATIONS

                    CERTIFICATION OF CHIEF EXECUTIVE OFFICER

     I, Ross Blechman certify that:

     1.  I have reviewed this annual report on Form 10-K of Twinlab Corporation;

     2.  Based on my knowledge, this annual report does not contain any untrue
statement of a material fact or omit to state a material fact necessary to make
the statements made, in light of the circumstances under which such statements
were made, not misleading with respect to the period covered by this annual
report;

     3.  Based on my knowledge, the financial statements, and other financial
information included in this annual report, fairly present in all material
respects the financial condition, results of operations and cash flows of the
registrant as of, and for, the periods presented in this annual report;

     4.  The registrant's other certifying officers and I are responsible for
establishing and maintaining disclosure controls and procedures (as defined in
Exchange Act Rules 13a-14 and 15d-14) for the registrant and we have:

          a) designed such disclosure controls and procedures to ensure that
     material information relating to the registrant, including its consolidated
     subsidiaries, is made known to us by others within those entities,
     particularly during the period in which this annual report is being
     prepared;

          b) evaluated the effectiveness of the registrant's disclosure controls
     and procedures as of a date within 90 days prior to the filing date of this
     annual report (the "Evaluation Date"); and

          c) presented in this annual report our conclusions about the
     effectiveness of the disclosure controls and procedures based on our
     evaluation as of the Evaluation Date;

     5.  The registrant's other certifying officers and I have disclosed, based
on our most recent evaluation, to the registrant's auditors and the audit
committee of registrant's board of directors (or persons performing the
equivalent function):

          a) all significant deficiencies in the design or operation of internal
     controls which could adversely affect the registrant's ability to record,
     process, summarize and report financial data and have identified for the
     registrant's auditors any material weaknesses in internal controls; and

          b) any fraud, whether or not material, that involves management or
     other employees who have a significant role in the registrant's internal
     controls; and

     6.  The registrant's other certifying officers and I have indicated in this
annual report whether or not there were significant changes in internal controls
or in other factors that could significantly affect internal controls subsequent
to the date of our most recent evaluation, including any corrective actions with
regard to significant deficiencies and material weaknesses.

                                                   /s/ ROSS BLECHMAN
                                          --------------------------------------
                                                      Ross Blechman
                                                 Chief Executive Officer

Dated: March 31, 2003

                                        36
<PAGE>

                    CERTIFICATION OF CHIEF FINANCIAL OFFICER

     I, Joseph Sinicropi certify that:

     1.  I have reviewed this annual report on Form 10-K of Twinlab Corporation;

     2.  Based on my knowledge, this annual report does not contain any untrue
statement of a material fact or omit to state a material fact necessary to make
the statements made, in light of the circumstances under which such statements
were made, not misleading with respect to the period covered by this annual
report;

     3.  Based on my knowledge, the financial statements, and other financial
information included in this annual report, fairly present in all material
respects the financial condition, results of operations and cash flows of the
registrant as of, and for, the periods presented in this annual report;

     4.  The registrant's other certifying officers and I are responsible for
establishing and maintaining disclosure controls and procedures (as defined in
Exchange Act Rules 13a-14 and 15d-14) for the registrant and we have:

          a) designed such disclosure controls and procedures to ensure that
     material information relating to the registrant, including its consolidated
     subsidiaries, is made known to us by others within those entities,
     particularly during the period in which this annual report is being
     prepared;

          b) evaluated the effectiveness of the registrant's disclosure controls
     and procedures as of a date within 90 days prior to the filing date of this
     annual report (the "Evaluation Date"); and

          c) presented in this annual report our conclusions about the
     effectiveness of the disclosure controls and procedures based on our
     evaluation as of the Evaluation Date;

     5.  The registrant's other certifying officers and I have disclosed, based
on our most recent evaluation, to the registrant's auditors and the audit
committee of registrant's board of directors (or persons performing the
equivalent function):

          a) all significant deficiencies in the design or operation of internal
     controls which could adversely affect the registrant's ability to record,
     process, summarize and report financial data and have identified for the
     registrant's auditors any material weaknesses in internal controls; and

          b) any fraud, whether or not material, that involves management or
     other employees who have a significant role in the registrant's internal
     controls; and

     6.  The registrant's other certifying officers and I have indicated in this
annual report whether or not there were significant changes in internal controls
or in other factors that could significantly affect internal controls subsequent
to the date of our most recent evaluation, including any corrective actions with
regard to significant deficiencies and material weaknesses.

                                                 /s/ JOSEPH SINICROPI
                                          --------------------------------------
                                                     Joseph Sinicropi
                                                 Chief Financial Officer

Dated: March 31, 2003

                                        37
<PAGE>

                          INDEPENDENT AUDITORS' REPORT

To the Shareholders of Twinlab Corporation
Hauppauge, New York

     We have audited the accompanying consolidated balance sheets of Twinlab
Corporation and subsidiaries (the "Company") as of December 31, 2002 and 2001,
and the related consolidated statements of operations, shareholders' (deficit)
equity and cash flows for each of the three years in the period ended December
31, 2002. Our audits also included the financial statement schedules listed in
the Index at Item 15 (a) (2). These financial statements and financial statement
schedules are the responsibility of the Company's management. Our responsibility
is to express an opinion on these financial statements and financial statement
schedules based on our audits.

     We conducted our audits in accordance with auditing standards generally
accepted in the United States of America. Those standards require that we plan
and perform the audit to obtain reasonable assurance about whether the financial
statements are free of material misstatement. An audit includes examining, on a
test basis, evidence supporting the amounts and disclosures in the financial
statements. An audit also includes assessing the accounting principles used and
significant estimates made by management, as well as evaluating the overall
financial statement presentation. We believe that our audits provide a
reasonable basis for our opinion.

     In our opinion, such consolidated financial statements present fairly, in
all material respects, the financial position of Twinlab Corporation and
subsidiaries as of December 31, 2002 and 2001, and the results of their
operations and their cash flows for each of the three years in the period ended
December 31, 2002 in conformity with accounting principles generally accepted in
the United States of America. Also in our opinion, such financial statement
schedules, when considered in relation to the basic consolidated financial
statements taken as a whole, present fairly, in all material respects, the
information set forth therein.

-s- Deloitte & Touche LLP

Jericho, New York
March 1, 2003

                                       F-1
<PAGE>

                      TWINLAB CORPORATION AND SUBSIDIARIES

                          CONSOLIDATED BALANCE SHEETS
                           DECEMBER 31, 2002 AND 2001
          (IN THOUSANDS OF DOLLARS EXCEPT SHARE AND PER SHARE AMOUNTS)

<Table>
<Caption>
                                                                2002        2001
                                                              ---------   ---------
<S>                                                           <C>         <C>
ASSETS (Note 7)
CURRENT ASSETS:
  Cash and cash equivalents.................................  $      --   $      --
  Accounts receivable, net of allowance for bad debts of
     $2,682 and $6,100, respectively (Note 13)..............     20,545      26,450
  Inventories (Note 4)......................................     29,254      42,645
  Prepaid expenses and other current assets.................      1,853       1,934
  Assets of discontinued operations (Note 3)................      6,370       6,676
                                                              ---------   ---------
     Total current assets...................................     58,022      77,705
PROPERTY, PLANT AND EQUIPMENT, Net (Note 5).................     34,019      46,148
OTHER ASSETS (Note 9).......................................      5,136       4,761
                                                              ---------   ---------
TOTAL.......................................................  $  97,177   $ 128,614
                                                              =========   =========
LIABILITIES AND SHAREHOLDERS' (DEFICIT) EQUITY
CURRENT LIABILITIES:
  Current portion of long-term debt (Note 7)................  $   6,565   $   2,241
  Accounts payable..........................................     16,132      19,352
  Accrued expenses and other current liabilities (Note 6)...     21,156       8,870
                                                              ---------   ---------
     Total current liabilities..............................     43,853      30,463
LONG-TERM DEBT, less current portion (Note 7)...............     64,451      77,129
                                                              ---------   ---------
     Total liabilities......................................    108,304     107,592
                                                              ---------   ---------
COMMITMENTS AND CONTINGENCIES (Note 12)
SHAREHOLDERS' (DEFICIT) EQUITY (Note 8):
  Preferred stock, $.01 par value; 2,000,000 shares
     authorized; none issued................................         --          --
  Common stock, $1.00 par value; 75,000,000 shares
     authorized; 33,041,756 issued and 29,128,356
     outstanding as of December 31, 2002 and 33,041,756
     issued and 28,940,856 outstanding as of December 31,
     2001...................................................     33,042      33,042
  Additional paid-in capital................................    288,582     290,001
  Accumulated deficit.......................................   (297,639)   (265,227)
                                                              ---------   ---------
                                                                 23,985      57,816
  Treasury stock at cost; 3,913,400 shares as of December
     31, 2002 and 4,100,900 shares as of December 31,
     2001...................................................    (35,112)    (36,794)
                                                              ---------   ---------
     Total shareholders' (deficit) equity...................    (11,127)     21,022
                                                              ---------   ---------
TOTAL.......................................................  $  97,177   $ 128,614
                                                              =========   =========
</Table>

                See notes to consolidated financial statements.
                                       F-2
<PAGE>

                      TWINLAB CORPORATION AND SUBSIDIARIES

                     CONSOLIDATED STATEMENTS OF OPERATIONS
              FOR THE YEARS ENDED DECEMBER 31, 2002, 2001 AND 2000
               (IN THOUSANDS OF DOLLARS EXCEPT PER SHARE AMOUNTS)

<Table>
<Caption>
                                                                2002       2001       2000
                                                              --------   --------   --------
<S>                                                           <C>        <C>        <C>
NET SALES (Notes 13 and 14.b.)..............................  $146,623   $187,107   $228,495
COST OF SALES...............................................    99,487    126,804    171,865
                                                              --------   --------   --------
GROSS PROFIT................................................    47,136     60,303     56,630
OPERATING EXPENSES..........................................    62,757     77,313     87,148
RESTRUCTURING CHARGES (Note 2)..............................     9,616         --         --
ASSET IMPAIRMENT CHARGES (Note 2)...........................     7,228      3,827         --
                                                              --------   --------   --------
LOSS FROM OPERATIONS........................................   (32,465)   (20,837)   (30,518)
                                                              --------   --------   --------
OTHER (EXPENSE) INCOME:
  Interest expense, net of interest income of $26, $129 and
     $314, respectively.....................................    (8,092)    (9,097)    (8,552)
  Other.....................................................       132         (5)        --
                                                              --------   --------   --------
                                                                (7,960)    (9,102)    (8,552)
                                                              --------   --------   --------
LOSS FROM CONTINUING OPERATIONS BEFORE INCOME TAXES.........   (40,425)   (29,939)   (39,070)
(BENEFIT FROM) PROVISION FOR INCOME TAXES (Note 10).........    (6,911)    22,801     11,252
                                                              --------   --------   --------
LOSS FROM CONTINUING OPERATIONS.............................   (33,514)   (52,740)   (50,322)
                                                              --------   --------   --------
DISCONTINUED OPERATIONS (Note 3):
  Income (loss) from discontinued operations, adjusted for
     applicable income taxes of $211 and $(864) in 2001 and
     2000, respectively.....................................     1,102    (30,131)    (1,613)
  Loss on disposal of subsidiary, adjusted for income taxes
     of $449................................................        --     (8,698)        --
                                                              --------   --------   --------
                                                                 1,102    (38,829)    (1,613)
                                                              --------   --------   --------
NET LOSS....................................................  $(32,412)  $(91,569)  $(51,935)
                                                              ========   ========   ========
BASIC AND DILUTED LOSS PER SHARE (Note 8):
  Loss from continuing operations...........................  $  (1.16)  $  (1.84)  $  (1.76)
  Income (loss) from discontinued operations................      0.04      (1.35)     (0.05)
                                                              --------   --------   --------
  Net loss..................................................  $  (1.12)  $  (3.19)  $  (1.81)
                                                              ========   ========   ========
  Basic and diluted weighted average shares outstanding.....    28,983     28,670     28,638
                                                              ========   ========   ========
</Table>

                See notes to consolidated financial statements.
                                       F-3
<PAGE>

                      TWINLAB CORPORATION AND SUBSIDIARIES

           CONSOLIDATED STATEMENTS OF SHAREHOLDERS' (DEFICIT) EQUITY
              FOR THE YEARS ENDED DECEMBER 31, 2002, 2001 AND 2000
                  (IN THOUSANDS OF DOLLARS EXCEPT SHARE DATA)

<Table>
<Caption>
                                    COMMON STOCK       ADDITIONAL                    TREASURY STOCK
                                --------------------    PAID-IN     ACCUMULATED   ---------------------
                                  SHARES     AMOUNT     CAPITAL       DEFICIT       SHARES      AMOUNT      TOTAL
                                ----------   -------   ----------   -----------   ----------   --------   ---------
<S>                             <C>          <C>       <C>          <C>           <C>          <C>        <C>
Balance at January 1, 2000....  32,706,233   $32,706    $289,336     $(121,723)    4,100,900   $(36,794)  $ 163,525
Net loss and comprehensive
  loss........................          --        --          --       (51,935)           --         --     (51,935)
Shares issued under Outside
  Directors Plan (Note
  8.a.).......................       2,280         2          18            --            --         --          20
Equity issued for professional
  services....................      40,354        41         336            --            --         --         377
                                ----------   -------    --------     ---------    ----------   --------   ---------
Balance at December 31,
  2000........................  32,748,867    32,749     289,690      (173,658)    4,100,900    (36,794)    111,987
Net loss and comprehensive
  loss........................          --        --          --       (91,569)           --         --     (91,569)
Shares issued under Outside
  Directors Plan (Note
  8.a.).......................      11,288        11           9            --            --         --          20
Equity issued for professional
  services....................     281,601       282         302            --            --         --         584
                                ----------   -------    --------     ---------    ----------   --------   ---------
Balance at December 31,
  2001........................  33,041,756    33,042     290,001      (265,227)    4,100,900    (36,794)     21,022
Net loss and comprehensive
  loss........................          --        --          --       (32,412)           --         --     (32,412)
Shares issued to guarantors of
  Revolving Credit Facility
  (Note 9)....................          --        --      (1,459)           --      (187,500)     1,682         223
Equity issued for professional
  services....................          --        --          40            --            --         --          40
                                ----------   -------    --------     ---------    ----------   --------   ---------
Balance at December 31,
  2002........................  33,041,756   $33,042    $288,582     $(297,639)    3,913,400   $(35,112)  $ (11,127)
                                ==========   =======    ========     =========    ==========   ========   =========
</Table>

                See notes to consolidated financial statements.
                                       F-4
<PAGE>

                      TWINLAB CORPORATION AND SUBSIDIARIES

                     CONSOLIDATED STATEMENTS OF CASH FLOWS
              FOR THE YEARS ENDED DECEMBER 31, 2002, 2001 AND 2000
                           (IN THOUSANDS OF DOLLARS)

<Table>
<Caption>
                                                                2002       2001       2000
                                                              --------   --------   --------
<S>                                                           <C>        <C>        <C>
CASH FLOWS FROM OPERATING ACTIVITIES:
  Net loss..................................................  $(32,412)  $(91,569)  $(51,935)
  Adjustments to reconcile net loss to net cash provided by
    (used in) operating activities:
    (Income) loss from discontinued operations..............    (1,102)    38,829      1,613
    Asset impairment charges................................     7,228      3,827         --
    Depreciation and amortization...........................     6,938      6,382      4,597
    Provision for excess and slow moving inventories........     6,681         --     10,601
    Bad debt expense........................................     1,009      2,156      4,415
    Deferred income taxes...................................        --     23,442     21,324
    Gain on sale of businesses and fixed assets.............       (60)      (971)        --
    Other...................................................        40        587      1,274
    Changes in operating assets and liabilities:
      Accounts receivable...................................     4,896     22,447     (3,014)
      Inventories...........................................     6,710      5,304      8,508
      Prepaid expenses and other current assets.............      (656)       132      1,234
      Prepaid taxes.........................................        --     11,692     (3,509)
      Accounts payable......................................    (3,220)    (8,144)    (4,566)
      Accrued expenses and other current liabilities........    10,505     (2,940)   (15,059)
                                                              --------   --------   --------
      Net cash provided by (used in) continuing
       operations...........................................     6,557     11,174    (24,517)
      Net cash provided by discontinued operations..........     1,408      3,016      2,004
                                                              --------   --------   --------
         Net cash provided by (used in) operating
           activities.......................................     7,965     14,190    (22,513)
                                                              --------   --------   --------
CASH FLOWS FROM INVESTING ACTIVITIES:
  Net proceeds from sale of businesses and fixed assets.....     2,721      5,114         --
  Acquisition of property, plant and equipment..............    (1,877)    (3,312)    (5,951)
  Decrease (increase) in other assets.......................        15       (210)      (347)
                                                              --------   --------   --------
         Net cash provided by (used in) investing
           activities.......................................       859      1,592     (6,298)
                                                              --------   --------   --------
CASH FLOWS FROM FINANCING ACTIVITIES:
  Net (repayments) borrowings under revolving credit
    facilities..............................................    (6,112)   (16,532)    31,000
  Payments of debt..........................................    (2,242)    (2,069)    (1,293)
  Payments of debt issuance costs...........................      (470)    (2,071)        --
                                                              --------   --------   --------
         Net cash (used in) provided by financing
           activities.......................................    (8,824)   (20,672)    29,707
                                                              --------   --------   --------
Net (decrease) increase in cash and cash equivalents........        --     (4,890)       896
Cash and cash equivalents at beginning of year..............        --      4,890      3,994
                                                              --------   --------   --------
Cash and cash equivalents at end of year....................  $     --   $     --   $  4,890
                                                              ========   ========   ========
Supplemental disclosures of cash flow information:
  Cash paid during the year for:
    Interest................................................  $  6,198   $  8,830   $  8,051
                                                              ========   ========   ========
    Income taxes, net of cash refunds.......................  $ (6,706)  $(11,540)  $ (7,104)
                                                              ========   ========   ========
    Acquisition of equipment and computer software and costs
     under lease obligations................................  $     --   $     --   $  3,374
                                                              ========   ========   ========
</Table>

                See notes to consolidated financial statements.
                                       F-5
<PAGE>

                      TWINLAB CORPORATION AND SUBSIDIARIES

                   NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
              FOR THE YEARS ENDED DECEMBER 31, 2002, 2001 AND 2000
                  (DOLLAR AMOUNTS ARE IN THOUSANDS OF DOLLARS)

1.  SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

     a.  Basis of presentation and principles of consolidation -- The
consolidated financial statements of Twinlab Corporation include the accounts of
Twinlab Corporation ("Twinlab") and its direct and indirect subsidiaries (the
"Company"). All intercompany accounts and transactions are eliminated in
consolidation.

     The Company is a leading manufacturer and marketer of high-quality,
science-based nutritional supplements sold through health and natural food
stores and national and regional drug store chains, supermarkets, and mass
market retailers.

     b.  Cash equivalents -- Investments with original maturities of three
months or less are considered cash equivalents.

     c.  Inventories -- Inventories are stated at the lower of cost (first-in,
first-out method) or market value.

     d.  Property, plant and equipment -- Depreciation is computed using the
straight-line method based upon the estimated useful lives of the related
assets. Useful lives are 10 to 40 years for buildings and improvements, 3 to 10
years for machinery and equipment and 3 to 8 years for office and computer
equipment. Amortization of leasehold improvements is computed by the
straight-line method over the shorter of the estimated useful lives of the
related assets or lease term.

     e.  Intangible assets -- The Company adopted Statement of Financial
Accounting Standards ("SFAS") No. 142, "Goodwill and Other Intangible Assets",
effective January 1, 2002. In accordance with SFAS No. 142, goodwill and
intangible assets with indefinite lives are no longer subject to amortization,
but are subject to at least an annual assessment for impairment by applying a
fair value based test. The Company has completed a transitional fair value based
impairment test on its goodwill and an annual impairment test as of December 31,
2002, neither of which resulted in an impairment charge.

     With the adoption of SFAS No. 142, the Company ceased the amortization of
goodwill with a book value of $350 as of January 1, 2002. Had amortization of
goodwill and tradenames not been recorded during the years ended December 31,
2001 and 2000, the net loss would have been reduced by approximately $842 and
$1,089, net of taxes, respectively, and basic and diluted net loss per share
would have decreased by $0.03 for both years.

     Intangible assets subject to amortization after the adoption of SFAS No.
142 are being amortized on the straight-line method and consist of the
following:

<Table>
<Caption>
                                                DECEMBER 31, 2002                  DECEMBER 31, 2001
                                         --------------------------------   --------------------------------
                                          GROSS                              GROSS
                              RANGE OF   CARRYING   ACCUMULATED             CARRYING   ACCUMULATED
                               LIVES      AMOUNT    AMORTIZATION    NET      AMOUNT    AMORTIZATION    NET
                              --------   --------   ------------   ------   --------   ------------   ------
<S>                           <C>        <C>        <C>            <C>      <C>        <C>            <C>
Trademarks..................    3-20      $2,191        $708       $1,483    $2,124        $651       $1,473
Other.......................       5         307         267           40       307         235           72
                                          ------        ----       ------    ------        ----       ------
                                          $2,498        $975       $1,523    $2,431        $886       $1,545
                                          ======        ====       ======    ======        ====       ======
</Table>

     Amortization expense for other intangible assets still subject to
amortization (excluding provision for impairment) was $89 and $92 for the years
ended December 31, 2002 and 2001, respectively. At December 31, 2002, estimated
future amortization expense of other intangible assets still subject to
amortization is as follows: approximately $125, $117, $103, $101 and $101 for
the years ended December 31, 2003, 2004, 2005, 2006 and 2007, respectively.

                                       F-6
<PAGE>
                      TWINLAB CORPORATION AND SUBSIDIARIES

           NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)

     f.  Income taxes -- The Company accounts for income taxes under the
provisions of SFAS No. 109, "Accounting For Income Taxes", which requires
recognition of deferred tax assets and liabilities for the expected future tax
consequences of events that have been included in the Company's financial
statements or tax returns. Under this method, deferred tax assets and
liabilities are determined based on the differences between the financial
accounting and tax bases of assets and liabilities using enacted tax rates in
effect for the year in which the differences are expected to reverse. The
Company records a valuation allowance to reduce its deferred tax assets to the
amount that is more likely than not to be realized.

     g.  Revenue recognition -- Revenue from product sales, net of estimated
credits for returns and allowances, is recognized at the time of shipment to the
customer. Revenue from magazine subscriptions was recorded as deferred revenue
at the time of sale and a pro rata share was included in revenue as magazines
were delivered to subscribers. Advertising revenue was recognized when the
related magazines were issued.

     h.  Advertising and promotions -- The Company advertises its branded
products through national and regional media, and through cooperative
advertising programs with customers. The Company's advertising expenses were
$14,051, $14,855 and $16,810 for the years ended December 31, 2002, 2001 and
2000, respectively. Customers are also offered in-store promotional allowances
and certain products are also promoted with direct to consumer rebate programs.
Costs for these advertising and promotional programs are expensed as incurred.
Costs for cooperative advertising programs are expensed at the time the related
revenues are recorded.

     i.  Research and development expenses -- The Company charges research and
development expenses to operations as incurred. Research and development
expenses were $1,977, $2,651 and $2,524 for the years ended December 31, 2002,
2001 and 2000, respectively.

     j.  Stock-based compensation -- At December 31, 2002, the Company has four
stock-based employee compensation plans, which are more fully described in Note
8. The Company accounts for these plans under the recognition and measurement
principles of APB Opinion No. 25, "Accounting for Stock Issued to Employees,"
and related interpretations. No stock-based employee compensation cost is
reflected in the net loss, as all options granted under these plans had an
exercise price equal to the market value of the underlying common stock on the
date of the grant.

     The following table illustrates the effect on net loss and loss per share
if the Company had applied the fair value recognition provisions of SFAS No.
123, "Accounting for Stock-Based Compensation," to stock-based employee
compensation. The Company's calculations were made using the Black-Scholes
option pricing model, which is more fully described in Note 8.

<Table>
<Caption>
                                                                 YEAR ENDED DECEMBER 31,
                                                              ------------------------------
                                                                2002       2001       2000
                                                              --------   --------   --------
<S>                                                           <C>        <C>        <C>
Net loss, as reported.......................................  $(32,412)  $(91,569)  $(51,935)
Deduct: Total stock based compensation expense determined
        under fair value based method for all awards, net of
        related tax effects.................................    (1,694)    (2,324)    (2,165)
                                                              --------   --------   --------
Pro forma net loss..........................................  $(34,106)  $(93,893)  $(54,100)
                                                              ========   ========   ========
Loss per share:
  Basic and diluted -- as reported..........................  $  (1.12)  $  (3.19)  $  (1.81)
  Basic and diluted -- pro forma............................  $  (1.18)  $  (3.27)  $  (1.89)
</Table>

     k.  Earnings per share -- The Company accounts for earnings per share in
accordance with SFAS No. 128, "Earnings Per Share". SFAS No. 128 requires
presentation of "basic" and "diluted" earnings per share.

                                       F-7
<PAGE>
                      TWINLAB CORPORATION AND SUBSIDIARIES

           NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)

     l.  Impairment of long-lived assets -- The Company adopted SFAS No. 144,
"Accounting for the Impairment or Disposal of Long-Lived Assets", effective
January 1, 2002. Accordingly, the Company reviews its long-lived assets,
including property and equipment and finite-lived intangible assets for
impairment whenever events or changes in circumstances indicate that the
carrying amount of the assets may not be fully recoverable. To determine
recoverability of its long-lived assets, the Company evaluates the probability
that future undiscounted net cash flows will be less than the carrying amount of
the assets. Impairment costs, if any, are measured by comparing the carrying
amount of the related assets to their fair value. (See Note 2).

     m.  Internal use software -- The Company follows the American Institute of
Certified Public Accountants' ("AICPA") Statement of Position ("SOP") 98-1,
"Accounting for the Costs of Computer Software Developed or Obtained for
Internal Use". In accordance with SOP 98-1, the Company expenses costs incurred
in the preliminary project stage and, thereafter, capitalizes costs incurred in
the developing or obtaining of internal use software. Certain costs, such as
maintenance and training, are expensed as incurred. Capitalized costs are
amortized over five years and are subject to impairment evaluation in accordance
with the provisions of SFAS No. 144.

     n.  Foreign currency translation -- The functional currency of the
Company's foreign subsidiaries is the U.S. dollar. However, the Company's
foreign subsidiaries' books and records are maintained in their respective
foreign currencies. Therefore, assets and liabilities of the foreign
subsidiaries are remeasured using a combination of current and historical rates.
Income and expense accounts are remeasured primarily using average rates in
effect during the year. Unrealized foreign exchange gains and losses resulting
from the remeasurement of these entities are included in the results of
operations. The Company does not engage in international currency hedging
transactions.

     o.  Use of estimates in the preparation of financial statements -- The
preparation of financial statements in conformity with accounting principles
generally accepted in the United States of America requires management to make
estimates and assumptions that affect the reported amounts of assets and
liabilities and disclosure of contingent assets and liabilities at the date of
the financial statements and the reported amounts of revenues and expenses
during the reporting period. On an on-going basis, the Company evaluates its
estimates and assumptions including those related to customer returns and
allowances, allowance for doubtful accounts, inventories, long-lived assets,
income taxes, contingencies and litigation. The Company bases its estimates on
historical experience and on various other factors that are believed to be
reasonable. Actual results could materially differ from those estimates.

     p.  Reclassifications -- Certain prior year balances have been reclassified
to conform with current year classifications.

     q.  New accounting pronouncements -- In August 2001, the Financial
Accounting Standards Board ("FASB") issued SFAS No. 143, "Accounting for Asset
Retirement Obligations", which is effective for fiscal years beginning after
June 15, 2002. SFAS No. 143 addresses financial accounting and reporting for
obligations associated with the retirement of tangible long-lived assets and the
associated asset retirement costs. The adoption of SFAS No. 143 is not expected
to have a significant impact on the Company's consolidated financial statements.

     Effective January 1, 2002, the Company adopted Emerging Issues Task Force
("EITF") No. 01-9, "Accounting for Consideration Given by a Vendor to a Customer
(Including a Reseller of the Vendor's Products)," which required that
consideration paid to a distributor or retailer to promote the vendor's
products, such as slotting fees or buydowns, generally be characterized as a
reduction of revenue when recognized in the vendor's income statement.
Accordingly, the Company reported such costs as a reduction of net sales rather
than as operating expenses during the year ended December 31, 2002 and
reclassified costs totaling $1,608 and $930 for the years ended December 31,
2001 and 2000, respectively.

                                       F-8
<PAGE>
                      TWINLAB CORPORATION AND SUBSIDIARIES

           NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)

     In April 2002, the FASB issued SFAS No. 145, "Rescission of FASB Statements
No. 4, 44 and 64, Amendment of FASB Statement No. 13, and Technical
Corrections". This statement provides guidance on the classification of gains
and losses from the extinguishment of debt and on the accounting for certain
specified lease transactions. The adoption of SFAS No. 145 is not expected to
have a significant impact on the Company's consolidated financial statements.

     In June 2002, the FASB issued SFAS No. 146, "Accounting for Costs
Associated with Exit or Disposal Activities". This statement provides guidance
on the recognition and measurement of liabilities associated with disposal
activities and will be adopted by the Company on January 1, 2003. The Company
currently accounts for costs associated with exit or disposal activities in
accordance with EITF 94-3, "Liability Recognition for Certain Employee
Termination Benefits and Other Costs to Exit an Activity (including Certain
Costs Incurred in a Restructuring)."

     In November 2002, the FASB approved FASB Interpretation ("FIN") No. 45,
"Guarantor's Accounting and Disclosure Requirements for Guarantees, including
Indirect Guarantees of Indebtedness of Others, an Interpretation of FASB
Statement No. 5, 57 and 107 and Rescission of FASB Interpretation No. 34". FIN
45 clarifies the requirements of SFAS No. 5, "Accounting for Contingencies",
relating to a guarantor's accounting for, and disclosure of, the issuance of
certain types of guarantees. Specifically, FIN 45 requires that a guarantor
recognize, at the inception of a guarantee, a liability for the fair value of
the obligation undertaken in issuing the guarantee. The provisions for initial
recognition and measurement are effective on a prospective basis for guarantees
that are issued or modified after December 31, 2002, irrespective of a
guarantor's fiscal year end. However, the disclosure provisions of FIN 45 are
effective for financial statements of interim or annual periods ending after
December 15, 2002. The adoption of FIN 45 is not expected to have a significant
impact on the Company's consolidated financial statements.

     In December 2002, the FASB issued SFAS No. 148, "Accounting for Stock-Based
Compensation -- Transition and Disclosure", an amendment of FASB Statement No.
123. SFAS No. 148 provides alternative methods of transition for a voluntary
change to the fair value based method of accounting for stock-based employee
compensation, as well as supplementary disclosure requirements giving more
prominence to the accounting method utilized and its effect on the reported
results. The statement is effective for the Company's 2002 consolidated
financial statements; however, the Company does not intend to change its policy
for accounting for stock options to the fair value method and, therefore, the
implementation of this statement did not have a significant impact on the
Company's consolidated financial statements.

2.  RESTRUCTURING AND ASSET IMPAIRMENT CHARGES

     On July 24, 2002, the Company announced a comprehensive restructuring of
its operations designed to improve the Company's financial performance and
operating results. The restructuring, designed to reduce costs and better align
the Company's operational infrastructure to its sales volume, resulted in the
consolidation of the New York manufacturing and distribution facilities into the
Company's modern FDA-registered facility located in American Fork, Utah. The
Company's corporate offices and certain operational functions remain in New
York. The consolidation of the facilities has been substantially completed
during fiscal 2002 and is anticipated to be completed during the first half of
2003.

                                       F-9
<PAGE>
                      TWINLAB CORPORATION AND SUBSIDIARIES

           NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)

     Significant components of the restructuring charges recorded during the
year ended December 31, 2002 and restructuring accrual as of December 31, 2002
include:

<Table>
<Caption>
                                                        TOTAL
                                                    RESTRUCTURING              RESTRUCTURING
                                                       CHARGES      PAYMENTS      ACCRUAL
                                                    -------------   --------   -------------
<S>                                                 <C>             <C>        <C>
Facility Costs....................................     $3,137       $  (594)      $2,543
Employee Costs....................................      5,163        (1,249)       3,914
Professional Fees.................................        703          (673)          30
Other.............................................        613          (613)          --
                                                       ------       -------       ------
  Total...........................................     $9,616       $(3,129)      $6,487
                                                       ======       =======       ======
</Table>

     Facility costs represent remaining lease payments for New York leased
properties and equipment, and holding and shutdown costs related to the New York
manufacturing and distribution facilities. Employee costs primarily represent
severance and related benefits associated with the separation of approximately
300 New York employees. The majority of the employees left during the fourth
quarter of 2002 and it is anticipated that the balance will be leaving during
the first half of 2003.

     In addition, as a result of the consolidation of the facilities, certain
manufacturing and distribution assets were determined to be impaired resulting
in asset impairment charges of $7,228. The Company anticipates selling these
assets during fiscal 2003.

     The Company anticipates recording additional restructuring charges of up to
$1,000 in connection with the consolidation of its facilities, substantially all
of which are expected to be recorded during the first half of 2003.

     In connection with its plan to consolidate the manufacturing and
distribution facilities, the Company incurred additional costs of approximately
$1,100 primarily relating to personnel costs associated with preparing the Utah
facility. These costs have been recorded in operating expenses in the
accompanying Consolidated Statements of Operations.

     In connection with its ongoing review of long-lived assets, the Company
recorded non-cash impairment charges totaling $33,832 during the year ended
December 31, 2001. These charges consisted of $30,005 related to the tradename,
customer lists and goodwill of Bronson Laboratories, Inc. ("Bronson") (included
in income (loss) from discontinued operations in the accompanying Consolidated
Statement of Operations) and $2,887 related to property and equipment and the
goodwill of Health Factors International, Inc. ("Health Factors"). The
impairment charges resulted from projected changes in the operating plans of
Bronson and Health Factors. The Company calculated the present value of expected
cash flows of these companies to determine the fair value of these assets. In
addition, the Company recorded an impairment charge of $940 related to idle
packaging equipment leased under operating leases.

3.  DISPOSITION OF OPERATIONS

     a.  Changes International, Inc. -- On April 17, 2001, the Company sold the
assets of its Changes International, Inc. ("Changes International") subsidiary
to Goldshield Group plc for approximately $4,405. The Company received $3,524
upon closing the transaction, $352 in October 2001 and $529 in April 2002. The
loss on the sale of the assets was $8,698. Changes International's results of
operations have been classified as discontinued operations and prior periods
have been reclassified.

                                       F-10
<PAGE>
                      TWINLAB CORPORATION AND SUBSIDIARIES

           NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)

     Net sales and income (loss) from discontinued operations related to Changes
International are as follows:

<Table>
<Caption>
                                                                 YEAR ENDED
                                                                DECEMBER 31,
                                                              ----------------
                                                               2001     2000
                                                              ------   -------
<S>                                                           <C>      <C>
Net sales...................................................  $8,407   $38,052
Operating income (loss).....................................     423    (1,564)
Provision for (benefit from) income taxes...................     211      (548)
Income (loss) from discontinued operations..................     164    (1,087)
Income (loss) from discontinued operations per diluted
  share.....................................................    0.01     (0.04)
</Table>

     At December 31, 2001, liabilities of discontinued operations of $251 have
been included in accrued expenses and other current liabilities in the
accompanying Consolidated Balance Sheet.

     b.  PR Nutrition, Inc. -- On April 17, 2001, the Company sold the assets of
PR Nutrition, Inc. to Goldshield Group plc for approximately $595. The Company
received $476 upon closing the transaction, $48 in October 2001 and $71 in April
2002. The Company recorded a pre-tax gain of approximately $297 in connection
with the sale of these assets which has been included as a reduction of
operating expenses in the accompanying Consolidated Statement of Operations.

     c.  Advanced Research Press, Inc. -- On June 1, 2001, the Company sold its
publishing subsidiary, Advanced Research Press, Inc. ("ARP"), to Steve Blechman,
Executive Vice President and a Director of Twinlab and President/CEO of ARP, for
$1,000. Concurrent with the sale of ARP, Steve Blechman elected to resign as an
Executive Vice President and employee of Twinlab. The Company recorded a pre-tax
gain of approximately $674 in connection with the sale, which has been included
as a reduction of operating expenses in the accompanying Consolidated Statement
of Operations.

     d.  Health Factors International, Inc. -- On May 22, 2002, the Company
completed the sale of substantially all of the fixed assets of Health Factors
for approximately $2,107 to Anabolic Laboratories, Inc ("Anabolic"). The
products manufactured by Health Factors were, in significant part, transferred
to other Twinlab manufacturing facilities. Other production related to Bronson
was outsourced to Anabolic while the manufacture of certain private label
products was discontinued.

     e.  Bronson Laboratories, Inc. -- On January 17, 2003, the Company sold
substantially all of the assets, including inventory, of Bronson to a privately
held dietary supplement manufacturer for approximately $8,000. The Company
anticipates recording an aggregate pre-tax gain of approximately $1,700 during
the first quarter of 2003 in connection with the sale of these assets. Bronson's
results of operations have been classified as discontinued operations and prior
periods have been reclassified.

     Net sales and income (loss) from discontinued operations related to Bronson
are as follows:

<Table>
<Caption>
                                                           YEAR ENDED DECEMBER 31,
                                                         ----------------------------
                                                          2002       2001      2000
                                                         -------   --------   -------
<S>                                                      <C>       <C>        <C>
Net sales..............................................  $10,108   $ 11,079   $12,904
Operating income (loss)................................    1,102    (30,295)     (851)
Benefit from income taxes..............................       --         --      (316)
Income (loss) from discontinued operations.............    1,102    (30,295)     (526)
Income (loss) from discontinued operations per diluted
  share................................................     0.04      (1.06)    (0.02)
</Table>

                                       F-11
<PAGE>
                      TWINLAB CORPORATION AND SUBSIDIARIES

           NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)

     The assets of discontinued operations are comprised of the following:

<Table>
<Caption>
                                                               2002     2001
                                                              ------   ------
<S>                                                           <C>      <C>
Inventories.................................................  $2,303   $1,332
Other current assets........................................     108      160
Property, plant and equipment, net..........................     499      706
Intangible assets...........................................   3,460    4,478
                                                              ------   ------
Assets of discontinued operations...........................  $6,370   $6,676
                                                              ======   ======
</Table>

4.  INVENTORIES

     Inventories, net of reserves for excess and obsolete inventory, consist of
the following:

<Table>
<Caption>
                                                               2002      2001
                                                              -------   -------
<S>                                                           <C>       <C>
Raw materials...............................................  $ 6,226   $10,284
Work in process.............................................    8,644     6,787
Finished goods..............................................   14,384    25,574
                                                              -------   -------
     Total..................................................  $29,254   $42,645
                                                              =======   =======
</Table>

     Reserves for excess and obsolete inventory totaled $5,770 and $14,187 as of
December 31, 2002 and 2001, respectively.

5.  PROPERTY, PLANT AND EQUIPMENT

     Property, plant and equipment consist of the following:

<Table>
<Caption>
                                                               2002      2001
                                                              -------   -------
<S>                                                           <C>       <C>
Land, building and leasehold improvements...................  $24,811   $30,161
Plant equipment.............................................   12,674    20,180
Office and computer equipment...............................   11,758    17,017
Automobiles.................................................       35        50
                                                              -------   -------
                                                               49,278    67,408
Less: accumulated depreciation and amortization.............   15,259    21,260
                                                              -------   -------
  Property, plant and equipment -- net......................  $34,019   $46,148
                                                              =======   =======
</Table>

     See Note 2 relating to asset impairment charges recorded during the years
ended December 31, 2002 and 2001.

                                       F-12
<PAGE>
                      TWINLAB CORPORATION AND SUBSIDIARIES

           NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)

6.  ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES

     Accrued expenses and other current liabilities consist of the following:

<Table>
<Caption>
                                                               2002      2001
                                                              -------   ------
<S>                                                           <C>       <C>
Accrued salaries, employee benefits and payroll taxes.......  $ 2,771   $3,746
Accrued restructuring costs.................................    6,487       --
Accrued litigation costs....................................    4,059       --
Other.......................................................    7,839    5,124
                                                              -------   ------
     Total..................................................  $21,156   $8,870
                                                              =======   ======
</Table>

7.  LONG-TERM DEBT

     Long-term debt consists of the following:

<Table>
<Caption>
                                                               2002      2001
                                                              -------   -------
<S>                                                           <C>       <C>
Revolving Credit Facility(a)................................  $24,356   $30,468
Senior subordinated notes(b)................................   39,915    39,915
Mortgage payable to a bank, collateralized by land and
  building, payable in monthly installments of $96,
  including interest at 7.57%, maturing April 2009(c).......    5,748     6,428
Lease obligations, payable in average monthly installments
  of $10, including interest at an average rate of 8.2%,
  maturing through December 2003............................      799     2,344
Note payable to a power authority, payable in monthly
  installments of $2, including interest at 6.38%, maturing
  February 2011.............................................      198       215
                                                              -------   -------
                                                               71,016    79,370
Less: current portion.......................................    6,565     2,241
                                                              -------   -------
     Total..................................................  $64,451   $77,129
                                                              =======   =======
</Table>

     (a)  Effective March 29, 2001, the Company entered into a new revolving
line of credit inclusive of a term loan (the "Revolving Credit Facility") with a
group of financial institutions. The Revolving Credit Facility, as amended,
provides for maximum borrowings of $45,000 ($60,000 as of December 31, 2001)
through March 29, 2004 with a termination fee of 2% for early cancellation. The
term loan portion of the Revolving Credit Facility totals $4,200 and is payable
at the expiration of the agreement. Borrowings are subject to certain
limitations based on a percentage of eligible accounts receivable and
inventories, as defined in the agreement. Interest is payable monthly at the
Prime Rate (4.25% as of December 31, 2002), plus 1.75% per annum (1.5% per annum
as of December 31, 2001). The Company is required to pay a commitment fee of
0.5% per annum on any unused portion of the Revolving Credit Facility.
Borrowings under the Revolving Credit Facility are secured by substantially all
of the Company's assets. In addition, certain current and former members of
senior management of the Company provided letters of credit aggregating $15,000
in respect of the Company's obligations under the Revolving Credit Facility. The
Revolving Credit Facility, among other things, requires the Company to maintain
specified levels of EBITDA (as defined therein), places limitations on capital
expenditures and restrictions on the ability to incur debt and prohibits the
payments of dividends. As a result of the sale of Bronson, effective January 17,
2003, the Company completed an amendment to the Revolving Credit Facility, which
among other things, revised the financial covenants relating to EBITDA and
reduced the total facility from $50,000 to $45,000. The Company was in
compliance with the covenants relating to the Revolving Credit Facility as of
December 31, 2002.

                                       F-13
<PAGE>
                      TWINLAB CORPORATION AND SUBSIDIARIES

           NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)

     As previously disclosed, the Company's Revolving Credit Facility expires on
March 29, 2004. The Company intends to enter into negotiations to extend the
term of the Revolving Credit Facility or to enter into an alternative borrowing
arrangement which would provide for future borrowings. There can be no
assurance, however, that by March 29, 2004, an extension of the Revolving Credit
Facility will be successfully negotiated or the Company will be able to enter
into an alternative borrowing arrangement on terms favorable to the Company. The
absence of an extension of the Revolving Credit Facility or alternative
borrowing arrangement would have a material adverse effect on the financial
condition of the Company. The Company anticipates that borrowings outstanding
under the Revolving Credit Facility will be classified as a current liability as
of March 31, 2003.

     (b)  In May 1996, Twin Laboratories Inc. ("Twin") issued $100,000 aggregate
principal amount of senior subordinated notes (the "Notes") which mature on May
15, 2006. In 1998 and 1999, Twin repurchased an aggregate $60,085 principal
amount of Notes. The Notes bear interest at a rate of 10 1/4% per annum and are
jointly and severally guaranteed by Twinlab and all subsidiaries of Twin on a
full and unconditional unsecured senior subordinated basis. Twinlab has no
separate operations and has no significant assets other than Twinlab's
investment in its subsidiaries. The Notes are callable, at the Company's option,
after May 15, 2001 at a premium to par which declines to par after 2003. Upon a
change of control, as defined, Twin is required to offer to redeem the Notes at
101% of the principal amount plus accrued and unpaid interest. Restrictive
covenants contained in the indenture governing the Notes (the "Note Indenture")
include, among other things, limitations on additional indebtedness,
investments, dividends and certain other significant transactions. The Company
was in compliance with such covenants at December 31, 2002.

     (c)  The Company was in default of certain financial covenants relating to
the mortgage payable during fiscal 2002 for which a waiver was obtained through
April 3, 2003. The Company will be subject to the financial covenant tests for
the quarter ended June 30, 2003 and does not currently anticipate being in
compliance. Accordingly, the mortgage payable has been classified as a current
liability as of December 31, 2002. The Company has entered into negotiations
with the lender to amend the mortgage agreement, however, there can be no
assurance that an amendment will be successfully negotiated. In the event that
the Company is unable to amend the mortgage agreement, the Company will be
required to repay the mortgage in order to avoid a cross-default under the terms
of the Revolving Credit Facility.

     The Revolving Credit Facility and the Note Indenture restrict the payment
of dividends and the making of loans, advances or other distributions of assets
to Twinlab, except in certain limited circumstances.

     Maturities of long-term debt are as follows:

<Table>
<S>                                                           <C>
YEAR ENDING DECEMBER 31,
2003........................................................  $ 6,565
2004........................................................   24,375
2005........................................................       20
2006........................................................   39,938
2007........................................................       23
Thereafter..................................................       95
                                                              -------
          Total.............................................  $71,016
                                                              =======
</Table>

     The carrying amount of the borrowings under the Revolving Credit Facility,
the mortgage payable, the lease obligations and the note payable approximated
fair value as of December 31, 2002 and 2001 based on borrowing rates available
to the Company at such dates for loans with similar terms. The fair value of the
Notes approximated $18,560 and $14,769 at December 31, 2002 and 2001,
respectively.

                                       F-14
<PAGE>
                      TWINLAB CORPORATION AND SUBSIDIARIES

           NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)

8.  SHAREHOLDERS' (DEFICIT) EQUITY

     (a)  Stock incentive plans -- In November 1996, the Board and stockholders
of the Company approved and adopted the Twinlab Corporation 1996 Stock Incentive
Plan (the "1996 Plan"). The 1996 Plan provides for the issuance of a total of up
to 400,000 authorized and unissued shares of common stock, treasury shares
and/or shares acquired by the Company for purposes of the 1996 Plan. Awards
under the 1996 Plan may be made in the form of (i) incentive stock options; (ii)
non-qualified stock options; (iii) stock appreciation rights; (iv) restricted
stock; and (v) performance shares. On June 17, 1998, the shareholders approved
the Twinlab Corporation 1998 Stock Incentive Plan (the "1998 Plan"). The 1998
Plan provides initially for the issuance of a total of up to 1,000,000
authorized and unissued shares of common stock, treasury shares and/or shares
acquired by the Company for purposes of the 1998 Plan, and may be increased
annually commencing January 1, 1999, at the discretion of the Board, by an
amount up to 1% of the shares of common stock outstanding at the beginning of
the year. The Board approved an increase of 327,050 shares and 315,662 shares to
the 1998 Plan in December 1999 and January 2000, respectively. Awards under the
1998 Plan may be made in the form of (i) incentive stock options; (ii)
non-qualified stock options; (iii) stock appreciation rights; (iv) restricted
stock; (v) restricted stock units; (vi) dividend equivalent rights; and (vii)
other stock based awards. The Company has only issued non-qualified stock
options under the 1996 Plan and the 1998 Plan. Options issued under the 1996
Plan and the 1998 Plan become exercisable and vest over five years from the date
of grant at the rate of 20% of the grant each year and expire up to ten years
after the date of grant.

     On June 17, 1999, the shareholders of the Company approved the Twinlab
Corporation 1999 Stock Incentive Plan for Outside Directors (the "Outside
Directors Plan"). The Outside Directors Plan provides for the granting of up to
an aggregate of 65,000 shares of common stock, subject to adjustment in the
event of certain capital changes as defined in the Outside Directors Plan.
Shares issued under the Outside Directors Plan may either be authorized but
unissued shares of common stock or treasury shares of common stock. The Outside
Directors Plan provides for the grant to participants of non-qualified stock
options and restricted shares of common stock. Awards will be granted each year,
as of the day following the day the Company's annual meeting takes place, to
individuals who qualify as participants as of such date. Options issued under
the Outside Directors Plan become exercisable and vest pro ratably over three
years from the date of grant and expire up to ten years after the date of grant.
The Company issued 10,000, 10,000 and 11,381 non-qualified stock options under
this plan during the years ended December 31, 2002, 2001 and 2000, respectively.

     In addition to the Outside Directors Plan, the Company maintains a Deferred
Compensation Plan for Outside Directors (the "Deferred Compensation Plan") which
provides that non-employee directors can elect each year to defer receipt of any
part or all of the cash portion of their annual retainer and convert such
deferred compensation into shares of "Phantom Stock" based on the fair market
value of the Company's common stock. Each share of Phantom Stock entitles the
participant to receive in cash the value of a share of common stock when he
ceases to be a director. In connection with the Deferred Compensation Plan, the
Company issued 39,349 and 30,252 shares of Phantom Stock relating to the years
ended December 31, 2001 and 2000, respectively. No Phantom Stock was issued
relating to the year ended December 31, 2002.

     On May 9, 2000, the shareholders approved the Twinlab Corporation 2000
Stock Incentive Plan (the "2000 Plan"). The 2000 Plan provides for the granting
of incentive awards (as defined below) with respect to up to an aggregate of
4,500,000 shares of common stock, subject to adjustment in the event of certain
capital changes. Awards under the 2000 Plan may be made in the form of (i)
non-qualified stock options; (ii) incentive stock options; (iii) limited stock
appreciation rights; (iv) tandem stock appreciation rights; (v) stand alone
stock appreciation rights; (vi) shares of restricted stock; (vii) shares of
phantom stock; (viii) stock bonuses; (ix) cash bonuses, (x) dividend equivalent
rights; and (xi) other types of stock based awards. The Company has only issued
non-qualified stock options under the 2000 Plan. Options issued under the 2000
Plan become exercisable and vest over three years from the date of grant at the
rate of 33 1/3% of the grant each year and expire up to ten years after the date
of grant.

                                       F-15
<PAGE>
                      TWINLAB CORPORATION AND SUBSIDIARIES

           NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)

The following table sets forth summarized information concerning stock option
activity relating to the Company's 1996 Plan, 1998 Plan, 2000 Plan, and the
Outside Directors Plan (collectively, the "Plans"):

<Table>
<Caption>
                                                                                WEIGHTED
                                                                                AVERAGE
                                                    NUMBER        EXERCISE      EXERCISE
                                                   OF SHARES    PRICE RANGE      PRICE
                                                   ---------   --------------   --------
<S>                                                <C>         <C>              <C>
Balance, January 1, 2000.........................  1,163,050   $8.00 - $29.38    $12.55
  Granted........................................  1,029,881   $ 5.34 - $ 8.19   $ 7.20
  Canceled.......................................   (310,850)  $7.38 - $29.38    $12.03
                                                   ---------
Balance, December 31, 2000.......................  1,882,081   $5.34 - $29.38    $ 9.72
  Granted........................................    774,000   $ 1.70 - $ 2.10   $ 2.02
  Canceled.......................................   (536,700)  $2.10 - $29.38    $ 8.54
                                                   ---------
Balance, December 31, 2001.......................  2,119,381   $1.70 - $29.38    $ 7.21
  Granted........................................    838,000   $ 0.33 - $ 0.57   $ 0.33
  Canceled.......................................   (771,900)  $0.33 - $29.38    $ 8.06
                                                   ---------
Balance, December 31, 2002.......................  2,185,481   $0.33 - $29.38    $ 4.27
                                                   =========   ==============    ======
Shares exercisable at December 31, 2002..........    701,792   $1.70 - $29.38    $ 7.95
                                                   =========   ==============    ======
Shares reserved for issuance at December 31,
  2002...........................................  6,579,160
                                                   =========
</Table>

     Significant option groups outstanding at December 31, 2002 and related
weighted average price and life information were as follows:

<Table>
<Caption>
                                WEIGHTED AVERAGE
                                   REMAINING          WEIGHTED                       WEIGHTED
   RANGE OF         NUMBER        CONTRACTUAL         AVERAGE         NUMBER         AVERAGE
EXERCISE PRICE    OUTSTANDING    LIFE IN YEARS     EXERCISE PRICE   EXERCISABLE   EXERCISE PRICE
---------------   -----------   ----------------   --------------   -----------   --------------
<S>               <C>           <C>                <C>              <C>           <C>
$ 0.33 - $ 2.10..  1,339,500          9.1              $ 1.06         180,894         $ 2.02
$ 5.34 - $ 7.38..    402,381          7.3              $ 7.17         229,597         $ 7.23
$ 8.00 - $ 9.19..    336,000          6.5              $ 8.10         195,101         $ 8.10
$12.00 - $29.38..    107,600          4.6              $21.48          96,200         $20.54
                   ---------                                          -------
                   2,185,481                                          701,792
                   =========                                          =======
</Table>

     SFAS No. 123 requires the disclosure (see Note 1.j.) of pro forma net loss
and net loss per share had the Company adopted the fair value method of
accounting for stock-based compensation as of the beginning of 1995. Under SFAS
No. 123, the fair value of stock-based awards is calculated through the use of
option pricing models, even though such models were developed to estimate the
fair value of freely tradable, fully transferable options without vesting
restrictions, which significantly differ from the Company's stock option awards.
These models also require subjective assumptions, including future stock price
volatility and expected time to exercise, which greatly affect the calculated
values. Using the Black-Scholes option pricing model, the weighted average fair
value of the options granted during 2002, 2001 and 2000 is estimated at $0.30,
$1.63 and $6.65 per share, respectively, on the date of grant with the following
weighted average assumptions for 2002, 2001 and 2000, respectively: volatility
of 188%, 111% and 125%, risk-free interest rate of 3.60%, 4.78% and 6.72%, an
expected life of five years for 2002 and 2001 and seven years for 2000, and no
dividends during the expected term.

     (b) Net loss per share -- Basic loss per share is determined by using the
weighted average number of shares of common stock outstanding during each
period. Diluted loss per share further assumes the issuance of

                                       F-16
<PAGE>
                      TWINLAB CORPORATION AND SUBSIDIARIES

           NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)

common shares for all dilutive outstanding common stock options. Potentially
dilutive securities totaling 2,185,481, 2,119,381 and 1,882,081 for the years
ended December 31, 2002, 2001 and 2000, respectively, were excluded from the
computation of diluted loss per share because they were anti-dilutive.

     (c) Share repurchase program -- On February 25, 1999, the Board approved a
share repurchase program authorizing the Company to purchase up to the greater
of 5 million shares or $40,000 of its common stock. The Company purchased
4,100,900 shares at a total cost of $36,794 under this program prior to its
termination in May 2000.

     (d) Shares issued for services rendered -- In January 2000, the Company
entered into a three year marketing services agreement with a spokesperson.
Under the agreement, the spokesperson was to be compensated $350, $400 and $500
in 2000, 2001 and 2002, respectively. Such amounts were payable in the Company's
common stock at the beginning of each fiscal year. Each annual grant contained a
put option that enabled the holder for one year from the issuance date, to sell
the shares back to the Company at the original issuance price. During 2000, the
Company issued 40,354 shares of the Company's common stock in connection with
this agreement and recorded an expense of approximately $417. In January 2001,
the holder exercised the put option relating to the 2000 share issuance. The
Company agreed to satisfy the obligation by paying $268 in cash and allowing the
holder to retain the original shares. In addition, in January 2001, the Company
issued 281,601 shares in connection with the second year of the agreement. In
2001, the Company and the spokesperson mutually agreed to terminate the
contract.

9.  RELATED PARTY TRANSACTIONS

     In connection with the Revolving Credit Facility, certain current and
former members of senior management of the Company provided a letter of credit
amounting to $15,000 with respect to the Company's obligations under the
Revolving Credit Facility. In consideration for providing this letter of credit,
effective April 1, 2002, the Company agreed to pay an aggregate annual fee of
$375 and 375,000 shares of common stock (to be issued from shares held in
treasury), payable in quarterly installments for the duration of the period that
the letter of credit remains outstanding. As of December 31, 2002, $188 has been
paid and 187,500 shares of common stock have been issued. The fair value of the
compensation for providing the letter of credit, $1,643, has been recorded as
deferred financing costs and is being amortized over the remaining term of the
Revolving Credit Facility.

     The Company paid approximately $111 for inventory consulting services
during the year ended December 31, 2002 to a company in which a director of
Twinlab serves as a director.

                                       F-17
<PAGE>
                      TWINLAB CORPORATION AND SUBSIDIARIES

           NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)

10.  INCOME TAXES

     The (benefit from) provision for income taxes consists of the following:

<Table>
<Caption>
                                                         2002       2001       2000
                                                        -------   --------   --------
<S>                                                     <C>       <C>        <C>
Current:
  Federal.............................................  $(6,911)  $     --   $(11,813)
  State and local.....................................       --         --        877
                                                        -------   --------   --------
                                                         (6,911)        --    (10,936)
                                                        -------   --------   --------
Deferred:
  Federal.............................................   (6,536)   (12,114)    (1,089)
  State and local.....................................   (2,471)    (3,095)    (2,723)
  Valuation allowance.................................    9,007     38,010     26,000
                                                        -------   --------   --------
                                                             --     22,801     22,188
                                                        -------   --------   --------
                                                        $(6,911)  $ 22,801   $ 11,252
                                                        =======   ========   ========
</Table>

     The Company recorded a federal benefit from income taxes of $6,911 during
the year ended December 31, 2002 representing a refund received by the Company
as a result of the Job Creation and Worker Assistance Act of 2002. The Company
did not record a benefit from income taxes for losses incurred during the years
ended December 31, 2002 and 2001 as it is more likely than not that such
benefits will not be realized.

     The difference between the statutory Federal tax rate and the Company's
effective tax rate is as follows (as a percentage of pre-tax loss):

<Table>
<Caption>
                                                              2002    2001    2000
                                                              -----   -----   -----
<S>                                                           <C>     <C>     <C>
Statutory Federal income tax rate...........................  (35.0)% (35.0)% (35.0)%
Increase in valuation allowance.............................   22.3   127.0    66.6
Non-deductible expenses.....................................    0.3     0.3     0.7
State and local income taxes (net of Federal tax benefit)...   (4.0)   (7.9)   (3.1)
Other.......................................................   (0.7)   (8.2)   (0.4)
                                                              -----   -----   -----
Effective tax rate..........................................  (17.1)% (76.2)%  28.8%
                                                              =====   =====   =====
</Table>

                                       F-18
<PAGE>
                      TWINLAB CORPORATION AND SUBSIDIARIES

           NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)

     At December 31, 2002 and 2001, the deferred tax assets (liabilities)
consisted of:

<Table>
<Caption>
                                                                2002       2001
                                                              --------   --------
<S>                                                           <C>        <C>
Accounts receivable.........................................  $  1,690   $  2,959
Inventories.................................................     2,296      5,604
Property, plant and equipment...............................    (5,729)    (5,145)
Intangible and other assets.................................    31,465     35,766
Accrued expenses............................................     4,714        185
Federal NOL and credit carryforwards........................    28,454     17,744
State NOL and credit carryforwards..........................    10,049      6,897
Other.......................................................        78         --
                                                              --------   --------
                                                                73,017     64,010
Less valuation allowance....................................   (73,017)   (64,010)
                                                              --------   --------
                                                              $     --   $     --
                                                              ========   ========
</Table>

     As a result of losses incurred, the Company has recorded a full valuation
allowance against its net deferred tax assets.

     As of December 31, 2002, the Company had Federal net operating loss
carryforwards of approximately $80,000. Such loss carryforwards expire through
fiscal 2022.

11.  EMPLOYEE BENEFIT PLANS

     The Company maintains the Twin Laboratories Inc. 401(k) Plan (the "401(k)
Plan"). Eligible employees may contribute up to 15% of their annual
compensation, subject to certain limitations, and the Company matched 50% of an
employee's contribution (up to a maximum of 6%) through December 31, 2001.
Effective January 1, 2002, the Company terminated the Company match.
Contributions to the 401(k) Plan are invested, at the employee's discretion, in
a variety of mutual funds. The total cost with respect to the 401(k) Plan
approximated $12, $781 and $757 for the years ended December 31, 2002, 2001 and
2000, respectively.

12.  COMMITMENTS AND CONTINGENCIES

     a.  Leases -- The Company leases certain office and warehouse space and
equipment under operating leases. Generally, the leases carry renewal provisions
and require the payment of maintenance costs. Rental payments may be adjusted
for increases in taxes and other costs above specific amounts. Rental expense
charged to operations for the years ended December 31, 2002, 2001 and 2000 was
approximately $4,598, $5,626 and $6,217, respectively.

     Future minimum payments under noncancellable operating leases with initial
or remaining terms of more than one year are as follows:

<Table>
<S>                                                           <C>
YEAR ENDING DECEMBER 31,
2003........................................................  $3,691
2004........................................................   2,997
2005........................................................   1,965
2006........................................................     543
                                                              ------
Total.......................................................  $9,196
                                                              ======
</Table>

                                       F-19
<PAGE>
                      TWINLAB CORPORATION AND SUBSIDIARIES

           NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)

     b.  Employment and severance/non-compete agreements -- In connection with
the resignations of Steve Blechman (see Note 3.c.), Dean Blechman, Brian
Blechman and Neil Blechman, each an Executive Vice President, the Company is
obligated to make severance and non-compete payments. Effective March 1, 2003,
the Company entered into a new employment agreement with Ross Blechman, Chairman
of the Board, President and Chief Executive Officer. Future minimum payments
under these agreements are as follows:

<Table>
<S>                                                           <C>
YEAR ENDING DECEMBER 31,
2003........................................................  $1,838
2004........................................................   1,700
2005........................................................     761
                                                              ------
Total.......................................................  $4,299
                                                              ======
</Table>

     c.  Legal matters -- A number of the Company's products include alkaloids
from the herb known as "Ma Huang," also known as ephedra, which contains
naturally-occurring ephedrine alkaloids. Some of the Company's products also
contain caffeine or other central nervous system stimulants. Products containing
Ma Huang accounted for approximately 21% of the Company's net sales in 2002.

     Ma Huang has been the subject of extensive negative publicity in the United
States and other countries relating to alleged harmful or adverse effects. This
publicity has led to recent congressional hearings addressing the safety of Ma
Huang and several state governments have passed legislation regulating the sale
of products that contain Ma Huang. Recently, the Suffolk County (New York)
legislature passed a bill that bans retail sales of ephedra products in Suffolk
County. Other jurisdictions have proposed similar legislation. The current media
and political attention to Ma Huang is likely to lead to further legislation
related to the sale of products containing Ma Huang including the possible ban
of sale of these products.

     The Company has been named as a defendant in a number of pending lawsuits,
alleging that its Ma Huang products caused injury, death and/or damages, as well
as certain proceedings seeking class action certification for consumer fraud
related to the sale of such products. The Company is vigorously defending these
lawsuits. However, the Company is incurring, and expects to incur, significant
costs associated with this litigation activity. These costs are due in part to:
(i) greater costs for insurance premiums; (ii) significant self-insured
retention limits for claims alleging injuries after December 31, 2000; and (iii)
legal fees that are not covered under certain of the Company's insurance
policies. In particular, several of the class actions, as economic injury cases,
are not generally covered by insurance. At least one of the Ma Huang lawsuits
involving a claim of wrongful death is not currently covered by insurance.

     On February 28, 2003, the U.S. Food and Drug Administration, Department of
Health and Human Services ("HHS") announced a series of actions that will
potentially regulate the manner in which products containing the ingredient
ephedra are marketed, including a thirty-day comment period to create a record
to support potential restrictions that could range from label requirements to a
ban of the ingredient. By letter dated March 13, 2003, the Committee on Energy
and Commerce of the U.S. House of Representatives requested certain information
from the Company related to, among other things, the sales history of its
products containing ephedra, any adverse health events associated with such
products, scientific studies related to such products and information related to
certain of the Company's non-ephedra products. The Company has provided a
comprehensive response to the Committee.

     The Company believes in the safety and efficacy of its products that
contain Ma Huang based on the scientific evidence. Nevertheless, as a result of
the increasing costs that are negatively impacting the profitability of these
products, coupled with consumer demand for non-ephedra weight loss products, the
Company decided to discontinue the sale of products that contain Ma Huang
effective on or about March 31, 2003. The Company expects to experience a
reduction in net sales due to the discontinuation of its products that contain
Ma Huang. Based upon anticipated costs savings expected to be achieved, however,
the Company

                                       F-20
<PAGE>
                      TWINLAB CORPORATION AND SUBSIDIARIES

           NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)

does not believe that the decision to discontinue the sale of products that
contain Ma Huang should have a material adverse effect on the profitability of
the Company. The Company is committed to the Diet and Energy category,
specifically its Diet Fuel, Ripped Fuel and Metabolift brands, and has launched
a line of patented and clinically tested ephedra-free products.

     The Company has been named as a defendant in a number of pending product
liability lawsuits that the Company is vigorously defending. In reviewing its
potential exposure for product liability matters, the Company considers, among
other factors, recent and historical settlements and judgments, if any, the
incidence and trend of recent and historical claims, the nature of any alleged
injuries, the amount and availability of insurance coverage and the status of
litigation proceedings and settlement discussions.

     Based on a current analysis prepared by management, with the assistance of
actuarial consultants, the Company has estimated a range of potential liability
in an amount it deems reasonable in connection with certain product liability
matters involving ephedra. Accordingly, the Company has established a reserve of
$3,800 for product liability indemnity claims that is primarily based on known
claims and an estimate of unasserted claims involving ephedra that are probable
of assertion and can be reasonably estimated as of the balance sheet date.
Management expects that any payments relating to these matters will occur over a
number of years and has not discounted the potential liability as of December
31, 2002, because the timing of any payments are not fixed or reliably
determinable at the present time. This reserve assumes continuing insurance for
ephedra related personal injury actions, albeit with a significant retention and
limited total coverage.

     Because of the uncertainties related to the number of potential future
claims, ultimate settlement amounts, dismissal of such claims or any adverse
judgments, it is difficult to obtain precise estimates of the Company's ultimate
liability for such claims. It is possible that the total exposure to product
liability claims may be less than or greater than an amount within the Company's
estimated range of potential liability due to changes in facts or circumstances
after the date of each estimate. As additional experience is gained regarding
the Company's product liability claims, possible settlement discussions,
litigation history and insurance coverage, the Company will reassess its
potential liability and revise the amount of its reserve as appropriate.

     There can be no assurance that the impact of the Company's self-insured
retention limits in the event of multiple damage awards or settlements, or any
award of damages in excess of the Company's insurance coverage limits (which
limits are significantly lower than in prior periods) or any materially
increased legal costs, will not have a material adverse effect on the financial
condition or results of operations of the Company. In addition, one or more
large punitive damage awards, which are generally not insurable, could have a
material adverse effect on the financial condition and results of operations of
the Company.

     Further, the Company's 2003 comprehensive general liability ("CGL")
insurance policy for non-Ma Huang products has a significantly higher
self-insured retention limit than in 2002 and the herbal product Kava-Kava is
expressly excluded from coverage under the 2003 policy. The Company has received
one Kava-Kava related wrongful death complaint in 2003. The Company plans to
vigorously defend itself against this action and is investigating whether any of
its CGL policies apply to this claim. If a CGL policy is not applicable to this
claim, a finding of liability and damages could have a material adverse effect
on the results of operation and financial condition of the Company. The Company
is unable to predict the outcome of this matter or to estimate a range of
potential loss. Accordingly, the effect, if any, that such action may have on
the Company's consolidated financial position or results of operations cannot be
determined at this time.

     In March 2001, the Company announced that it reached an agreement in
principle to settle a shareholder securities class action lawsuit that was
pending against the Company and certain of its officers and directors before the
United States District Court for the Eastern District of New York (the "Court").
The lawsuit alleged that the Company and the other defendants violated the
securities laws by making material misstatements and failing to state material
facts about the Company's business and financial condition, among other things,
in securities act filings and public statements. The class of plaintiffs
included all buyers of the

                                       F-21
<PAGE>
                      TWINLAB CORPORATION AND SUBSIDIARIES

           NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)

Company's stock from April 8, 1998 through February 24, 1999, other than the
defendants and certain related parties. The Court approved the settlement in
February 2002. Pursuant to the settlement, the Company paid $26,000, all of
which was covered by the Company's insurance.

     A series of shareholder securities class action lawsuits were filed in late
2000 and are pending before the Court against the Company and certain of its
officers and directors. The plaintiffs allege that the Company and the other
defendants violated the securities laws by making material misstatements and
failing to state material facts about the Company's business and financial
condition, among other things, in securities act filings and public statements.
The alleged class of plaintiffs includes all buyers of the Company's stock from
April 27, 1999 to November 15, 2000, other than the defendants and certain
related parties. A derivative action against certain of the Company's directors
was filed in June of 2001. The derivative action alleges that the named
directors violated certain fiduciary duties and alleges mismanagement, based
upon the facts alleged in the two securities class actions described above. The
Company believes that the claims are without merit and intends to vigorously
defend against the securities action and the derivative action. The Company has
filed a motion to dismiss the securities action and the derivative action,
however, the Company is unable to predict the outcome of these uncertainties or
to estimate a range of potential losses. Accordingly, the effect, if any, that
such actions may have on the Company's consolidated financial position or
results of operations cannot be determined at this time.

     The Company is presently engaged in various other legal actions in the
ordinary course of business including product liability, breach of contract
claims and employment related claims. Management is of the opinion that the
amounts which may be awarded or assessed, if any, in connection with these
matters, after taking into consideration the Company's insurance coverage, will
not have a material adverse effect on its results of operations or financial
condition.

     Included in operating expenses for the year ended December 31, 2002 is a
net expense of approximately $640 relating to litigation matters. Such expense
relates to the recording of reserves for litigation matters and related costs
offset by proceeds of $5,427 received from litigation settlements. Included in
operating expenses for the years ended December 31, 2001 and 2000, is $2,489 and
$2,251, respectively, of proceeds from litigation settlements.

13.  MAJOR CUSTOMERS AND CREDIT CONCENTRATIONS

     During the years ended December 31, 2002, 2001 and 2000, the Company
recognized net sales to significant customers as set forth below:

<Table>
<Caption>
                                                              2002   2001   2000
                                                              ----   ----   ----
<S>                                                           <C>    <C>    <C>
MAJOR CUSTOMERS:
Customer A..................................................   18%    13%    16%
Customer B..................................................   14     12      9
Customer C..................................................   13     13      9
Customer D..................................................    2     10     15
</Table>

     At December 31, 2002 and 2001, approximately 48% and 73%, respectively, of
accounts receivable related to these customers.

                                       F-22
<PAGE>
                      TWINLAB CORPORATION AND SUBSIDIARIES

           NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)

14.  QUARTERLY FINANCIAL DATA (UNAUDITED)

<Table>
<Caption>
                                 QUARTER ENDED   QUARTER ENDED   QUARTER ENDED       QUARTER ENDED
                                   MARCH 31,       JUNE 30,      SEPTEMBER 30,       DECEMBER 31,
                                 -------------   -------------   -------------       -------------
<S>                              <C>             <C>             <C>                 <C>
2002
Net sales......................    $ 45,457         $40,175        $ 22,737(b)         $  38,254
Gross profit...................      16,459          13,156           3,410(b)            14,111
(Loss) income from continuing
  operations...................       3,521(a)       (3,748)        (26,509)(b)(c)        (6,778)
Net (loss) income..............       3,737(a)       (3,625)        (26,035)(b)(c)        (6,489)
(Loss) income from continuing
  operations per share.........        0.12(a)        (0.13)          (0.91)(b)(c)(d)       (0.23)(d)
Diluted net (loss) income per
  share........................        0.13(a)        (0.13)          (0.90)(b)(c)(d)       (0.22)(d)

2001
Net sales......................    $ 49,690         $46,243        $ 51,338            $  39,836
Gross profit...................      18,242          13,714          17,154               11,193
Loss from continuing
  operations...................      (7,302)         (6,947)         (1,741)             (36,750)(d)(e)
Net loss.......................     (15,908)         (7,059)         (1,776)             (66,826)(d)(e)
Loss from continuing operations
  per share....................       (0.26)          (0.24)          (0.06)               (1.28)(d)(e)
Diluted net loss per share.....       (0.56)          (0.25)          (0.06)               (2.33)(d)(e)
</Table>

     a.  As discussed in Note 10, during the quarter ended March 31, 2002, the
Company recorded a federal benefit from income taxes of $6,911 representing a
refund received by the Company.

     b.  In connection with a continuing review of its operations, the Company
committed to a plan to rationalize product offerings to several key customers in
the retail segment. This plan was aimed at reducing the number of active SKUs
and achieving a more appropriate product mix. In connection with this plan, the
Company is allowing these customers to return inventory resulting in an
incremental charge for sales returns and allowances of approximately $8,800
during the quarter ended September 30, 2002.

     c.  As discussed in Note 2, the Company recorded restructuring charges of
$6,006 and $3,610 during the quarters ended September 30, 2002 and December 31,
2002, respectively.

     d.  As discussed in Note 2, the Company recorded asset impairment charges
of $6,894 and $334 during the quarters ended September 30, 2002 and December 31,
2002, respectively. In addition, the Company recorded asset impairment charges
of $33,832 (of which $30,005 is included in income (loss) from discontinued
operations) during the quarter ended December 31, 2001.

     e.  As discussed in Note 10, the Company recorded a full valuation
allowance against its deferred tax assets as of December 31, 2001.

15.  OPERATING SEGMENTS

     As previously disclosed, the Company completed the sale of substantially
all of the assets of Bronson on January 17, 2003 and Bronson's results of
operations have been classified as discontinued operations. As a result of this
transaction, the Company no longer operates in the direct-to-consumer segment.
Accordingly, the Company conducts its operations through one reportable segment,
the retail segment. Products sold by the retail segment include vitamins,
minerals and specialty supplements, sports nutrition products and diet and
energy products primarily under the Twinlab, Ironman Triathlon, "Fuel" and other
brand names; an extensive

                                       F-23
<PAGE>
                      TWINLAB CORPORATION AND SUBSIDIARIES

           NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)

line of herbal supplements and phytonutrients under the Nature's Herbs brand
name; and a full line of herbal teas under the Alvita brand name. In addition,
the Company distributed vitamins, herbs, nutritional supplements and health and
beauty aids under the Bronson brand name, through catalogs and specialty direct
mailings to customers, including healthcare and nutritional professionals, and
also manufactured, through Health Factors, private label vitamins and
supplements for a number of other companies on a contract manufacturing basis.
On May 22, 2002, the Company sold its Health Factors' operations and on January
17, 2003, the Company sold substantially all of the assets of Bronson. The
Company also marketed nutritionally enhanced food bars and other nutritional
products under the PR*Bar trademark through PR*Nutrition and conducted its
publishing activities through ARP. On April 17, 2001, the Company sold the
assets of its Changes International and PR*Nutrition subsidiaries and on June 1,
2001, the Company sold ARP. Bronson's and Changes International's results of
operations have been classified as discontinued operations and prior periods
have been reclassified.

     The accounting policies of the segments are the same as those described in
the summary of significant accounting policies. The Company evaluates the
financial performance of its business units based on operating income of the
respective business units.

     Segment information for the years ended December 31, 2002, 2001 and 2000
was as follows:

<Table>
<Caption>
                                                                              INTER-
                                                                              COMPANY
                                                     RETAIL(1)   OTHER(2)   ELIMINATION    TOTAL
                                                     ---------   --------   -----------   --------
<S>                                                  <C>         <C>        <C>           <C>
2002
Net sales to external customers....................  $146,623     $   --       $  --      $146,623
Intersegment net sales.............................       175         --        (175)           --
Operating loss.....................................   (32,258)      (207)         --       (32,465)
Interest expense...................................     8,118         --          --         8,118
Interest income....................................        26         --          --            26
Total assets(3)....................................    90,807         --          --        90,807
Capital expenditures...............................     1,877         --          --         1,877
Depreciation and amortization......................     5,373         --          --         5,373
2001
Net sales to external customers....................  $184,422     $2,685       $  --      $187,107
Intersegment net sales.............................        --        113        (113)           --
Operating (loss) income............................   (21,205)       368          --       (20,837)
Interest expense...................................     9,226         --          --         9,226
Interest income....................................       129         --          --           129
Total assets(3)....................................   121,938         --          --       121,938
Capital expenditures...............................     3,302         10          --         3,312
Depreciation and amortization......................     5,480         19          --         5,499
</Table>

                                       F-24
<PAGE>
                      TWINLAB CORPORATION AND SUBSIDIARIES

           NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)

<Table>
<Caption>
                                                                              INTER-
                                                                              COMPANY
                                                     RETAIL(1)   OTHER(2)   ELIMINATION    TOTAL
                                                     ---------   --------   -----------   --------
<S>                                                  <C>         <C>        <C>           <C>
2000
Net sales to external customers....................  $220,859     $7,636       $  --      $228,495
Intersegment net sales.............................        --        480        (480)           --
Operating loss.....................................   (30,026)      (492)         --       (30,518)
Interest expense...................................     8,866         --          --         8,866
Interest income....................................       311          3          --           314
Total assets(3)....................................   192,012      3,780          --       195,792
Capital expenditures...............................     5,933         18          --         5,951
Depreciation and amortization......................     4,202         66          --         4,268
</Table>

---------------

(1) Interest expense relating to borrowings under the revolving credit
    facilities and the Notes has been recorded in the retail segment and not
    allocated to the other operating segments.

(2) The "other" column includes corporate-related items and the results of two
    operating segments, PR*Nutrition and ARP, whose segment information is below
    the reportable quantitative thresholds. The Company marketed nutritionally
    enhanced food bars and other nutritional products through PR*Nutrition and
    published a sports fitness magazine and health and fitness-related books,
    audios and newsletters through ARP.

(3) Total assets exclude the assets from discontinued operations of
    approximately $6,370, $6,676 and $52,383 as of December 31, 2002, 2001 and
    2000, respectively.

     Total net sales to customers outside the U.S. were $12,919, $15,632 and
$15,967 for the years ended December 31, 2002, 2001 and 2000, respectively.
Export net sales from the Company's U.S. operations to unaffiliated customers
were $12,518, $14,753 and $15,967 for the years ended December 31, 2002, 2001
and 2000, respectively.

     The Company primarily distributes its products through the retail channel
which includes health and natural food stores, drug store chains, supermarkets
and mass market retailers. Net sales by distribution channel were as follows:

<Table>
<Caption>
                                                         2002       2001       2000
                                                       --------   --------   --------
<S>                                                    <C>        <C>        <C>
Retail:
  Health and natural food stores.....................  $ 92,341   $117,805   $166,438
  Mass market........................................    54,282     66,617     54,421
Other................................................        --      2,685      7,636
                                                       --------   --------   --------
                                                       $146,623   $187,107   $228,495
                                                       ========   ========   ========
</Table>

                                       F-25
<PAGE>

                                   SCHEDULE I
                      TWINLAB CORPORATION AND SUBSIDIARIES
                             (PARENT COMPANY ONLY)

                 SCHEDULE I -- CONDENSED FINANCIAL INFORMATION
                                 BALANCE SHEETS
                           DECEMBER 31, 2002 AND 2001
                 (IN THOUSANDS EXCEPT SHARE AND PER SHARE DATA)

<Table>
<Caption>
                                                                2002        2001
                                                              ---------   ---------
<S>                                                           <C>         <C>
ASSETS
Investment in subsidiaries..................................  $      --   $  21,022
                                                              =========   =========
LIABILITIES AND SHAREHOLDERS' (DEFICIT) EQUITY
Liabilities to subsidiaries.................................  $  11,127   $      --
Preferred stock, $.01 par value; 2,000,000 shares
  authorized; none issued...................................         --          --
Common stock, $1.00 par value; 75,000,000 shares authorized;
  33,041,756 issued and 29,128,356 outstanding as of
  December 31, 2002 and 33,041,756 issued and 28,940,856
  outstanding as of December 31, 2001.......................     33,042      33,042
Additional paid-in capital..................................    288,582     290,001
Accumulated Deficit.........................................   (297,639)   (265,227)
                                                              ---------   ---------
                                                                 23,985      57,816
Treasury stock at cost; 3,913,400 shares as of December 31,
  2002 and 4,100,900 shares as of December 31, 2001.........    (35,112)    (36,794)
                                                              ---------   ---------
Total shareholders' (deficit) equity........................    (11,127)     21,022
                                                              ---------   ---------
Total.......................................................  $      --   $  21,022
                                                              =========   =========
</Table>

NOTE: Investment in subsidiaries is accounted for under the equity method of
accounting.

   See notes to consolidated financial statements included elsewhere herein.

                                       S-1
<PAGE>

                                                                      SCHEDULE I

                      TWINLAB CORPORATION AND SUBSIDIARIES
                             (PARENT COMPANY ONLY)

                 SCHEDULE I -- CONDENSED FINANCIAL INFORMATION
                            STATEMENTS OF OPERATIONS
              FOR THE YEARS ENDED DECEMBER 31, 2002, 2001 AND 2000
                                 (IN THOUSANDS)

<Table>
<Caption>
                                                                2002       2001       2000
                                                              --------   --------   --------
<S>                                                           <C>        <C>        <C>
Equity interest in net loss of subsidiaries.................  $(32,205)  $(91,362)  $(51,806)
Operating expenses..........................................       207        207        207
Interest income.............................................        --         --          1
                                                              --------   --------   --------
Loss before benefit from income taxes.......................   (32,412)   (91,569)   (52,012)
Benefit from income taxes...................................        --         --        (77)
                                                              --------   --------   --------
Net loss....................................................  $(32,412)  $(91,569)  $(51,935)
                                                              ========   ========   ========
</Table>

   See notes to consolidated financial statements included elsewhere herein.

                                       S-2
<PAGE>

                                                                      SCHEDULE I

                      TWINLAB CORPORATION AND SUBSIDIARIES
                             (PARENT COMPANY ONLY)

                 SCHEDULE I -- CONDENSED FINANCIAL INFORMATION
                            STATEMENTS OF CASH FLOWS
              FOR THE YEARS ENDED DECEMBER 31, 2002, 2001 AND 2000
                                 (IN THOUSANDS)

<Table>
<Caption>
                                                                2002       2001       2000
                                                              --------   --------   --------
<S>                                                           <C>        <C>        <C>
CASH FLOWS FROM OPERATING ACTIVITIES:
  Net loss..................................................  $(32,412)  $(91,569)  $(51,935)
  Equity investment in subsidiaries.........................    32,412     91,569     51,597
                                                              --------   --------   --------
  Net cash used in operating activities.....................        --         --       (338)
Cash at beginning of year...................................        --         --        338
                                                              --------   --------   --------
Cash at end of year.........................................  $     --   $     --   $     --
                                                              ========   ========   ========
</Table>

   See notes to consolidated financial statements included elsewhere herein.

                                       S-3
<PAGE>

                                                                     SCHEDULE II

                      TWINLAB CORPORATION AND SUBSIDIARIES

                SCHEDULE II -- VALUATION AND QUALIFYING ACCOUNTS
                                 (IN THOUSANDS)

<Table>
<Caption>
              COLUMN A                    COLUMN B               COLUMN C               COLUMN D         COLUMN E
              --------                 --------------   ---------------------------   ------------     ------------
                                                                 ADDITIONS
                                                        ---------------------------
                                                                        CHARGED TO
                                         BALANCE AT      CHARGED TO       OTHER                         BALANCE AT
                                        BEGINNING OF      COST AND       ACCOUNTS      DEDUCTIONS         END OF
DESCRIPTIONS                               PERIOD         EXPENSES     -- DESCRIBE    -- DESCRIBE         PERIOD
------------                           --------------   ------------   ------------   ------------     ------------
<S>                                    <C>              <C>            <C>            <C>              <C>
YEAR ENDED DECEMBER 31, 2002:
  Allowance for bad debts............  $       6,100    $     1,009    $        --    $     4,427(1)   $      2,682
                                       ==============   ============   ============   ============     ============
  Reserve for excess and slow moving
     inventory.......................  $      14,187    $     6,681    $        --    $    15,098(1)   $      5,770
                                       ==============   ============   ============   ============     ============
YEAR ENDED DECEMBER 31, 2001:
  Allowance for bad debts............  $       4,879    $     2,156    $        --    $       935(1)   $      6,100
                                       ==============   ============   ============   ============     ============
  Reserve for excess and slow moving
     inventory.......................  $      15,403    $        --    $        --    $     1,216(1)   $     14,187
                                       ==============   ============   ============   ============     ============
YEAR ENDED DECEMBER 31, 2000:
  Allowance for bad debts............  $         918    $     4,415    $        --    $       454(1)   $      4,879
                                       ==============   ============   ============   ============     ============
  Reserve for excess and slow moving
     inventory.......................  $       8,058    $    10,601    $        --    $     3,256(1)   $     15,403
                                       ==============   ============   ============   ============     ============
</Table>

---------------

(1) Amounts written off.

   See notes to consolidated financial statements included elsewhere herein.

                                       S-4